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Chapter 1: “History and Introduction to Chromatographic   
  Techniques” 
 
 
1.0 General Introduction 
 
1.1 History of chromatography 
In 1903 a Russian botanist Mikhail Tswett produced a colorful separation of plant 
pigments through calcium carbonate column. Chromatography word came from 
Greek language chroma = color and graphein = to write i.e. color writing or 
chromatography [1][2]. 
 
1.2 Introduction of Chromatography 
Modern pharmaceutical formulations are complex mixtures containing one or more 
therapeutically active ingredients, to a number of inert materials like excipients, 
disintegrates, colors and flavors. In order to ensure quality and stability of the final 
product, the pharmaceutical analyst must be able to separate the mixtures into 
individual components prior to quantitative analysis. Chromatography is the powerful 
techniques in which differential migration of components take place between two 
phases, one is stable which is known as stationary phase and another is movable 
which is known as a mobile phase. Species in the sample undergo repeated 
interactions (partitions) between the mobile phase and stationary phase. The 
stationary phase may be solid or a liquid (supported on a solid or a gel), and packed in 
a column, spread as a layer or film. The mobile phase may be gaseous or liquid. 
Those solutes, distributed preferentially in the mobile phase, will move rapidly 
through the system than those distributed preferentially in the stationary phase. This 
forms the basis of separation of component present in a sample. The distribution of a 
solute between two phases results from the balance of forces between solute 
molecules and the molecule of each phase. It reflects the relative attraction or 
repulsion that molecule or ions of the competing phase shown for the solute and for 
them. These forces can be polar in nature arising from permanent on induced and 
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dipole moment. In ion exchange chromatography, the forces on the solute molecules 
are substantially ionic in nature but include polar and non-polar forces as well [3][4][5]. 
 
Chromatographic method must having essentially, 
 Stationary phase, 
 Mobile phase, 
 Sample injection system, 
 Solvent delivery system, 
 Column (support for stationary phase), 
 Detection by detecting agent 
All chromatographic methods involve modifications in these basic components. 
 
2.0 HISTORY OF HPLC 
Prior to the 1970's, few reliable chromatographic methods were commercially 
available to the laboratory scientist. During 1970's, most chemical separations were 
carried out using a variety of techniques including open-column chromatography, 
paper chromatography, and thin-layer chromatography. However, these 
chromatographic techniques were inadequate for quantification of compounds and 
resolution between similar compounds. During this time, pressure liquid 
chromatography began to be used to decrease flow through time, thus reducing 
purification times of compounds being isolated by column chromatography. 
However, flow rates were inconsistent, and the question of whether it was better to 
have constant flow rate or constant pressure was debated [6].  
 
High pressure liquid chromatography was developed in the mid-1970's and quickly 
improved with the development of column packing materials and the additional 
convenience of on-line detectors. In the late 1970's, new methods including reverse 
phase liquid chromatography allowed for improved separation between very similar 
compounds.  
 
By the 1980's HPLC was commonly used for the separation of chemical compounds. 
New techniques improved separation, identification, purification and quantification 
far above the previous techniques. Computers and automation added to the 
convenience of HPLC. Improvements in type of columns and thus reproducibility 
were made as such terms as micro-column, affinity columns, and Fast HPLC began to 
immerge. 
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By the 2000 very fast development was undertaken in the area of column material 
with small particle size technology and other specialized columns. The dimensions of 
the typical HPLC column are 100-300 mm in length with an internal diameter 
between 3-5 mm. The usual diameter of micro-columns, or capillary columns, ranges 
from 3 µm to 200 µm [7].  
 
In this decade sub 2 micron particle size technology (column material packed with 
silica particles of < 2µm size) with modified or improved HPLC instrumentation 
becomes a popular with different instrument brand name like UPLC (Ultra 
Performance Liquid Chromatography) of Waters and RRLC (Rapid Resolution 
Liquid Chromatography) of Agilent. 
 
2.1 Modern High Performance Liquid Chromatography (HPLC) 
The highly sophisticated reliable and fast liquid chromatographic (LC) separation 
techniques are become a requirement in many industries like pharmaceuticals, 
agrochemicals, dyes, petrochemicals, natural products and others. Early LC used 
gravity fed open tubular columns with particles 100s of microns in size; the human 
eye was used for a detector and separations often took hours to develop. Today's 
HPLC requires very special apparatus which includes the following. 
 
i. Extremely precise gradient mixers. 
ii. HPLC high pressure pumps with very constant flow. 
iii. Unique high accuracy, low dispersion, HPLC sample valves. 
iv. Very high efficiency HPLC columns with inert packing materials. 
v. High sensitivity low dispersion HPLC detectors. 
vi. High speed data acquisition systems. 
vii. Low dispersion connecting tubes for valve to column and column to detector. 
 
2.2 HPLC Gradient mixtures 
HPLC gradient mixers must provide a very precise control of solvent composition to 
maintain a reproducible gradient profile. This can be complicated in HPLC by the 
small elution volumes required by many systems. It is much more difficult to produce 
a constant gradient when mixing small volumes then when mixing large volumes. For 
low pressure systems this requires great precision in the operation of the miniature 
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mixing valves used and low dispersion flows throughout the mixer. For multi-pump 
high pressure systems it requires a very precise control of the flow rate while making 
very small changes of the flow rate. 
 
2.3 HPLC Pumps 
Because of the small particles used in modern HPLC, modern LC pumps need to 
operate reliably and precisely at pressures of 10,000 p.s.i. or at least 6,000 p.s.i. To 
operate at these pressures and remain sensibly inert to the wide variety of solvents 
used HPLC pumps usually have sapphire pistons, stainless steel cylinders and return 
valves fitted with sapphire balls and stainless steel seats. For analytical purposes 
HPLC pumps should have flow rates that range from 0 to 10 ml/min., but for 
preparative HPLC, flow rates in excess of 100 ml/min may be required. It is 
extremely difficult to provide a very constant flow rate at very low flow rates. If 1% 
is considered acceptable then for 1ml/min a flow variation of less than 10µl/min is 
required. This level of constancy is required because most HPLC detectors are flow 
sensitive and errors in quantization will result from change in flow rate. 
 
2.4 HPLC Sample Valves 
Since sample valves come between the pump and the column it follows that HPLC 
sample valves must also tolerate pressures up to 10,000 p.s.i., For analytical HPLC, 
the sample volume should be selectable from sub micro liter to a few micro liters, 
whereas in preparative HPLC the sample volume may be even greater than 10 ml. To 
maintain system efficiency the sample valve must be designed to have very low 
dispersion characteristics, this is true not only for flow dispersion but also for the less 
obvious problems of dispersion caused by sample adsorption/desorption on valve 
surfaces and diffusion of sample into and out of the mating surfaces between valve 
moving parts. It goes without saying that the valves must deliver a very constant 
sample size but this is usually attained by the use of a constant size sample loop. 
 
2.5 HPLC Columns 
HPLC columns are packed with very fine particles (usually a few microns in 
diameter). The very fine particles are required to attain the low dispersion that give 
the high plate counts expected of modern HPLC. Plate counts in excess of 25,000 
plates per column are possible with modern columns, however, these very high 
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efficiencies are very rarely found with real samples because of the dispersion 
associated with injection valves, detectors, data acquisition systems and the 
dispersion due to the higher molecular weight of real samples as opposed to the 
common test samples. Packing these small particles into the column is a difficult 
technical problem but even with good packing a great amount of care must be given 
to the column end fittings and the inlet and outlet connection to keep dispersion to a 
minimum. The main consideration with HPLC is the much wider variety of solvents 
and packing materials that can be utilized because of the much lower quantities of 
both which are required. In particular very expensive optically pure compounds can 
be used to make Chiral HPLC stationary phases and may even be used as (disposable) 
HPLC solvents. 
 
2.6 HPLC Detectors 
In order to give an accurate chromatographic profile the detector sampling (cell) 
volume must be a small fraction of the solute elution volume. If the detector volume 
were larger than the elution volume then you would have peaks that appeared with 
flat tops as the whole peak would be resident in the detector at the same time. This 
means that as column volumes decrease and system efficiencies increase the volume 
of the detector cell volume must also decrease. It is odds for the requirement for 
detector to maintain high sensitivity as this is usually dependant on having a larger 
cell volume. Again, this requires the very careful design of modern detectors. Many 
types of detectors can use with HPLC system like UV-Visible or PDA (Photo Diode 
Array), RI (Refractive Index), Fluorescence, ECD (Electro Chemical Detector), 
ELSD (Evaporative Light Scattering Detector), and many others hyphenated 
techniques like MS, MS/MS and NMR as well as evaporative IR. 
 
2.7 HPLC Data acquisition 
In HPLC data acquisition system the higher sampling rate needed for the rapidly 
eluting narrow peaks of the HPLC chromatogram. Although the theoretical number of 
samples needed for good quantization are actually quite small, for real systems a 
hundred samples or more per peak is recommended; thus, for a 4 sec wide peak, a rate 
of 25 samples per second may be required. The same data analysis and reporting 
software can be used as in ordinary LC. 
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2.8 Conclusion 
HPLC is probably the most universal type of analytical procedure; its application 
areas include quality control, process control, forensic analysis, environmental 
monitoring and clinical testing. In addition HPLC also ranks as one of the most 
sensitive analytical procedures and is unique in that it easily copes with multi-
component mixtures. It has achieved this position as a result of the constant evolution 
of the equipment used in LC to provide higher and higher efficiencies at faster and 
faster analysis times with a constant incorporation of new highly selective column 
packing. 
 
3.0 Effect of Variables on Column Efficiency 
A mathematical approximation of the behavior of chromatographic column efficiency 
is obtained from the Van Deemter equation: 
 
 
 
Where, H is the plate height, u is the linear velocity of the mobile phase,  
 A is the eddy diffusion term,   
 B is the longitudinal diffusion coefficient, and  
 C is the coefficient of the mass transfer term.  
 
The lower the value of H, the more efficient the column. The eddy diffusion term A, 
represents the multitude of pathways by which a component finds its way through the 
column. In a poorly packed column, the retention time for molecules of the same 
component can vary significantly depending on the numerous flow paths that could 
be taken. This effect results in band-broadening. The mobile phase velocity also 
affects the eddy diffusion parameter, and at moderate to high flow rates the zone-
broadening is greater. At low flow rates, the molecules of a component are not 
significantly dispersed by multi-channeling; diffusion averaging results in this case. 
The longitudinal diffusion term, B/U, describes a band-broadening process that is 
inversely related to the mobile phase velocity. The analyte is in the column for a 
shorter time when the flow rate is high; hence the diffusion term is less. In HPLC, this 
term is negligible since diffusion coefficients of liquids are very small relative to 
gases (as in GC). The mass transfer term, C·U, describes the time available for 
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equilibrium of an analyte to be established between the mobile and stationary phases. 
At high mobile flow rates there is less time for this equilibrium to take place and a 
contribution to the broadening effect is observed. 
 
3.1 Parameters affected by the changes in chromatographic conditions [8] 
a. Resolution (Rs), 
b. Capacity factor (k'), 
c. Selectivity (α ), 
d. Column efficiency (N) and 
e. Peak asymmetry factor (As). 
 
a. Resolution (Rs) 
Resolution is the parameter describing the separation power of the complete 
chromatographic system relative to the particular components of the mixture. The 
resolution, Rs, of two neighboring peaks is defined as the ratio of the distance 
between two peak maxima. It is the difference between the retention times of two 
solutes divided by their average peak width. For baseline separation, the ideal value 
of Rs is 1.5. It is calculated by using the formula, 
 
 
 
Where, Rt1 and Rt2 are the retention time of components 1 and 2 and W1 and W2 are 
peak width of components 1 and 2. There are three fundamental parameters that 
influence the resolution of a chromatographic separation: 
i. Capacity factor 
ii. Selectivity 
iii. Column efficiency 
 
b. Capacity Factor (k') 
Capacity factor is the ratio of the reduced retention volume to the dead volume. 
Capacity factor, k', is defined as the ratio of the number of molecules of solute in the 
stationary phase to the number of molecules of the same in the mobile phase. 
Capacity factor is a measure of how well the sample molecule is retained by a column 
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during an isocratic separation. The ideal value of k' ranges from 2-10. Capacity factor 
can be determined by using the formula, 
 
 
 
Where, V1 = retention volume at the apex of the peak (solute) and  
 V0 = void volume of the system.  
The values of k' of individual bands increase or decrease with changes in solvent 
strength. In reversed phase HPLC, solvent strength increases with the increase in the 
volume of organic phase in water/ organic mobile phase. Typically an increase in 
percentage of the organic phase by 10% by volume will decrease k' of the bands by a 
factor of 2-3. 
 
Adjusting capacity factor (k'): 
Good isocratic method usually have a capacity factor (k') in the range of 2 -10 
(typically 2 – 5). Lower values may give inadequate resolution. Higher values are 
usually associated with excessively broad peak and unacceptably long run time. If 
the shift in k' value is observed with both analyst and the column test solution, the 
problem is most likely due to change in column, temperature or mobile phase 
composition. This is true if the shift occurs gradually over series of run. 
 
Capacity factor (k') values are sensitive to: 
i. Solvent strength 
ii. Composition 
iii. Purity 
iv. Temperature 
v. Column chemistry 
vi. Sample 
 
c. Selectivity (α) 
The selectivity (or separation factor), is a measure of relative retention of two 
components in a mixture. Selectivity is the ratio of the capacity factors of both peaks, 
and the ratio of its adjusted retention times. Selectivity represents the separation 
power of particular adsorbent to the mixture of these particular components. This 
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parameter is independent of the column efficiency; it only depends on the nature of 
the components, eluent type, and eluent composition, and adsorbent surface 
chemistry. In general, if the selectivity of two components is equal to 1, then there is 
no way to separate them by improving the column efficiency. 
The ideal value of α is 2. It can be calculated by using formula, 
 
 
 
Where, V0 = the void volume of the column, 
V1 and V2 = the retention volumes of the second and the first peak respectively. 
 
Adjusting selectivity 
When troubleshooting changes in selectivity (α), the approach is similar to the 
approach used in the capacity factor. When selectivity (α) is affected, the 
corrective action depends on whether the problem is mobile phase or column 
related. Be sure to compare results obtained with the test solution to those 
observed when the column was new. 
Selectivity (α) values are sensitive to: 
i. Changes in mobile phase composition (pH ionic strength) 
ii. Purity 
iii. Temperature 
 
d. Column efficiency/ Band broadening 
Efficiency N, of a column is measured by the number of theoretical plates per meter. 
It is a measure of band spreading of a peak. Similar the band spread, higher is the 
number of theoretical plates, indicating good column and system performance. 
Column with N ranging from 5,000 to 1,00,000 plates/meter are ideal for a good 
system. Efficiency is calculated using the formula, 
 
 
 
Where, Rt is the retention time and  
 W is the peak width. 
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A decline in measured column efficiency may be due to  
i. Age and history of the column 
ii. Extra column band broadening  (such as due to malfunctioning injector or 
improper tubing id.) 
iii. Inappropriate detector setting 
iv. Change in flow rate and solvent viscosity 
 
You can recognize problems in your separation due to a loss of column efficiency 
when the width or shapes of all peaks are affected. 
 
Methods of measuring column efficiency (N) 
Method used for the measurement and calculation of column include (in order to 
sensitivity to abnormal peak shape): 
Asymmetry based (most sensitive to tailing or fronting) 
5 sigma 
4 sigma 
Tangent 
3 sigma 
½ height 
2 sigma (least sensitive to tailing or fronting) 
 
Chose the method that best suits your operating requirements. It is critical that 
the same method always be used and executed reproducibly. 
 
e. Peak asymmetry factor (As) 
Peak asymmetry factor, As, can be used as a criterion of column performance. The 
peak half width, b, of a peak at 10% of the peak height, divided by the corresponding 
front half width, a, gives the asymmetry factor. 
 
 
 
For a well-packed column, an asymmetry factor of 0.9 to 1.1 should be achievable. 
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4.0 Separation Mechanisms 
A useful classification of the various LC techniques is based on the type of 
distribution (or equilibrium) that is responsible for the separation. The common 
interaction mechanisms encountered in LC are classified as adsorption, partition, ion 
exchange, gel permeation or size exclusion, and chiral interaction. In practice, most 
LC separations are the result of mixed mechanisms. A brief description of the 
separation mechanisms is as under. 
 
4.1 Adsorption 
When the stationary phase in HPLC is a solid, the type of equilibrium between this 
phase and the liquid mobile phase is termed adsorption. All of the pioneering works 
in chromatography was based upon adsorption methods, in which the stationary phase 
is a finely divided polar solid that contains surface sites for retention of analyte. The 
composition of the mobile phase is the main variable that affects the partitioning of 
analyte. Silica and alumina are the only stationary phases used, the former being 
preferred for most applications. Applications of adsorption chromatography include 
the separation of relatively non-polar water-insoluble organic compounds. Because of 
the polar nature of the stationary phase and the impact of slight variations in mobile 
phase composition on the retention time, adsorption chromatography is very useful 
for the separation of isomers in a mixture. 
 
4.2 Partition 
The equilibrium between the mobile phase and a stationary phase comprising of 
either a liquid adsorbed on a solid or an organic species bonded to a solid is described 
as partition. The predominant type of separation in HPLC today is based on partition 
using bonded stationary phases. Bonded stationary phases are prepared by reaction of 
organochlorosilane with the reactive hydroxyl groups on silica. The organic 
functional group is often a straight chain octyl (C-8) or octyldecyl (C-18); in some 
cases a polar functional group such as cyano, diol, or amino may be part of the 
siloxane structure. Two types of partition chromatography may be distinguished, 
based on the relative polarities of the phases. When the stationary phase is polar and 
the mobile phase relatively less polar (nhexane, ethyl ether, chloroform), this type of 
chromatography is referred to as normalphase chromatography. For this reason, the 
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use of silica as the stationary phase (as in adsorption chromatography) is also 
considered to be a normal phase separation method. When the mobile phase is more 
polar than the stationary phase (which may be a C-8 or C- 18 bonded phase), this type 
of chromatography is called reversed-phase chromatography. Reversed-phase 
chromatography separations are carried out using a polar aqueous-based mobile phase 
mixture that contains an organic polar solvent such as methanol or acetonitrile. 
Because of its versatility and wide range of applicability, reversed-phased 
chromatography is the most frequently used HPLC method. Applications include 
nonionic compounds, polar compounds, and in certain cases ionic compounds. 
 
4.3 Ion-exchange 
Ion-exchange separations are carried out using a stationary phase that is an ion 
exchange resin. Packing materials are based either on chemically modified silica or 
on styrene-divinylbenzene copolymers, onto which ionic side groups are introduced. 
Examples of the ionic groups include (a) Sulfonic acid (strong cation exchanger), (b) 
Carboxylic acid (weak cation exchanger), (c) Quaternary ammonium groups (strong 
anion exchanger), and (d) Tertiary amine group (weak anion exchanger). The most 
important parameters that govern the retention are the type of counter-ion, the ionic 
strength, pH of the mobile phase, and temperature. Ion chromatography is the term 
applied for the chromatographic separation of inorganic anions/cations, low 
molecular weight organic acids, drugs, serums, preservatives, vitamins, sugars, ionic 
chelates, and certain organometallic compounds. The separation can be based on ion-
exchange, ion-exclusion effects, or ion pairing. Conductivity detectors in ion 
chromatography provide universal and sensitive detection of charged species. The 
employment of some form of ion-suppression immediately after the analytical column 
eliminates the limitation of high background signal from the mobile phase in 
conductivity detection. 
 
4.4 Size Exclusion 
High molecular weight solutes (>10,000) are typically separated using size exclusion 
chromatography – gel filtration or gel permeation. In size-exclusion LC, the 
components of a mixture are separated according to their ability to penetrate into the 
pores of the stationary phase material. Packing materials used are wide-pore silica 
gel, polysaccharides, and synthetic polymers like polyacrylamide or styrene-
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divinylbenzene copolymer. In gel filtration the mobile phase is aqueous and the 
packing material is hydrophilic, while in gel permeation an organic mobile phase is 
used and the stationary phase is hydrophobic. Size-exclusion applications include the 
separation of large molecular weight biomolecules, and molecular weight distribution 
studies of large polymers and natural products. For a homologous series of oligomers, 
the retention time (volume) can be related to the logarithm of the molecular mass. 
 
4.5 Chiral Interaction 
Chiral compounds or enantiomers have identical molecular structures that are non 
superposable mirror images of each other. Rapid and accurate stereo chemical 
resolution of enantiomers is a challenge in the field of pharmaceuticals and drug 
discovery. A chiral stationary phase contains one form of an enantiomeric compound 
immobilized on the surface of the support material. Typically, derivatives of optically 
active polysaccharides that are chemically bonded to silica form the packing material. 
A chiral separation is based on differing degrees of stereo chemical interaction 
between the components of an enantiomeric sample mixture and the stationary phase. 
 
 
5.0 Introduction to Gas Chromatography 
Gas chromatography - specifically gas-liquid chromatography - involves a sample 
being vapourised and injected onto the head of the chromatographic column. The 
sample is transported through the column by the flow of inert, gaseous mobile phase. 
The column itself contains a liquid stationary phase which is adsorbed onto the 
surface of an inert solid. 
 
 
Schematic diagram of a gas chromatograph 
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5.1 Instrumental components 
 
5.1.1 Carrier gas 
The carrier gas must be chemically inert. Commonly used gases include nitrogen, 
helium, argon, and carbon dioxide. The choice of carrier gas is often dependant upon 
the type of detector which is used. The carrier gas system also contains a molecular 
sieve to remove water and other impurities. 
 
5.1.1 Sample injection port 
For optimum column efficiency, the sample should not be too large, and should be 
introduced onto the column as a "plug" of vapor - slow injection of large samples 
causes band broadening and loss of resolution. The most common injection method is 
where a micro syringe is used to inject sample through a rubber septum into a flash 
vaporizer port at the head of the column. The temperature of the sample port is 
usually about 50C higher than the boiling point of the least volatile component of 
the sample. For packed columns, sample size ranges from tenths of a micro liter up to 
20 micro liters. Capillary columns, on the other hand, need much less sample, 
typically around 10-3 µL. For capillary GC, split/splitless injection is used. Have a 
look at this diagram of a split/splitless injector. 
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The injector can be used in one of two modes; split or splitless. The injector contains 
a heated chamber containing a glass liner into which the sample is injected through 
the septum. The carrier gas enters the chamber and can leave by three routes (when 
the injector is in split mode). The sample vapourises to form a mixture of carrier gas, 
vapourised solvent and vapourised solutes. A proportion of this mixture passes onto 
the column, but most exits through the split outlet. The septum purge outlet prevents 
septum bleed components from entering the column. 
 
5.1.3 Columns 
There are two general types of column, packed and capillary (also known as open 
tubular). Packed columns contain a finely divided, inert, solid support material 
(commonly based ondiatomaceous earth) coated with liquid stationary phase. Most 
packed columns are 1.5 - 10m in length and have an internal diameter of 2 - 4mm. 
Capillary columns have an internal diameter of a few tenths of a millimeter. They can 
be one of two types; wall-coated open tubular (WCOT) or support-coated open 
tubular (SCOT). Wall-coated columns consist of a capillary tube whose walls are 
coated with liquid stationary phase. In support-coated columns, the inner wall of the 
capillary is lined with a thin layer of support material such as diatomaceous earth, 
onto which the stationary phase has been adsorbed. SCOT columns are generally less 
efficient than WCOT columns. Both types of capillary column are more efficient than 
packed columns. 
 
In 1979, a new type of WCOT column was devised - the Fused Silica Open 
Tubular (FSOT) column: 
 
 
 
These have much thinner walls than the glass capillary columns, and are given 
strength by the polyimide coating. These columns are flexible and can be wound into 
coils. They have the advantages of physical strength, flexibility and low reactivity. 
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5.1.4 Column temperature 
For precise work, column temperature must be controlled to within tenths of a degree. 
The optimum column temperature is dependent upon the boiling point of the sample. 
As a rule of thumb, a temperature slightly above the average boiling point of the 
sample results in an elution time of 2 - 30 minutes. Minimal temperatures give good 
resolution, but increase elution times. If a sample has a wide boiling range, then 
temperature programming can be useful. The column temperature is increased (either 
continuously or in steps) as separation proceeds. 
 
5.1.5 Detectors 
There are many detectors which can be used in gas chromatography. Different 
detectors will give different types of selectivity. A non-selective detector responds to 
all compounds except the carrier gas, a selective detector responds to a range of 
compounds with a common physical or chemical property and a specific 
detector responds to a single chemical compound. Detectors can also be grouped 
into concentration dependant detectors and mass flow dependant detectors. The signal 
from a concentration dependant detector is related to the concentration of solute in the 
detector, and does not usually destroy the sample Dilution of with make-up gas will 
lower the detectors response. Mass flow dependant detectors usually destroy the 
sample, and the signal is related to the rate at which solute molecules enter the 
detector. The response of a mass flow dependant detector is unaffected by make-up 
gas. Have a look at this tabular summary of common GC detectors: 
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Detector Type Support gases Selectivity Detectability 
Dynamic 
range 
Flame 
Ionization 
(FID) 
Mass flow Hydrogen and air 
Most organic 
cpds. 100 pg 10
7 
Thermal 
Conductivity 
(TCD) 
Concentration Reference Universal 1 ng 107 
Electron 
Capture 
(ECD) 
Concentration Make-up 
Halides, 
nitrates, 
nitriles, 
peroxides, 
anhydrides, 
organometallics 
50 fg 105 
Nitrogen-
phosphorus Mass flow 
Hydrogen 
and air 
Nitrogen, 
phosphorus 10 pg 10
6 
Flame 
photometric 
(FPD) 
Mass flow 
Hydrogen 
and air 
possibly 
oxygen 
Sulphur, 
phosphorus, 
tin, boron, 
arsenic, 
germanium, 
selenium, 
chromium 
100 pg 103 
Photo-
ionization 
(PID) 
Concentration Make-up 
Aliphatics, 
aromatics, 
ketones, esters, 
aldehydes, 
amines, 
heterocyclics, 
some 
organometallics 
2 pg 107 
Hall 
electrolytic 
conductivity 
Mass flow Hydrogen, oxygen 
Halide, 
nitrogen, 
nitrosamine, 
sulphur 
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5.1.5.1 Flame Ionization Detector (FID) 
The detector is very sensitive towards organic molecules (10-12 g/s, linear range: 106 –
107), but relative insensitive to a few small molecules e.g. N2, NOx, H2S, CO, CO2, 
H2O. If proper amounts of hydrogen/air are mixed, the combustion does not afford 
any ions. If other components are introduced that contain carbon atoms cations are 
produced in the effluent stream. The more carbon atoms are in the molecule, the more 
fragments are formed and the more sensitive the detector is for this compound (-- > 
response factor). However, due to the fact that the sample is burnt (pyrolysis), this 
technique is not suitable for preparative GC. 
 
 
 
The effluent from the column is mixed with hydrogen and air, and ignited. Organic 
compounds burning in the flame produce ions and electrons which can conduct 
electricity through the flame. A large electrical potential is applied at the burner tip, 
and a collector electrode is located above the flame. The current resulting from the 
pyrolysis of any organic compounds is measured. FIDs are mass sensitive rather than 
concentration sensitive; this gives the advantage that changes in mobile phase flow 
rate do not affect the detector's response. The FID is a useful general detector for the 
analysis of organic compounds; it has high sensitivity, a large linear response range, 
and low noise. It is also robust and easy to use, but unfortunately, it destroys the 
sample.  
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5.1.5.2 Thermal Conductivity Detector (TCD)  
This detector is less sensitive than the FID (10-5-10-6g/s, linear range: 103-104), but is 
well suited for preparative applications, because the sample is not destroyed. It is 
based on the comparison of two gas streams, one containing only the carrier gas, the 
other one the carrier gas and the compound. Naturally, a carrier gas with a high 
thermal conductivity e.g. helium or hydrogen is used in order to maximize the 
temperature difference (and therefore the difference in resistance) between two thin 
tungsten wires. The large surface-to-mass ratio permits a fast equilibration to a steady 
state. The temperature difference between the reference cell and the sample cell 
filaments is monitored by a Wheatstone bridge circuit. 
 
5.1.5.3 Electron Capture Detector (ECD) 
The detector consists of a cavity that contains two electrodes and a radiation source 
that emits radiation (e.g. 63Ni, 3H). The collision between electrons and the carrier gas 
(methane plus an inert gas) produces plasma containing electrons and positive ions. If 
a compound is present that contains electronegative atoms, those electrons are 
“captured” and negative ions are formed, and the rate of electron collection decreases. 
The detector is extremely selective for compounds with atoms of high electron 
affinity (10-14 g/s), but has a relatively small linear range (~102-103). This detector is 
frequently used in the analysis of chlorinated compounds e.g. pesticides, 
polychlorinated biphenyls, which show are very high sensitivity. 
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6.0 Method Development 
Method development should be based on several considerations. It is preferable to 
have maximum sample information to make development fast and desired for 
intended analytical method application, physical and chemical properties are most 
preferable as primary information. Moreover, separation goal needs to define at 
beginning so; appropriate method can be developed for the purpose. An LC method 
development is very huge area for even pharmaceuticals with regulatory requirement 
of international standards. So, prior to method validation and usage at quality control 
many aspects need to focus as per ICH guideline. Method development can be based 
on sample and goal as well as available resources for chromatography but few basic 
steps for method development are can be discussed as below [9]. 
 
6.1 Steps in method development 
i. Sample information, define separation goals 
ii. Sample pretreatment, need of special HPLC procedure 
iii. Selection of detector and detector settings 
iv. Selection of LC method; preliminary run; estimate best separation 
conditions 
v. Optimize separation conditions 
vi. Check for problems or requirement for special procedure 
vii. Method validation 
 
6.2 Sample information 
i. Number of compounds present 
ii. Chemical structure of compounds 
iii. Chemical nature 
iv. Molecular weight of compounds 
v. pKa Value(s) of compounds 
vi. Sample solubility 
vii. Sample stability and storage 
viii. Concentration range of compounds in sample 
ix. UV spectra of compounds or properties for detection of compounds 
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7.0 Method Validation 
A developed analytical method for routine use needs to be validated as per ICH 
guideline for following validation parameters based on its intended application [10, 11]: 
 
Parameters of method development as per ICH Guide lines 
i. Specificity 
ii. Linearity & Range 
iii. Precision 
(A) Method precision / Repeatability 
(B) Intermediate precision / Ruggedness 
iv. Accuracy / Recovery 
v. Robustness 
vi. Solution stability 
vii. System suitability 
 
7.1 SPECIFICITY 
An investigation of specificity should be conducted during the validation of 
identification tests, the determination of impurities and the assay. The procedures 
used to demonstrate specificity will depend on the intended objective of the analytical 
procedure. It is not always possible to demonstrate that an analytical procedure is 
specific for a particular analyte (complete discrimination). In this case a combination 
of two or more analytical procedures is recommended to achieve the necessary level 
of discrimination. 
 
7.1.1 Identification 
Suitable identification tests should be able to discriminate between compounds of 
closely related structures which are likely to be present. The discrimination of a 
procedure may be confirmed by obtaining positive results (perhaps by comparison 
with a known reference material) from samples containing the analyte, coupled with 
negative results from samples which do not contain the analyte. In addition, the 
identification test may be applied to materials structurally similar to or closely related 
to the analyte to confirm that a positive response is not obtained. The choice of such 
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potentially interfering materials should be based on sound scientific judgment with a 
consideration of the interferences that could occur. 
 
7.1.2 Assay and Impurity Test(s) 
For chromatographic procedures, representative chromatograms should be used to 
demonstrate specificity and individual components should be appropriately labelled. 
Similar considerations should be given to other separation techniques. Critical 
separations in chromatography should be investigated at an appropriate level. For 
critical separations, specificity can be demonstrated by the resolution of the two 
components which elute closest to each other. In cases where a non-specific assay is 
used, other supporting analytical procedures should be used to demonstrate overall 
specificity. For example, where a titration is adopted to assay the drug substance for 
release, the combination of the assay and a suitable test for impurities can be used. 
The approach is similar for both assay and impurity tests: 
 
7.1.2.1 Impurities are available 
For the assay, this should involve demonstration of the discrimination of the analyte 
in the presence of impurities and/or excipients; practically, this can be done by 
spiking pure substances (drug substance or drug product) with appropriate levels of 
impurities and/or excipients and demonstrating that the assay result is unaffected by 
the presence of these materials (by comparison with the assay result obtained on 
unspiked samples). For the impurity test, the discrimination may be established by 
spiking drug substance or drug product with appropriate levels of impurities and 
demonstrating the separation of these impurities individually and/or from other 
components in the sample matrix. 
 
7.1.2.2 Impurities are not available 
If impurity or degradation product standards are unavailable, specificity may be 
demonstrated by comparing the test results of samples containing impurities or 
degradation products to a second well-characterized procedure e.g.: Pharmacopeial 
method or other validated analytical procedure (independent procedure). As 
appropriate, this should include samples stored under relevant stress conditions: light, 
heat, humidity, acid/base hydrolysis and oxidation. 
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 For the assay, the two results should be compared. 
 For the impurity tests, the impurity profiles should be compared. 
Peak purity tests may be useful to show that the analyte chromatographic peak is not 
attributable to more than one component (e.g., diode array, mass spectrometry). 
 
7.2 LINEARITY 
A linear relationship should be evaluated across the range (see section 3) of the 
analytical procedure. It may be demonstrated directly on the drug substance (by 
dilution of a standard stock solution) and/or separate weighings of synthetic mixtures 
of the drug product components, using the proposed procedure. The latter aspect can 
be studied during investigation of the range. 
 
Linearity should be evaluated by visual inspection of a plot of signals as a function of 
analyte concentration or content. If there is a linear relationship, test results should be 
evaluated by appropriate statistical methods, for example, by calculation of a 
regression line by the method of least squares. In some cases, to obtain linearity 
between assays and sample concentrations, the test data may need to be subjected to a 
mathematical transformation prior to the regression analysis. Data from the regression 
line itself may be helpful to provide mathematical estimates of the degree of linearity.  
 
The correlation coefficient, y-intercept, slope of the regression line and residual sum 
of squares should be submitted. A plot of the data should be included. In addition, an 
analysis of the deviation of the actual data points from the regression line may also be 
helpful for evaluating linearity. Some analytical procedures, such as immunoassays, 
do not demonstrate linearity after any transformation. In this case, the analytical 
response should be described by an appropriate function of the concentration 
(amount) of an analyte in a sample. For the establishment of linearity, a minimum of 
5 concentrations is recommended. Other approaches should be justified. 
 
7.3 RANGE 
The specified range is normally derived from linearity studies and depends on the 
intended application of the procedure. It is established by confirming that the 
analytical procedure provides an acceptable degree of linearity, accuracy and 
precision when applied to samples containing amounts of analyte within or at the 
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extremes of the specified range of the analytical procedure. The following minimum 
specified ranges should be considered: 
 For the assay of a drug substance or a finished (drug) product: normally from 
80 to 120 percent of the test concentration; 
 For content uniformity, covering a minimum of 70 to 130 percent of the test 
concentration, unless a wider more appropriate range, based on the nature of 
the dosage form (e.g., metered dose inhalers), is justified; 
 For dissolution testing: +/-20 % over the specified range; 
 e.g., if the specifications for a controlled released product cover a region from 
 20%, after 1 hour, up to 90%, after 24 hours, the validated range would be 0-
 110% of the label claim. 
 For the determination of an impurity: from the reporting level of an impurity1 
to 120% of the specification; 
 
For impurities known to be unusually potent or to produce toxic or unexpected 
pharmacological effects, the detection/quantitation limit should be commensurate 
with the level at which the impurities must be controlled. 
 
Note: for validation of impurity test procedures carried out during development, it 
may be necessary to consider the range around a suggested (probable) limit;  if assay 
and purity are performed together as one test and only a 100% standard is used, 
linearity should cover the range from the reporting level of the impurities to 120% of 
the assay specification. 
 
7.4 ACCURACY 
Accuracy should be established across the specified range of the analytical procedure. 
 
7.4.1 Assay 
7.4.1.1 Drug Substance 
Several methods of determining accuracy are available: 
(a) Application of an analytical procedure to an analyte of known purity (e.g. 
reference material); 
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(b) Comparison of the results of the proposed analytical procedure with those of a 
second well-characterized procedure, the accuracy of which is stated and/or 
defined (independent procedure, see 1.2.); 
(c) Accuracy may be inferred once precision, linearity and specificity have been 
established. 
 
7.4.1.2 Drug Product 
Several methods for determining accuracy are available: 
(a) Application of the analytical procedure to synthetic mixtures of the drug product 
components to which known quantities of the drug substance to be analyzed have 
been added; 
(b) In cases where it is impossible to obtain samples of all drug product components, 
it may be acceptable either to add known quantities of the analyte to the drug 
product or to compare the results obtained from a second, well characterized 
procedure, the accuracy of which is stated and/or defined (independent 
procedure, see 1.2.). 
(c) Accuracy may be inferred once precision, linearity and specificity have been 
established. 
 
7.4.2 Impurities (Quantitation) 
Accuracy should be assessed on samples (drug substance/drug product) spiked with 
known amounts of impurities. In cases where it is impossible to obtain samples of 
certain impurities and/or degradation products, it is considered acceptable to compare 
results obtained by an independent procedure (see 1.2.). The response factor of the 
drug substance can be used. It should be clear how the individual or total impurities 
are to be determined e.g., weight/weight or area percent, in all cases with respect to 
the major analyte. 
 
7.4.3 Recommended Data 
Accuracy should be assessed using a minimum of 9 determinations over a minimum 
of 3 concentration levels covering the specified range (e.g. 3 concentrations/3 
replicates each of the total analytical procedure). Accuracy should be reported as 
percent recovery by the assay of known added amount of analyte in the sample or as 
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the difference between the mean and the accepted true value together with the 
confidence intervals. 
 
7.5 PRECISION 
Validation of tests for assay and for quantitative determination of impurities includes 
an investigation of precision. 
 
7.5.1 Repeatability 
Repeatability should be assessed using: 
(a) A minimum of 9 determinations covering the specified range for the procedure 
(e.g. 3 concentrations/3 replicates each) or 
(b) A minimum of 6 determinations at 100% of the test concentration. 
 
7.5.2 Intermediate Precision 
The extent to which intermediate precision should be established depends on the 
circumstances under which the procedure is intended to be used. The applicant should 
establish the effects of random events on the precision of the analytical procedure. 
Typical variations to be studied include days, analysts, equipment, etc. It is not 
considered necessary to study these effects individually. The use of an experimental 
design (matrix) is encouraged. 
 
7.5.3 Reproducibility 
Reproducibility is assessed by means of an inter-laboratory trial. Reproducibility 
should be considered in case of the standardization of an analytical procedure, for 
instance, for inclusion of procedures in pharmacopoeias. These data are not part of 
the marketing authorization dossier. 
 
7.5.4 Recommended Data 
The standard deviation, relative standard deviation (coefficient of variation) and 
confidence interval should be reported for each type of precision investigated. 
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7.6 DETECTION LIMIT 
Several approaches for determining the detection limit are possible, depending on 
whether the procedure is a non-instrumental or instrumental. Approaches other than 
those listed below may be acceptable. 
 
7.6.1 Based on Visual Evaluation 
Visual evaluation may be used for non-instrumental methods but may also be used 
with instrumental methods. The detection limit is determined by the analysis of 
samples with known concentrations of analyte and by establishing the minimum level 
at which the analyte can be reliably detected. 
 
7.6.2 Based on Signal-to-Noise 
This approach can only be applied to analytical procedures which exhibit baseline 
noise. Determination of the signal-to-noise ratio is performed by comparing measured 
signals from samples with known low concentrations of analyte with those of blank 
samples and establishing the minimum concentration at which the analyte can be 
reliably detected. A signal-to-noise ratio between 3 or 2:1 is generally considered 
acceptable for estimating the detection limit. 
 
7.6.3 Based on the Standard Deviation of the Response and the Slope 
The detection limit (DL) may be expressed as: 
DL = 3.3 óS 
where  ó = the standard deviation of the response 
 S = the slope of the calibration curve 
The slope S may be estimated from the calibration curve of the analyte. The estimate 
of s may be carried out in a variety of ways, for example: 
 
7.6.3.1 Based on the Standard Deviation of the Blank 
Measurement of the magnitude of analytical background response is performed by 
analyzing an appropriate number of blank samples and calculating the standard 
deviation of these responses. 
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7.6.3.2 Based on the Calibration Curve 
A specific calibration curve should be studied using samples containing an analyte in 
the range of DL. The residual standard deviation of a regression line or the standard 
deviation of y-intercepts of regression lines may be used as the standard deviation. 
 
7.6.4 Recommended Data 
The detection limit and the method used for determining the detection limit should be 
presented. If DL is determined based on visual evaluation or based on signal to noise 
ratio, the presentation of the relevant chromatograms is considered acceptable for 
justification. 
In cases where an estimated value for the detection limit is obtained by calculation or 
extrapolation, this estimate may subsequently be validated by the independent 
analysis of a suitable number of samples known to be near or prepared at the 
detection limit. 
 
7.7 QUANTITATION LIMIT 
Several approaches for determining the quantitation limit are possible, depending on 
whether the procedure is a non-instrumental or instrumental.  
Approaches other than those listed below may be acceptable. 
 
7.7.1 Based on Visual Evaluation 
Visual evaluation may be used for non-instrumental methods but may also be used 
with instrumental methods. The quantitation limit is generally determined by the 
analysis of samples with known concentrations of analyte and by establishing the 
minimum level at which the analyte can be quantified with acceptable accuracy and 
precision. 
 
7.7.2 Based on Signal-to-Noise Approach 
This approach can only be applied to analytical procedures that exhibit baseline noise. 
Determination of the signal-to-noise ratio is performed by comparing measured 
signals from samples with known low concentrations of analyte with those of blank 
samples and by establishing the minimum concentration at which the analyte can be 
reliably quantified. A typical signal-to-noise ratio is 10:1. 
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7.7.3 Based on the Standard Deviation of the Response and the Slope 
The quantitation limit (QL) may be expressed as: 
QL = 10 óS 
 
Where ó = the standard deviation of the response 
S = the slope of the calibration curve 
 
The slope S may be estimated from the calibration curve of the analyte. The estimate 
of s may be carried out in a variety of ways for example: 
 
7.7.3.1 Based on Standard Deviation of the Blank 
Measurement of the magnitude of analytical background response is performed by 
analyzing an appropriate number of blank samples and calculating the standard 
deviation of these responses. 
 
7.7.3.2 Based on the Calibration Curve 
A specific calibration curve should be studied using samples, containing an analyte in 
the range of QL. The residual standard deviation of a regression line or the standard 
deviation of y-intercepts of regression lines may be used as the standard deviation. 
 
7.7.4 Recommended Data 
The quantitation limit and the method used for determining the quantitation limit 
should be presented. The limit should be subsequently validated by the analysis of a 
suitable number of samples known to be near or prepared at the quantitation limit. 
 
7.8 ROBUSTNESS 
The evaluation of robustness should be considered during the development phase and 
depends on the type of procedure under study. It should show the reliability of an 
analysis with respect to deliberate variations in method parameters. If measurements 
are susceptible to variations in analytical conditions, the analytical conditions should 
be suitably controlled or a precautionary statement should be included in the 
procedure. One consequence of the evaluation of robustness should be that a series of 
system suitability parameters (e.g., resolution test) is established to ensure that the 
validity of the analytical procedure is maintained whenever used. 
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Examples of typical variations are: 
 stability of analytical solutions, 
 extraction time 
 
In the case of liquid chromatography, examples of typical variations are 
 Influence of variations of pH in a mobile phase, 
 Influence of variations in mobile phase composition, 
 Different columns (different lots and/or suppliers), 
 Temperature, 
 Flow rate. 
 
In the case of gas-chromatography, examples of typical variations are 
 Different columns (different lots and/or suppliers), 
 Temperature, 
 Flow rate. 
 
7.9 SYSTEM SUITABILITY TESTING 
System suitability testing is an integral part of many analytical procedures. The tests 
are based on the concept that the equipment, electronics, analytical operations and 
samples to be analyzed constitute an integral system that can be evaluated as such. 
System suitability test parameters to be established for a particular procedure depend 
on the type of procedure being validated. See Pharmacopoeias for additional 
information. 
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Chapter 2: “Method Development and Validation for Assay of  
  Magnesium Valproate by Gas Chromatography” 
 
1.0 Introduction 
Various valproic acid salts have diverse biological activity specifically it is used as 
anticonvulsant medicine from last few decades. Presently this  work describes the 
analysis of magnesium salt of valproic acid through gas Chromatography and the 
same method of analysis can also applicable to Sodium, Calcium and Lithium 
valproate, all the valproate has explicit biologically activity. Few of them are included 
in pharmacopeia while others are under advance clinical trials.  
Magnesium Valproate is white or almost white hygroscopic crystalline powder, 
slightly soluble in water, freely soluble in heptane and methanol. The molecular 
weight of Magnesium Valproate is 310.71 g/mole with molecular formula of 
C16H30O4Mg and its dissociation constant (pKa) 4.6 reported, the melting point of  
Magnesium Valproate is 220°C and Flash point of the same 166.6°C. 
 
Magnesium Valproate is chemically known as Magnesium 2-propylpentanoate. 
Magnesium Valproate dissociates in the gastrointestinal tract and is absorbed into the 
circulation as magnesium ions and Valproic acid ions; Valproic acid may inhibit 
histone deacetylases, inducing tumor cell differentiation, apoptosis, and growth arrest. 
In addition, Valproic acid exerts an antiepileptic effect, likely by inhibiting enzymes 
that catabolize the inhibitory neurotransmitter gamma-amino butyric acid (GABA) 
catabolism and so increasing concentrations of GABA in the central nervous system 
(CNS). The presence of the magnesium in this agent may contribute to its 
anticonvulsant activity and sedative properties. As an anticonvulsant, used in the 
treatment of epilepsy and bipolar disorder, as well as other psychiatric conditions 
requiring the administration of a mood stabilizer. Rationale Valproic acid is a 
psychoactive drug currently used for the treatment of epilepsy. Recently it has been 
introduced in psychiatry for the treatment of bipolar disorders, aggression, 
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impulsivity, and resistant schizophrenia, although the mechanism by which VPA acts 
on these psychiatric diseases remains still unknown [1][2][3][4][5][6]. 
 
1.1 Impurity 
The process related major known impurities of magnesium valproate are Pentanoic 
Acid, 2-Ethyl Pentanoic acid, 2-(1-Methyl, ethyl) Pentanoic acid and Valeronitrile. 
Present work describes the conformation of all the four known impurities and 
quantification of magnesium valproate for assay determination. 
 
1.1.1 Impurities due to starting raw materials 
Two main raw materials are used for manufacturing are Diethyl malonate and n-
Propylbromide. The impurities are found in both the raw materials are as under 
 
1. Diethylmalonate :  
Ethyl alcohol     Trace Amount 
Mono ethyl ester     Trace Amount 
Malonic acid esters of higher alcohol  Trace Amount 
Ethyl cyano acetate    Trace Amount 
2. n-Propylbromide : 
n-Propanol     Trace Amount 
Iso-propylbromide    Trace Amount 
 
 
1.1.2 Self-elimination of impurities during manufacturing process 
According to route of synthesis, above two reacts in presence of sodium alkylate is 
affording esters, which is further hydrolyzed to prepare dipropylmalonic acid. During 
this process dialkylated impurity (from trace amount of, i.e. ethyl cyano acetate, and 
malonic acid esters of higher alcohols) are also subsequently hydrolyzed and get 
converted into desired product i.e. dipropyl malonic acid. So these impurities are may 
not be further extended in subsequent steps. Other probabilities of impurities are ∝-
propyl- ∝-isopropyl malonic acid and n-propylmalonic acid is reduced to minimum 
level by crystallizing intermediate-1, which is known compound as, mentioned 
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earlier. Further during the making of Valproic acid, presence of probable impurities 
and structures are summarized as under: 
 
 
and enantiomer 
 
 
A. R = R1 = H: pentanoic acid (valeric acid),  
B. R = H, R1 = CH2-CH3: (2RS)-2-ethylpentanoic acid,  
C. R = H, R1 = CH (CH3)2: (2RS)-2-(1-methylethyl) pentanoic acid,  
D. R = R1 = CH2-CH2-CH3: 2, 2-dipropylpentanoic acid,  
E. Others = Linear or branched aliphatic acid. 
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    2-Ethyl Pentanoic Acid       2-(1-Methyl, ethyl) Pentanoic Acid  
 
Figure 1: Chemical Structure of Magnesium Valproate and its related impurities 
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2.0 Literature Review 
The literature reviews concerning analytical method of magnesium valproate and its 
impurities, there is no method which describes the gas chromatographic quantification 
of magnesium valproate for the determination of assay either in bulk or in tablet 
formulation. However various analytical methods are reported for determination of 
Sodium Valproate and Valproic acid in pharmaceutical dosage as well as in biological 
matrix, which provides the important reference and the initiative information about 
the molecule behavior under various chromatographic conditions. Few of them are 
mentioning below. 
 
2.1 Runxi H, Caiping Y, Yuxi L have reported a method for Determination of 
magnesium and sodium valproates in serum by high   performance   liquid 
chromatography after precolumn derivatization, they derivetised both molecules by 2-
Bromo-4'-nitroacetophenone and the separation was achieved using reversed-phase 
C18 column (150 mm x 4.6 mm) and methanol-water (72:25v/v) as mobile phase. The 
UV detection was performed at 265 nm using Cyclohexane carboxylic acid as an 
internal standard. 
 
2.2 Lau-Cam CA, Roos RW have reported a HPLC   method with precolumn 
phenacylation for the assay of valproic   acid and its salts in pharmaceutical dosage 
forms. 
  
2.3 Shaofang Y, Huanian Z, Hua X Have reported a Capillary column gas   
chromatography determination of sodium   valproate in its tablets. The determination 
method of sodium valproate tablets was established by capillary column gas 
chromatography.  Sodium valproate was inverted into valproic acid at pH < 4.5, and 
was extracted and purified with ether.  Valproic acid was separated and identified on 
capillary column (15 m × 0.25 mm, 0.33 µm) by gas chromatography with the 
following conditions: the column temp. 180º C, split injection with the temperature of 
215º C, FID detector with the temperature of 215º C, carrier gas N2 at the flow rate of 
18 mL/min, air 150 mL/min, H2 62 mL/min, Makeup (N2) 10 mL/min.  The 
calibration curve was linear within the concentration range of 2-20 g/L, r=0.9998.  
The average recovery for valproic acid was 100.3%, 99.0% and 98.8%, with the RSD 
of 0.15%, 0.20% and 0.21%, respectively. 
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2.4 Acharya S, Pulluru S, Srinivasulu C and Raoutray H stability-indicating gas   
chromatography method for determination of divalproex sodium impurities in 
pharmaceutical preparation. A stability-indicating gas chromatographic method has 
been developed and validated for the quantitative determination of divalproex sodium 
impurities in pharmaceutical preparation. The chromatographic separation was 
performed on a fused silica capillary (Quadrex-FFAP, 30 m, 0.32 mm and 1 µm film 
thickness) column.  The method validation results indicate that the method is specific, 
accurate, linear, reproducible, rugged, and robust.  The effectiveness of the technique 
was demonstrated with stability sample analysis of divalproex sodium in its 
pharmaceutical preparation. 
  
2.5 Balbi A, Sottofattori E, Mazzei M and Sannita WG have reported High 
performance liquid chromatographic method for Study of bioequivalence of 
magnesium and sodium valproates.  
 
2.6 Manling H, Songling H and Bo X have reported method for determination of 
magnesium valproate in serum by gas chromatography. They have extracted the 
valproic acid by chloroform and cyclohexanecarboxylic acid used as an internal 
standard. 
 
2.7 Wiktor C and Beata H have  quantified the valproic acid and its salts using 
colorimetric method The method is based on the condensation of valproic chloride 
with 2,4-dinitrophenylhydrazine in an alkaline medium . 
 
Many Methods are available for determination of Sodium or Magnesium valproate by 
GC and HPLC in biological fluids [11] [12] [13] [14]. Some research papers describes the 
detection of valproate by refractive index detection and the fluorescence detection [15] 
[16] [17]. Few methods for determination for valproic acid are with photodiode array 
detection[19] and UV detection[20]. 
 
Overall, literature review suggests that there are many methods for analysis of 
valproic acid, valproic acid salts with or without derivatization by different regents. In 
addition some methods with different detection technique are easily available. But up 
to our knowledge no GC method reported for assay determination of magnesium 
Valproate. 
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3.0 Objective of Present Work 
The objective of this work is to develop a Gas Chromatographic method for assay of 
Magnesium Valproate in bulk formulation and to validate the method in accordance with 
ICH guidelines [21]. Though Valproic Acid and its Sodium salt is already included in 
various pharmacopoeias since long back, different kinds of methods are already available 
in pharmacopoeias for the determination of assay, purity and related substance. Aim of 
current work is to develop simple, precise, rapid and reliable Capillary Gas 
Chromatographic method for assay determination of Magnesium Valproate, Method 
which can easily separate Valproic Acid, its process impurities and its by-products with 
good resolution as most of the impurities and Valproic acid are eluting at the same time. 
Method is well applicable to Valproic Acid and its salts.  
 
The validation procedure followed the guidelines of USP 30 [22]. The method can be 
successfully used for assay of Magnesium Valproate in bulk and tablet formulation.  
 
 
4.0 Experimental 
 
4.1 Materials, Chemicals and Reagents 
Magnesium Valproate standards and working standards (label claim 99.92% pure) and 
were provided by the PARTH LABORATORIES PVT LTD, Rajkot, Gujarat, India. All 
chemical used were of analytical grade. HPLC-grade water and heptane was from 
Spectrochem Pvt. Ltd. (Mumbai, India).  Hydrochloric Acid (35%) and Sodium 
hydroxide (30% v/v) were from Ranbaxy fine chemicals (New Delhi, India). 
 
4.2 Instrumental 
The Chromatographic system used to perform development and validation of this 
assay method consisted of Shimadzu 2014 G.C. with Flame Ionization Detector and a 
manual injector (Shimadzu, Kyoto, Japan) connected to a multi-instrument data 
acquisition and data processing system, GC Solutions. 
 
4.3 Carrier Gas 
Helium (UHP) gas was used as carrier gas through out the work. 
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4.4 Diluent 
HPLC-grade Heptane was used as diluent through out the work. 
 
4.5 Preparation of Standard Solutions 
Dissolve 1.000 g of the Magnesium Valproate (WS) in 20 ml of water. Add 10 ml of 
dilute sulphuric acid and shake with 20 ml of heptane and allow to stand for 10 
minutes. Separate out the upper layers containing Valproic Acid and shake with pinch 
of anhydrous sodium sulphate. Filter and evaporate the filtrate, at a temperature not 
exceeding 30 °C, using a rotary evaporator. Take up the residue, accurately weigh 
0.250g of residue in 5 mL vol. flask and dilute up to the mark with diluent, shake well 
and pipette out 1mL of solution in to the 10 ml vol. flask and dilute up to the mark 
with diluent. 
 
4.6 Preparation of Test Solutions 
Dissolve 1.000 g of the Magnesium Valproate to be examined in 20 ml of water. Add 
10 ml of dilute sulphuric acid and shake with 20 ml of heptane and allow to stand for 
10 minutes. Separate out the upper layers containing Valproic Acid and shake with 
pinch of anhydrous sodium sulphate. Filter and evaporate the filtrate, at a temperature 
not exceeding 30 °C, using a rotary evaporator. Take up the residue, accurately weigh 
0.250g of residue in 5 mL vol. flask and dilute up to the mark with diluent, shake well 
and pipette out 1mL of solution in to the 10 ml vol. flask and dilute up to the mark 
with diluent. 
 
4.7 Chromatographic Condition 
   
GC   :  SHIMADZU 2014 
Column  :  BP-20, fused-silica capillary column 30m × 0.53mm, 
coated with wide-bore macrogol 20000,                         
2-nitroterephthalate (0.5µm) 
Detector   :  FID, 220º C 
Injector   :  Manual Injector, 220º C 
Column Flow  :  8.25 mL/minute 
Total Flow   :  36 mL/minute 
Purge Flow   :  3 mL/minute 
Split Ratio   :  3 
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4.8 Column Temperature Programming   
Rate (˚C/min) Temperature (˚C) Hold Time (min) 
- 80˚c 2 min. 
10 130˚c 10 min. 
 
 
5.0 Result and Discussion 
5.1 Development and Optimization of the Method 
Proper selection of the methods depends upon the nature of the sample (ionic or 
ionisable or neutral molecule) its molecular weight and solubility. Magnesium 
Valproate is freely soluble in methanol and heptane and sparingly soluble in water 
more over Gas Chromatographic method for it parent molecule, Valproic Acid is well 
acceptable by various pharmacopoeia. To develop a rugged and suitable GC method 
for the quantitative determination of Magnesium Valproate, the analytical condition 
were selected after testing the different parameters such as isocratic and gradient 
programming, initial temperature of the column, column flow, injection and detector 
temperature and other chromatographic conditions. Our preliminary trials using 
isocratic programming at 130˚ C did not give good resolution and method fail to 
separate some of the process impurities eluting just before the Magnesium Valproate 
as shown in figure 1 and 2. 
 
2.5 5.0 7.5 10.0 12.5 min
0.00
0.25
0.50
0.75
1.00
1.25
uV(x10,000,000)
 Chromatogram
 
 Fig 2: Chromatogram of trial run 
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2.5 5.0 7.5 10.0 12.5 min
-0.25
0.00
0.25
0.50
0.75
1.00
1.25
1.50
1.75
2.00
2.25
2.50uV(x10,000) Chromatogram
 
 Fig 3: Zoom view of trial run 
 
 
5.2 Specificity Study 
 
5.2.1 Chemical forced degradation 
Acidic degradation 
For acidic degradation study, dissolve 1.000 g of the Magnesium Valproate to be 
examined in 20 ml of water. Add 10 ml of dilute sulphuric acid, 20 ml of 0.1N HCl 
and reflux the content at 80˚ to 85˚c for 2 hours, allow cooling at room temperature 
and shake with 20ml of heptane, allow to stand for 10 minutes. Separate out the upper 
layers containing Valproic Acid and shake with pinch of anhydrous sodium sulphate. 
Filter and evaporate the filtrate, at a temperature not exceeding 30 °C, using a rotary 
evaporator. Take up the residue, accurately weigh 0.250g of residue in 5 mL vol. flask 
and dilute up to the mark with diluent, shake well and pipette out 1mL of solution in 
to the 10 ml vol. flask and dilute up to the mark with diluent. 
 
Alkali degradation  
For alkali degradation study, dissolve 1.000 g of the Magnesium Valproate to be 
examined in 20 ml of water. Add 10 ml of dilute sulphuric acid, 20 ml of 0.1N NaOH 
and reflux the content at 80˚ to 85˚c for 2 hours, allow to cool at room temperature 
and shake with 20ml of heptane, allow to stand for 10 minutes. Separate out the upper 
layers containing Valproic Acid and shake with pinch of anhydrous sodium sulphate. 
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Filter and evaporate the filtrate, at a temperature not exceeding 30° C, using a rotary 
evaporator. Take up the residue, accurately weigh 0.250g of residue in 5 mL vol. flask 
and dilute up to the mark with diluent, shake well and pipette out 1mL of solution in 
to the 10 ml vol. flask and dilute up to the mark with diluent. 
 
5.2.2 Physical forced degradation: 
 
Thermal degradation 
Thermal degradation was performed by exposing solid drug product at 110° C for 72 
hrs. After that weigh and dissolve 1.000 g of the Magnesium Valproate to be 
examined in 20 ml of water. Add 10 ml of dilute sulphuric acid and shake with 20 ml 
of heptane and allow to stand for 10 minutes. Separate out the upper layers containing 
Valproic Acid and shake with pinch of anhydrous sodium sulphate. Filter and 
evaporate the filtrate, at a temperature not exceeding 30 °C, using a rotary evaporator. 
Take up the residue, accurately weigh 0.250g of residue in 5 mL vol. flask and dilute 
up to the mark with diluent, shake well and pipette out 1mL of solution in to the 10 ml 
vol. flask and dilute up to the mark with diluent. 
 
Photolytic degradation 
Photolytic degradation study was performed by exposing the solid drug product to UV 
light for 24 hours. After that weigh and dissolve 1.000 g of the Magnesium Valproate 
to be examined in 20 ml of water. Add 10 ml of dilute sulphuric acid and shake with 
20 ml of heptane and allow to stand for 10 minutes. Separate out the upper layers 
containing Valproic Acid and shake with pinch of anhydrous sodium sulphate. Filter 
and evaporate the filtrate, at a temperature not exceeding 30 °C, using a rotary 
evaporator. Take up the residue, accurately weigh 0.250g of residue in 5 mL vol. flask 
and dilute up to the mark with diluent, shake well and pipette out 1 mL of solution in 
to the 10 ml vol. flask and dilute up to the mark with diluent. 
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5.2.3 Result of Forced Degradation study: 
 
Sr. No. Conditions used Reflux time Results 
1 0.1N HCl 2 hrs. No degradation 
2 0.1N NaOH 2 hrs. No degradation 
3 Light 24 hrs. No degradation 
4 Heat 110˚C, 3 days No degradation 
 
 
Fig 4: Chromatogram of acidic stress test preparation: 
 
 
 
Fig 5: Chromatogram of alkali stress test preparation: 
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Fig 6: Chromatogram of thermal stress test preparation: 
 
 
 
Fig 7: Chromatogram of photolytic stress test preparation: 
 
 
 
Conclusion: 
The above observations and data and suggests that Magnesium Valproate is quite 
stable compound when refluxed with acid or alkali and even when heated in oven for 
3 days at 110˚c or expose to UV light for 24 hrs in closed condition. 
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5.3 Linearity 
Seven points calibration curve were obtained by plotting concentration of Magnesium 
Valproate against peak area, in the concentration range 2000-8000 µg/mL (corresponded 
to 40% to 160%, respectively, of the test solution concentration) The regression equation 
was y= 39847x + 62325 where x is the concentration in µg/mL and y is the peak area in 
absorbance units; the correlation coefficient was 0.999. 
 
Preparation of solutions for linearity study: 
 
Linearity Level 1 (40%) 
0.4 ml of stock solution was pipette out and transferred into 10 ml volumetric flask. 
The solution was diluted to volume with diluent. The concentration obtained is about 
2000 µg/ml of Magnesium Valproate 
 
Linearity Level 2 (60%) 
0.6 ml of stock solution was pipette out and transferred into 10 ml volumetric flask. 
The solution was diluted to volume with diluent. The concentration obtained is about 
3000 µg/ml of Magnesium Valproate 
 
Linearity Level 3 (80%) 
0.8 ml of stock solution was pipette out and transferred into 10 ml volumetric flask. 
The solution was diluted to volume with diluent. The concentration obtained is about 
4000 µg/ml of Magnesium Valproate 
 
Linearity Level 4 (100%) 
1.0 ml of stock solution was pipette out and transferred into 10 ml volumetric flask. 
The solution was diluted to volume with diluent. The concentration obtained is about 
5000 µg/ml of Magnesium Valproate 
 
Linearity Level 5 (120%) 
1.2 ml of stock solution was pipette out and transferred into 10 ml volumetric flask. 
The solution was diluted to volume with diluent. The concentration obtained is 6000 
about µg/ml of Magnesium Valproate 
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Linearity Level 6 (140%) 
1.4 ml of stock solution was pipette out and transferred into 10 ml volumetric flask. 
The solution was diluted to volume with diluent. The concentration obtained is 7000 
about µg/ml of Magnesium Valproate 
 
Linearity Level 7 (160%) 
1.6 ml of stock solution was pipette out and transferred into 10 ml volumetric flask. 
The solution was diluted to volume with diluent. The concentration obtained is about 
8000 µg/ml of Magnesium Valproate 
 
 
Fig 8: Linearity curve for magnesium valproate 
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Fig 9: Chromatogram of 40% Linearity level: 
 
 
Fig 10: Chromatogram of 60% Linearity level: 
 
 
Fig 11: Chromatogram of 80% Linearity level: 
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Fig 12: Chromatogram of 100% Linearity level: 
 
 
 
Fig 13: Chromatogram of 120% Linearity level: 
 
 
 
Fig 14: Chromatogram of 140% Linearity level: 
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5.4 Limit of detection and Limit of quantitation study 
The limit of detection (LOD) and limit of quantification (LOQ) were evaluated by 
serial dilutions of Magnesium Valproate stock solution in order to obtain signal to 
noise ratio of 3:1 for LOD and 10:1 for LOQ. The LOD value for Magnesium 
Valproate was found to be 0.1 ppm and the LOQ value 0.4 ppm respectively. 
Chromatogram of LOQ and LOD study were shown in Fig. 15-16. 
 
Six replicate sample preparations were determined and standard deviation, % relative 
standard deviation was calculated to find out the reproducibility at LOQ level.  
 
 
Fig 15: Chromatogram of LOQ Preparation: 
 
 
Fig 16: Chromatogram of LOD Preparation: 
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5.5 Precision Study  
 
Precision study was established by evaluating method precision and intermediate 
precision study. 
 
System precision was evaluated by analyzing the standard solution five times. Method 
precision of the analytical method was determined by analyzing six sets of sample 
preparation. Assay of all six replicate sample preparations was determined and 
mean % assay value, standard deviation and % relative standard deviation was 
calculated. 
 
Intermediate precision of the analytical method was determined by performing 
method precision on another day by another analyst under same experimental 
condition. Assay of all six replicate sample preparations was determined and mean % 
assay value, standard deviation, % relative standard deviation was calculated. 
 
The result of repeatability and intermediate precision study are shown in Table-1. The 
developed method was found precise as the %RSD for the system precision was 
0.67% for method precision, on the same day (intraday) and 0.70% for intermediate 
precision on next day (interday). 
 
Table 2: Evaluation data of precision study 
Set No. Intraday (Day-1) Interday (Day-2) 
1 100.62 100.22 
2 100.44 100.38 
3 100.88 99.80 
4 99.43 99.73 
5 99.86 99.66 
6 100.25 100.33 
Mean 100.24 100.02 
SD 0.5280 0.3248 
%RSD 0.52 0.32 
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Fig 17: Chromatogram of standard preparation of method precision study: 
 
 
 
Fig 18: Chromatogram of test preparation (set 1) of method precision study: 
 
 
 
 
5.6 Accuracy Study 
Accuracy was assessed by determination of the recovery of the method at three different 
concentrations (corresponding to 50, 100 and 150% of test solution concentration) Known 
amounts of Magnesium Valproate (2500, 50000, and 7500 µg/ml) were added to a 
placebo preparation and the amount of Magnesium Valproate recovered, in the presence 
of placebo interference, was calculated. For each concentration, three sets were prepared 
and injected in duplicate. % Recovery was calculated at each level and recorded as shown in 
Table-x. The mean recovery of Magnesium Valproate was between 99.48 and 100.28%, 
which is satisfactory. 
Chapter 2      Magnesium Valproate 
 
       51 
Table 3: Summary for Added Amount 
Accuracy 
level Set. No. 
Wt. taken 
(in gms) Vol.-1 Vol.-2 Vol.-3 
Amount 
added 
µg/ml 
50% 
1 0.1252 5 1 10 2504 
2 0.1248 5 1 10 2496 
3 0.1246 5 1 10 2492 
100% 
1 0.2501 5 1 10 5002 
2 0.2500 5 1 10 5000 
3 0.2496 5 1 10 4992 
150% 
1 0.3750 5 1 10 7500 
2 0.3748 5 1 10 7496 
3 0.3747 5 1 10 7494 
 
Calculation: 
Volume
WeightmlmgAddedAmount =)/(  
 
Table 4: Summery for % Recovery 
Accuracy 
Level 
Amount 
added 
Amount 
found 
% 
Recovery Mean 
Standard 
dev. % RSD 
50% 
2504 2504.62 100.02 
100.28 0.45 0.45 2496 2496.31 100.01 
2492 2512.28 100.81 
100% 
5002 5003.45 100.02 
99.48 1.01 1.02 5000 4915.65 98.31 
4992 4998.12 100.12 
150% 
7500 7459.79 99.46 
99.54 0.16 0.16 7496 7454.46 99.44 
7494 7474.83 99.74 
 
ionConcentratStandard
AreaMean
AreaTestMean
mlmgFoundAmount ×=
Standard
)/(  
 
100
AddedAmount
FoundAmount
Recovery% ×=  
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Fig 19: Chromatogram of accuracy level-I (50 %): 
 
 
 
Fig 20: Chromatogram of accuracy level-II (100 %): 
 
 
 
Fig 21: Chromatogram of accuracy level-III (150 %): 
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 5.7 Robustness Study 
The robustness of the method was evaluated by assaying test solutions after slight but 
deliberate changes in the analytical conditions. The factor chosen for this study were the 
carrier gas flow rate (±1 mL/min), change in initial temperature of the column (±10˚c) 
and using different lot of GC column. 
Change in column flow 
In this parameter, analytical method was deliberately changed to flow rate of carrier gas. 
Sample was assayed by changing flow rate to 9.25 ml min-1 and 7.25 ml min-1 flow 
respectively. 
Fig 22: Chromatogram of test preparation at 9.25 ml/min flow rate: 
 
 
 
Fig 23: Chromatogram of test preparation at 7.25 ml/min flow rate: 
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Change in column temperature  
In this parameter, analytical method was deliberately changed to temperature. Sample was 
assayed by changing initial temperature of column from 80˚ C to 90˚ C (+10˚ C) and 
70˚c (-10˚ C) respectively. 
 
Fig 24: Chromatogram of test preparation at column temp. 90˚c 
 
Fig 25: Chromatogram of test preparation at column temp. 70˚c 
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Change in column lot 
In this parameter, column used in analytical method was changed to different lot. 
Sample was assayed by changing the lot of column (Part No.054440), keeping other 
conditions as such. 
Fig 26: Chromatogram of test preparation of column change parameter 
 
 
 
5.8 Solution stability Study 
The stability of the test solution was evaluated by two ways as short term stock 
solution stability (STSSS) for 12 hours & long term stock solution stability (LTSSS) 
for 12 days the solution was stored at room temperature and 2-5[degrees] C and tested 
at intervals of 12 hours & 12 days. The responses for the aged solution were evaluated 
using a freshly prepared standard solution. 
Table 5 shows the results obtained in the solution stability study at different time 
intervals for the test preparations. It was concluded that the test preparation solution 
was stable up to 12 hrs at room temp. And 12 days at 2˚-5˚C because during this time, 
the result did not decrease below the minimum percentage 
 
 
Chapter 2      Magnesium Valproate 
 
       56 
Table 5: Evaluation of solution study data 
Replicate 
STSSS (At RT) LTSSS (At 3-5ºC) 
0.0 hr(Area) 12.0 hr(Area) 0 DAY(Area) 12 DAY(Area) 
1 40561441 40621234 40635252 40664178 
2 40513412 40617451 40613472 40411136 
3 40646419 40713772 40773145 40560958 
4 40629145 40695518 40719242 40420968 
5 40497724 40721738 40400786 40776174 
Average 40569628 40673942 40628379 40566683 
Mean Area 
Ratio 0.9974 1.0015 
 
5.9 System Suitability Study 
A system suitability test for the chromatographic system was performed before 
each validation parameter. Five replicate injections of standard preparation were 
injected and Mean, Standard Deviation and % RSD of peak area were 
determined for same. 
 
Table 6: Summery of System suitability  
System suitability data Mean SD RSD (%) 
In-House limit - - NMT 2.0 
    
Linearity 40948951 187631 0.45 
LOD & LOD 41113931 190180 0.46 
Method Precision 40676288 273407 0.67 
Intermediate Precision 40779575 287533 0.70 
Accuracy 40531457 477979 1.179 
Solution stability 40665412 334072 0.86 
Robustness    
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6.0 Calculation and Data 
 
Calculation formula 
 
1.  Calculation formula for % assay  
 
potency
TestWeight
WeightStandard
AreaStandardMean
AreaTestMean
Assay ××××=
10
510
5
%  
 
 
2. Relative standard deviation  
 
100
tsMeasuremenofValueMean
tMeasuremenofDeviationStandard
RSD ×=
 
 s
%  
 
3. Recovery  
 
100
AddedAmount
FoundAmount
Recovery% ×=  
 
4. Amount Found  
 
ionConcentratStandard
AreaMean
AreaTestMean
mlmgFoundAmount ×=
Standard
)/(  
 
5. Amount added 
 
Volume
WeightmlmgAddedAmount =)/(  
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6.1 Observation and calculation for linearity study: 
Data for Standard Preparation 
Replicate Area 
1 40923214 
2 40977851 
3 41000917 
4 41181296 
5 40661479 
Mean 40948951 
SD 187631 
%RSD 0.45 
 
Data for Linearity Level Preparation: 
Linearity Level Replicate Area Mean Area 
Level-1 (40%) 
1 16057412 
16054626 
2 16051841 
Level-2 (60%) 
1 24633593 
24627526 
2 24621460 
Level-3 (80%) 
1 32487209 
32493683 
2 32500157 
Level-4 (100%) 
1 40984123 
40853740 
2 40723357 
Level-5 (120%) 
1 48928162 
48920830 
2 48913499 
Level-6 (140%) 
1 56908287 
56897364 
2 56886440 
Level-7 (160%) 
1 63334022 
63447738 
2 63561455 
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6.2 Observation and calculation for LOD & LOQ study: 
Data for Standard preparation 
Replicate Area 
1 41283354 
2 41096687 
3 40970995 
4 40891136 
5 41327485 
Mean 41113931 
SD 190180 
%RSD 0.46 
 
Data for LOQ preparation 
Replicate Area 
1 955586 
2 963910 
3 954747 
4 964602 
5 947781 
Mean 957325 
SD 7019 
%RSD 0.73 
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6.3 Observation and calculation for method precision study: 
Data for standard preparation: 
Replicate Area 
1 40731345 
2 40820783 
3 40687062 
4 40926697 
5 40215553 
Mean 40676288 
SD 273407 
%RSD 0.67 
 
Data for test preparations 
Set No. Replicate Area Mean area 
1 
1 41552148 
41013798 
2 40475448 
2 
1 40720575 
40841848 
2 40963121 
3 
1 41103147 
40975112 
2 40847077 
4 
1 40666659 
40590658 
2 40514656 
5 
1 40762178 
40836194 
2 40910211 
6 
1 40901421 
40912946 
2 40924471 
 
Prototype calculation for method precision set-1: 
 
potency
TestWeight
WeightStandard
AreaStandardMean
AreaTestMean
Assay ××××=
10
510
5
%  
88.99
10
5
2502.0
10
5
2500.0
40676288
41013798% ××××=Assay  
     = 100.62% 
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6.4 Calculation for intermediate precision study: 
Data for standard preparations: 
Replicate Area 
1 40786696 
2 40898209 
3 41006644 
4 40921578 
5 40284751 
Mean 40779575 
SD 287533 
%RSD 0.70 
 
Data for Test preparations: 
Set No. Replicate Area Mean area 
1 
1 40971101 
40942444 
2 40913787 
2 
1 40980933 
41016188 
2 41051444 
3 
1 40895723 
40917522 
2 40939322 
4 
1 40883591 
40840523 
2 40797456 
5 
1 40879010 
40891747 
2 40904483 
6 
1 40943121 
40919946 
2 40896771 
Prototype calculation for intermediate precision set-1: 
potency
TestWeight
WeightStandard
AreaStandardMean
AreaTestMean
Assay ××××=
10
510
5
%  
88.99
10
5
2501.0
10
5
2500.0
40779575
40942444% ××××=Assay  
    = 100.22% 
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6.5 Calculation for accuracy study: 
Data for Standard preparation 
 
Replicate Area 
1 40582979 
2 40714214 
3 40483274 
4 39783364 
5 41093452 
Mean 40531457 
SD 477979 
%RSD 1.17 
Data for test preparation: 
Accuracy Level Set No. Replicate Area Mean area 
50% 
1 
1 20312253 
20295115 
2 20277976 
2 
1 20206641 
20227749 
2 20248858 
3 
1 20324154 
20357143 
2 20390133 
100% 
1 
1 40581491 
40543242 
2 40504992 
2 
1 39222435 
39831785 
2 40441134 
3 
1 40523271 
40500082 
2 40476892 
150% 
1 
1 60541742 
60447091 
2 60352440 
2 
1 60446540 
60403914 
2 60361288 
3 
1 60611722 
60568936 
2 60526150 
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Prototype calculation for set-1: 
 
Amount added 
 
3
2
1 −
−×
−
=
Vol
Vol
Vol
WeightAddedAmount  
10
1
5
1252.0 ×=AddedAmount  = 0.002504gm/ml = 2504µg/ml 
 
Amount Found  
 
ionConcentratStandard
AreaMean
AreaTestMean
FoundAmount ×=
Standard
 
5001.9FoundAmount ×=
40531457
20295115
= 2504.62 µg/ml 
 
% Recovery  
100
AddedAmount
FoundAmount
Recovery% ×=  
100
2504.62
2504Recovery% ×= = 100.02% 
Chapter 2      Magnesium Valproate 
 
       64 
6.6 Calculation for robustness study: 
 
6.6.1 Calculation for flow change parameter of Robustness study: 
 
Data for standard preparation: 
[Flow Rate 9.25mL/min] 
Replicate Area 
1 35178943 
2 35094011 
3 35282701 
4 35242354 
5 35104211 
Mean 35180444 
SD 83026 
%RSD 0.23 
 
Calculation for flow rate 9.25: 
potency
TestWeight
WeightStandard
AreaStandardMean
AreaTestMean
Assay ××××=
10
510
5
%  
88.99
10
5
2503.0
10
5
2499.0
35180444
35090057% ××××=Assay  
= 99.46% 
Data for test preparation: 
[Flow Rate 9.25mL/min] 
Replicate Area 
1 35064401 
2 35115713 
Mean 35090057 
Std wt. 0.2499 
Test wt 0.2503 
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Data for standard preparation: 
[Flow Rate 7.25mL/min] 
 Replicate Area 
1 49395054 
2 48561473 
3 48610950 
4 48424200 
5 49400505 
  
AVG 48878437 
SD 479008 
%RSD 0.97 
 
Calculation for flow rate 7.25: 
potency
TestWeight
WeightStandard
AreaStandardMean
AreaTestMean
Assay ××××=
10
510
5
%  
88.99
10
5
2511.0
10
5
2499.0
48878437
48785336% ××××=Assay  
= 99.20% 
 
Data for test preparation: 
[Flow Rate 7.25mL/min] 
Replicate Area 
1 48450575 
2 49120097 
  
Mean 48785336 
Std wt. 0.2499 
Test wt 0.2511 
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6.6.2 Calculation column temp. change parameter of Robustness study: 
 
Data for standard preparation: 
[Column initial temp. 90˚c] 
Replicate Area 
1 40445621 
2 40254167 
3 40671250 
4 39997821 
5 40103719 
Mean 40294516 
SD 269638 
%RSD 0.66 
 
Calculation for column initial temp 90º C: 
potency
TestWeight
WeightStandard
AreaStandardMean
AreaTestMean
Assay ××××=
10
510
5
%  
88.99
10
5
2490.0
10
5
2499.0
40294516
39570610% ××××=Assay  
= 98.44% 
Data for test preparation: 
[Column initial temp. 90˚c] 
Replicate Area 
1 39317073 
2 39824147 
Mean 39570610 
Std wt. 0.2499 
Test wt 0.2490 
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Data for standard preparation: 
[Column initial temp. 70˚c] 
Replicate Area 
1 35241818 
2 35367415 
3 35760987 
4 34997921 
5 35036135 
Mean 35280855 
SD 308010 
%RSD 0.87 
 
 
Calculation for column initial temp 70º C: 
potency
TestWeight
WeightStandard
AreaStandardMean
AreaTestMean
Assay ××××=
10
510
5
%  
88.99
10
5
2505.0
10
5
2499.0
35280855
35303480% ××××=Assay  
= 99.70% 
Data for test preparation: 
[Column initial temp. 70˚c] 
Replicate Area 
1 35235718 
2 35371241 
Mean 35303480 
Std wt. 0.2499 
Test wt 0.2505 
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Data for standard preparation: 
[Column change] 
Replicate Area 
1 41551147 
2 40913348 
3 40887150 
4 41375163 
5 40984627 
Mean 41142287 
SD 301563 
%RSD 0.73 
 
Calculation for column change: 
potency
TestWeight
WeightStandard
AreaStandardMean
AreaTestMean
Assay ××××=
10
510
5
%  
88.99
10
5
2508.0
10
5
2499.0
41142287
40916877% ××××=Assay  
= 98.98% 
Data for test preparation:  
[Column change] 
Replicate Area 
1 40942587 
2 40891168 
Mean 40916877 
Std wt. 0.2499 
Test wt. 0.2508 
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Chapter 3: “Development and Validation of Stability-Indicating RP-
  HPLC Method of Rosuvastatin calcium for its Assay and 
  Content Uniformity in Tablets dosage form” 
 
 
1.0 Introduction to Rosuvastatine Calcium 
Rosuvastatin calcium is, chemically, bis [(E)-7[4-(4-fluorophenyl)-6 isopropyl-2-
[methyl (methyl-sulphonyl) amino] pyrimidin-5-yl] (3R, 5S) -3, 5-dihydroxyhept-6-
enoic acid] calcium salt. Molecular formula of Rosuvastatine Calcium is 
(C22H27FN3O6S)2Ca having molecular weight 1001.14 g/mole. Its melting point is 
122º C [1][2]. 
 
Rosuvastatin Calcium is lipid lowering drug and use to prevent. It inhibits the enzyme 
3-hydroxy-3-methyl glutaryl coenzyme A (HMG-CoA) reductage, the rate limiting 
enzyme that converts HMG-CoA to mevalonate a precursor of cholesterol and thereby 
checks the synthesis of cholesterol. It is used in the treatment of hyper-
cholesterolemia and dyslipidemia[2][3][4][5]. 
 
 
 
Chemical Structure of Rosuvastatine Calcium 
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1.1 Pharmaceutical aspects 
Rosuvastatin tablets containing of Rosuvastatine Calcium available in different 
strengths as of Rosuvastatine base they are 5 mg, 10 mg, 20 mg, 40 mg and 120mg as 
an active ingredient 
 
1.2 Pharmacology 
Rosuvastatin is a selective and competitive inhibitor of HMG-CoA reductase, the 
enzyme responsible for the conversion of HMG-CoA to mevalonate, and decreases 
hepatic biosynthesis of cholesterol. As a result, hepatocytes compensate by increasing 
the number of LDL surface receptors to increase LDL reuptake from the circulation. 
This process reduces the serum LDL concentration. 
 
Rosuvastatin is synthetically produced to contain a unique methylsulfonamide group 
(sulfone) with high affinity for HMG-CoA reductase. This sulfone group creates an 
additional polar bond with the side chain Arg of HMG-CoA, which gives 
Rosuvastatin the highest affinity for HMG-CoA reductase among all marketed statins. 
In addition, this extra sulfone group increases the hydrophilicity of Rosuvastatin. The 
statin octanol-water coefficient for Rosuvastatin is -0.33 log D at pH 7.4, compared 
with -0.84 for pravastatin and between 1.0 and 2.0 for simvastatin, atorvastatin, and 
fluvastatin (where octanol coefficients < 1 indicate hydrophilicity). Hydrophilic drug 
distribution is primarily limited to hepatocytes; therefore, peripheral concentrations 
are decreased. Studies in rats show that, after the intravenous administration of 
Rosuvastatin, uptake clearance is highest in hepatocytes compared with renal tissue 
and other tissues (0.9, 0.2, and ≤ 0.2 ml/min, respectively).  
 
1.3 Pharmacokinetics 
After oral administration, the absolute bioavailability of Rosuvastatin is 20%, and 
peak plasma concentrations are reached in 3-5 hours. The peak concentration (Cmax) 
and the area under the plasma concentration-time curve (AUC) of Rosuvastatin 
increase in a dose-dependent manner. Plasma concentrations and LDL reductions do 
not differ significantly when Rosuvastatin is administered with or without food or in 
the morning or evening. At steady state, the mean volume of distribution of 
Rosuvastatin is approximately 134 L, and the elimination half-life is approximately 19 
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hours.  Rosuvastatin is excreted primarily in the feces. It is not metabolized by means 
of cytochrome P450 (CYP) 3A4, but it is minimally metabolized in the CYP2C9 
isoenzyme pathway and to lesser extent in the CYP2C19 isoenzyme pathway. In 
addition, rosuvastatin does not have any inhibitory or inducing effects on the CYP 
system. Results of animal and human studies have also suggested that glucuronidation 
may be an additional metabolic pathway for statins, including rosuvastatin. About 
10% of a dose is metabolized to N-desmethylrosuvastatin in the CYP2C9 pathway, 
which has one sixth to one half the HMG-CoA reductase inhibition of rosuvastatin. 
Therefore, rosuvastatin accounts for more than 90% of the inhibition of plasma HMG-
CoA reductase.  
 
Age and sex do not affect the pharmacokinetic profile of rosuvastatin. In addition, no 
pharmacokinetic differences have been observed among Caucasian, Hispanic, and 
African-American or African-Caribbean populations. A 2-fold increase in the AUC of 
rosuvastatin has been observed in Japanese subjects residing in Japan and in Chinese 
subjects in Singapore compared with Caucasian subjects in North America and in 
Europe. A potential explanation for this effect may be a decrease in hepatic 
metabolism of rosuvastatin by means of the CYP2C19 pathway. Data suggest that as 
many as 30% of East Asians are poor metabolizers in terms of CYP2C19 isoenzyme. 
However, increased drug toxicity is usually observed only with drugs that are 
extensively metabolized in this pathway.  
 
Rosuvastatin is minimally eliminated in the urine; therefore, plasma concentrations 
were not altered in patients with mild-to-moderate renal impairment (creatinine 
clearance 8E 30 ml/min/1.73 m2) after the oral administration of Rosuvastatin 20 mg 
for 14 days. Plasma concentrations increased approximately 3-fold when Rosuvastatin 
was administered to patients with severe renal impairment (creatinine clearance < 30 
ml/min) compared with healthy subjects. Plasma concentrations also increased by 
approximately 50% in patients receiving hemodialysis compared with healthy 
volunteers. Results from A Study Evaluating the Use of Rosuvastatin in Patients 
Requiring Ongoing Renal Dialysis (AURORA) may explain this effect. 
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Patients with alcohol-induced Child-Pugh A hepatic disease taking Rosuvastatin had 
an increased Cmax and AUC of approximately 60% and 5%, respectively, compared 
with patients with normal hepatic function. In patients with alcohol-induced Child-
Pugh B hepatic disease, Cmax and AUC increased by approximately 100% and 21%, 
respectively.   
 
 
2.0 Literature Review 
 
2.1 Sankar DG,  Babu PJ, Kumar AB, Vamsi KM have developed RP- HPLC   
method for the estimation of Rosuvastatin   calcium in bulk and pharmaceutical 
dosage forms. The separation was achieved on a reversed phase C18 column (4.6 mm 
x 250 mm, 5 µm) using with a mobile phase comprising of water and acetonitrile (pH 
3.0 adjusted with phosphoric acid) in the ratio of (48: 52 vol./vol.) containing 0.30% 
of triethylamine. The mobile phase was pumped at a flow rate of 1 mL/min with UV 
detection at 245 nm.  The calibration curve was linear in the range of 5.0-30 µg/mL 
with a coefficient of correlation 0.9999. 
 
2.2 Guiqin L, Changjiang M, Liyun Z, Guangcai N, Jichu Y have developed 
method for analysis of Rosuvastatin   calcium’s diastereomer. The diastereomer of 
Rosuvastatin calcium was prepared by acid dissolved method, and its structure was 
confirmed by LC-MS method.  The HPLC method for analyzing Rosuvastatin 
calcium and diastereomer was established.  The chromatog column of Kromasil C18 
(4.6 mm x 250 mm, 5 µm) was used.  The mobile phase consisted of water-methanol-
acetonitrile (60:10:30, adjusted to pH 3.5 by glacial acetic acid).  The flow rate was 
1.0 mL/min-1. The detection wavelength was 242 nm.  The temperature of column 
was controlled at 30˚c. This method could separate Rosuvastatin calcium and 
diastereomer, and it was confirmed that the isomer was diastereomer by LC-MS 
method. 
 
2.3 Pereira GF, Lopez GP, Porto AM, Singh AK, Hackmann K, Erika R have 
developed and validate HPLC method for simultaneous determination of 
determination pravastatin sodium (PS), fluvastatin sodium (FVS), atorvastatin 
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calcium (ATC), and Rosuvastatin calcium (RC) in pharmaceuticals.  Two stability-
indicating HPLC methods were developed with a small change (10%) in the 
composition of the organic modifier in the mobile phase.  The HPLC method for each 
statin was validated using isocratic elution.  An RP-18 column was used with mobile 
phases consisting of methanol-water (60:40, vol./vol., for PS and RC and 70:30, 
vol./vol., for FVS and ATC).  The pH of each mobile phase was adjusted to 3.0 with 
orthophosphoric acid, and the flow rate was 1.0 mL/min.  Calibration plots showed 
correlation coefficients  (r) > 0.999, The detection limit (DL) and quantitation limit 
(QL) were 1.22 and 3.08 µg/mL for PS, 2.02 and 6.12 µg/mL for FVS, 0.44 and 1.34 
µg/mL for ATC, and 1.55 and 4.70 µg/mL for RC. The methods were applied 
successfully for quant. determination of statins in pharmaceuticals. 
 
2.4 Gupta A, Mishra P, Shah K have developed UV spectrophotometric method for 
determination of Rosuvastatin calcium in pure form and in pharmaceutical 
formulations. Rosuvastatin exhibits absorption maxima at 244 nm with apparent 
molar absorptivity of 7.2345-104 L/mol/cm in methanol.  Beer's law was found to be 
obeyed in the concentration range of 2-18 µg/mL.  The method is accurate, precise 
and economical. This method is extended to pharmaceutical preparations.  In this 
method, there is no interference from any common pharmaceutical additives and 
diluents.  Results of the analysis were validated statistically and by recovery studies. 
 
2.5 Rajkondawar VV  has developed and validate method for Simultaneous 
estimation of  Rosuvastatin  and ezetimibe by reverse phase high performance liquid 
chromatography using a mobile phase consisting 0.05 M potassium dihydrogen 
phosphate and acetonitrile in the ratio of 55: 45 at a flow rate 1.0 mL/min.  A Zorbax 
XDB 150 x 4.6 mm, C18 column was used as a stationary phase.  Quantification was 
performed using UV detector at 235 nm. 
 
2.6 Sankar DG, Babu PJ, Kumar AB, Latha, PM have developed a simple and 
sensitive UV spectrophotometric method for the determination. of gefitinib (GFB) 
and Rosuvastatin calcium (RSV) in bulk and pharmaceutical formulations.  These 
compounds had max absorption (λmax) at 264 nm for GFB and 258 nm for RSV and 
both the methods obeyed Beer's law in the concentration range 5-25 µg/mL.  The 
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methods were accurate and precise and were extended to pharmaceutical formulations 
and there was no interference from any common pharmaceutical additives and 
excipients. The results of the analysis were validated statistically and by recovery 
studies. 
 
2.7 Sane RT, Kamat SS, Menon SN, Inamdar SR, Mote MR have developed 
method for determination of  Rosuvastatin Calcium  in its bulk drug and 
pharmaceutical preparations by high-performance thin-layer chromatography. A 
normal-phase TLC method was established for the estimation of Rosuvastatin calcium 
in its bulk drug and pharmaceutical formulations. Analysis was performed in a Camag 
twin-trough chamber on silica gel 60F254 HPTLC plates. Aceclofenac was used as 
internal standard. The optimized mobile phase was toluene-methanol-Et acetate-
formic acid, 6.0 + 1.0 + 3.0 + 0.1 (vol./vol.).  Quantitation was performed 
densitometrically at 265 nm. A good correlation coefficient (r2 = 0.9999) was 
obtained for the linearity for amts. of sample in the range 1.0 to 15.0 µg.   
 
2.8 Uyar B, Celebier M, Altinoz S have developed method for Spectrophotometric 
determination of Rosuvastatin calcium in tablets. The solutions of standard and 
pharmaceutical samples were prepared in methanol. 243 nm was chosen for 
measuring absorbance of Rosuvastatin calcium.  The developed method was validated 
with respect to linearity range, limit of detection and quantitation, accuracy, precision, 
specificity and ruggedness. The linearity range of the method was 1.0-60.0 mL (-1). 
The limit of detection was 0.33 µg mL(-1).  The developed and validated method was 
applied to the determination of Rosuvastatin calcium in pharmaceutical preparations. 
Chapter 3   Rosuvastatin calcium 
77 
 
3.0 Aim of Present Work 
 
The objective of this work was to develop a stability-indicating liquid chromatographic 
method of Rosuvastatin calcium for its assay and content uniformity in tablet formulation 
and to validate the method in accordance with ICH guidelines. 
 
There are few method reported in the literature for analysis of Rosuvastatin calcium in 
the pure form and pharmaceuticals formulation by UV- spectrophotometer [6]. 
Reversed phase HPLC and High performance thin layer chromatography (HPTLC) [7] 
[8] [9] [10] But HPLC method has many advantages over HPTLC method for 
quantitation. Moreover, HPLC is often the first choice of chromatographers compared 
to HPTLC. The pharmaceuticals and bioequivalence of Rosuvastatin capsules by high 
performance liquid chromatographic mass spectrometric method also reported [11]. 
There are no reports of methods for study of the effect of stress on pharmaceutical 
dosage forms and there is no validated HPLC method, which enable both assay and 
determination of content uniformity of Rosuvastatin calcium in pharmaceuticals 
dosage forms.   
 
The validation procedure followed the guidelines of ICH and USP 32 [12] [13]. The method 
was successfully used for assay of Rosuvastatin calcium and determination of the content 
uniformity of the tablet formulation. Determination of content uniformity is, nowadays, 
an important analytical tool and also included in U.S. Pharmacopoeia [12]. 
 
4.0 Experimental 
 
4.1 Chemicals and Reagents 
Rosuvastatin calcium reference standard (label claim 99.8% pure) was provided by the 
Glenmark Pharma, Ankleshwar, India. The pharmaceutical dosage form of Rosuvastatin 
calcium, Zyrova tablets, a formulation with a 10 mg label claim, was manufactured by 
Zydus cadila, Ahmedabad, India. Hydrochloric acid (35%), orthophosphoric acid (88%), 
Sodium hydroxide pellets and 30% (v/v) hydrogen peroxide solution both analytical-
grade, were from Ranbaxy Fine Chemicals (New Delhi, India). acetonitrile and water, 
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both HPLC-grade, were from Spectrochem Pvt. Ltd. (Mumbai, India). Nylon syringe 
filters (0.45 µm) were from Millex-HN, Millipore (Mumbai, India). 
 
4.2 Instrumental 
The chromatographic system used to perform development and validation of this 
assay method consisted of an LC-10ATvp binary pump, an SPD-M10Avp photodiode 
array detector and a rheodyne manual injector model 7725i with 20μl loop (Shimadzu, 
Kyoto, Japan) connected to a multi-instrument data acquisition and data processing 
system (Class-VP 6.13 SP2, Shimadzu). 
 
4.3 Mobile Phase Preparation 
The mobile phase consist of acetonitrile and water (pH 3.5 adjusted with ortho-
phosphoric acid) in the ratio of (40:60, v/v). Mobile phase was degassed by 
sonication with an ultrasonic bath. 
 
4.4 Diluent Preparation 
Mixed both the solvents Acetonitrile : Water, 50:50. 
 
4.5 Preparation of stock and standard solutions: 
Stock solution (500 µg/ml) of rosuvastatin calcium reference standard was pre-
pared by transferring 25 mg, accurately weighed, into a 50 ml volumetric flask and adding 
20 ml water- acetonitrile (50:50, v/v). The mixture was sonicated for 2 min to dissolve 
the rosuvastatin calcium and the solution was then diluted to volume with the same 
solvent mixture. Standard solution (50 µg/ml) was prepared by diluting 5 ml standard 
stock solution to 50 ml, in a volumetric flask, with the same solvent mixture. 
 
4.6 Preparation of stock and test solutions: 
To prepare stock solution (500 µg/ml) for assay, 20 tablets were weighed and mixed. An 
aliquot of powder equivalent to the weight of 5 tablets was accurately weighed and 
transferred to 100 ml volumetric flask. Water- acetonitrile (50:50, v/v), 60 ml was added 
to the flask and the mixture was sonicated for 10 min with normal hand shaking. The 
contents of the flask were then left to return to room temperature and diluted to volume 
with the same solvent mixture. This solution (10 ml) was filtered through a 0.45-µm 
nylon syringe filter. 
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To prepare test solution (50 µg/ml) for assay 5 ml test stock solution was transferred to 50 
ml volumetric flask and diluted to volume with water-acetonitrile (50:50, v/v). 
 
To prepare test solution (50 µg/ml) for determination of content uniformity one tablet 
was accurately weighed and transferred to a 200-ml volumetric flask. Water- acetonitrile 
(50:50, v/v) 100 ml was added to the flask and the mixture was sonicated for 10 min 
with normal hand shaking. The contents of the flask were left to return to room 
temperature, then diluted to volume with the same solvent mixture and filtered through 
a 0.45µm nylon syringe filter. Twenty tablets were weighed and the average weight of a 
tablet was used for assay calculation.  
 
4.7 Chromatographic Condition 
Chromatographic analysis was performed on YMC C8 (150mm × 4.6mm id, 5 µm 
particle size) column. The mobile phase consisted of acetonitrile and water (pH 3.5 
adjusted with phosphoric acid) in the ratio of (40:60, v/v). The flow rate was 1.5 
mL/min, column temperature 25°C, the injection volume was 20 µL, and detection was 
performed at 242 nm using a photodiode array detector (PDA). 
 
 
5.0 Result and Discussion 
 
5.1 Development and Optimization of the HPLC method 
Selection of method depends upon nature of the sample, its molecular weight and 
solubility. Rosuvastatine Calcium can be easily extracted from the pharmaceutical 
dosage form by using of water-acetonitrile (50:50, v/v). The tablet dispersed readily in 
mobile phase as Rosuvastatine is freely soluble in acetonitrile. 
 
To develop a rugged and suitable method for quantitative determination of 
Rosuvastatine, the analytical conditions were selected after the consideration of 
different parameters such as diluents, buffer, buffer concentration, and organic solvent 
for mobile phase, mobile phase composition and other chromatographic conditions. 
preliminary trials using mobile phases of different composition containing water adjusted 
to acid pH by addition of orthophosphoric acid and methanol resulted in poor peak 
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shape. When methanol was replaced by acetonitrile, better peak shape was obtained with 
shorter retention time as compare to methanol. The proportion of the mobile phase 
components was optimized to reduce retention times and enable good resolution of 
Rosuvastatine from the degradation products. 
 
A detection wavelength of 242 nm was selected after scanning the standard solution 
over the range 190-370 nm by use of the PDA detector. Detection at 242 nm resulted in 
good response and good linearity. Hence selected diluent was best among all trials by 
many aspects. Fig.1 to Fig.2 represents the chromatogram of standard preparation, sample 
preparation and blank respectively. 
 
Fig.1: Chromatogram of Standard Preparation 
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Fig.2: Chromatogram of Sample Preparation 
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3D PDA Mixed view of Standard Preparation 
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5.2 Degradation study 
The degradation samples were prepared by transferring intact tablets. In chemical 
force degradation study, samples were employed for acidic, alkaline and oxidant 
media and in physical force degradation study sample were employed for thermal and 
photolytic conditions. After the completion of degradation treatments, the stress 
content solutions were diluted with diluent to attain standard concentration. Specific 
conditions were described as follows. 
 
5.2.1 Acidic degradation 
Acidic degradation study was performed by heating the content in 20 ml of 0.1N HCl 
at about 80° to 85° C for 2 hrs and after cooling to room temperature it was 
neutralized with 0.1N NaOH solution. Rosuvastatine was found to be degrading up to 
57% in acidic condition. The major impurity peaks was found at 5.8 min. 
 
Fig.3: Chromatogram of acidic forced degradation study 
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5.2.2 Alkali degradation 
Alkali degradation study was performed by heating the content in 20 ml of 0.1N 
NaOH at about 80° to 85°C for 2 hrs and after cooling to room temperature it was 
neutralized with 0.1N HCl solution. Rosuvastatine was found to be degrading up to 
36% in alkaline condition (Fig.5). 
 
Fig.4: Chromatogram of alkali forced degradation study (zoom view) 
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5.2.3 Oxidative degradation 
Oxidative degradation study was performed by heating the drug product in 30ml of 
30% v/v H2O2 at 80° to 85° C for 45 minutes. Rosuvastatine was found to be 
degrading up to 32% in oxidative condition. 
 
Fig.5: Chromatogram of oxidative forced degradation study 
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5.2.4 Thermal degradation 
Thermal degradation was performed by exposing solid drug product at 80° C for 72 
hrs. Rosuvastatine was found to be degrading up to 15% in Thermal degradation study 
(Fig.7). 
 
Fig.6: Chromatogram of thermal degradation study 
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5.2.5 Photolytic degradation 
Photolytic degradation study was performed by exposing the drug product to UV light 
for 24 hours. Rosuvastatine was found to be degrading up to 30% in photolytic 
degradation study. The major impurity peaks was found at 7.1 and 7.9 min (Fig.8). 
 
Fig.7: Chromatogram of Photolytic degradation study 
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5.3 Method validation 
 
Specificity 
 
The specificity of the method was determined by checking the interference of placebo 
with analyte and the proposed method was eluted by checking the peak purity of 
Rosuvastatine during the force degradation study. The peak purity of the 
Rosuvastatine was found satisfactory (0.999) under different stress condition. There 
was no interference of any peak of degradation product with drug peak. 
 
5.3.1 Linearity 
Seven points calibration curve were obtained by plotting Rosuvastatine calcium 
concentration against peak area, in the concentration range 20-80 µg/mL (corresponded to 
40% to 160%, respectively, of the test solution concentration) The regression equation 
was y = 25167x + 69092 where x is the concentration in µg/mL and y is the peak area 
in absorbance units; the correlation coefficient was 0.999 
 
Fig.8 Linearity curve for rosuvastatin calcium 
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Fig.9: Linearity study chromatogram of level-1 (40%) 
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Fig.10: Linearity study chromatogram of level-2 (60%) 
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Fig.11: Linearity study chromatogram of level-3 (80%) 
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Fig.12: Linearity study chromatogram of level-4 (100%) 
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Fig.13: Linearity study chromatogram of level-5 (120%) 
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Fig.14: Linearity study chromatogram of level-6 (140%) 
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Fig.15: Linearity study chromatogram of level-7 (160%) 
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5.3.6 Limit of detection and Limit of quantitation study 
The limit of detection (LOD) and limit of quantitation (LOQ) were determined by 
calculating the signal to noise (S/N) ratio of the LOD preparation and LOQ 
preparation concentration for LOQ level and LOD level were 0.5µg/ml and 0.1µg/ml 
respectively. Six replicate sample preparations were determined and standard 
deviation, % relative standard deviation was calculated to find out the reproducibility 
at LOQ level.  
 
LOD and LOQ preparation: 
1.0 ml of standard solution was pipette out and transferred into 50 ml volumetric flak. 
The solution was diluted to volume with diluent (Solution-A). The concentration 
obtained is 1.00 µg/ml of Rosuvastatine Calcium, Further pipette out 25 ml of this 
solution and transferred into 50 ml volumetric flak and dilute up to the mark with 
diluent (LOQ Level 0.5ppm), for LOD preparation pipette out 1 ml of Solution –A in 
to 10 ml vol. flask and dilute up the mark with diluent (LOD Level 0.1ppm). 
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Fig.16: Chromatogram of LOD preparation: 0.1ppm 
Minutes
0 1 2 3 4 5 6 7 8 9 10
m
A
U
-7.5
-5.0
-2.5
0.0
2.5
 
 
Fig.17: Chromatogram of LOQ preparation: 0.5ppm 
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5.3.2. Precision Study  
 
Precision study was established by evaluating method precision and intermediate 
precision study. System precision was evaluated by analyzing the standard solution five 
times. Method precision of the analytical method was determined by analyzing six 
sets of sample preparation. Assay of all six replicate sample preparations was 
determined and mean % assay value, standard deviation, % relative standard deviation 
was calculated. 
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Intermediate precision of the analytical method was determined by performing 
method precision on another day by another analyst under same experimental 
condition. Assay of all six replicate sample preparations was determined and mean % 
assay value, standard deviation, % relative standard deviation was calculated. 
 
The result of repeatability and intermediate precision study are shown in Table-1. The 
developed method was found precise as the %RSD for the system precision was 
0.45% and 0.37%, respectively, on the same day (intraday) and 0.41% and 0.55% on dif-
ferent days (interday). 
 
Fig.18: Chromatogram of standard preparation of method precision study: 
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Fig.19: Chromatogram of test preparation of method precision study (set-1): 
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Fig.20: Chromatogram of standard preparation of intermediate precision study: 
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Fig.21: Chromatogram of test preparation of intermediate precision study (set-1): 
Minutes
0 1 2 3 4 5 6 7 8 9 10
m
A
U
0
100
200
300
 
5.3.3 Accuracy Study 
Accuracy was assessed by determination of the recovery of the method at three different 
concentrations (corresponding to 50, 100 and 150% of test solution concentration) Known 
amounts of Rosuvastatine calcium (25, 50, and 75 µg/ml) were added to a placebo prepa-
ration and the amount of Rosuvastatine recovered, in the presence of placebo interference, 
was calculated. For each concentration, three sets were prepared and injected in duplicate. % 
Recovery was calculated at each level and recorded as shown in Table 1. The mean recovery 
of Rosuvastatine calcium was between 99.6 and 101.7%, which is satisfactory. 
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Table 1: Evaluation Data of Accuracy Study 
Results from evaluation of the accuracy of the method 
Level % No 
Amount of 
Drug 
Added 
(ug/mL) 
Amount of 
Drug Found 
(ug/mL) 
Recovery (%) 
Mean 
Recovery (%) 
RSD (%) 
50 
1 25.21 25.19 99.88 
100.55 0.78 2 25.41 25.77 101.42 
3 25.52 25.61 100.35 
100 
1 50.4 50.25 99.70 
99.59 0.12 2 50.83 50.56 99.47 
3 50.72 50.51 99.59 
150 
1 74.97 76.01 101.40 
101.66 0.23 2 75.24 76.55 101.74 
3 75.45 76.84 101.84 
 
 
Fig.22: Chromatogram of accuracy level-1 (50%) 
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Fig.23: Chromatogram of accuracy level-2 (100%) 
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Fig.24: Chromatogram of accuracy level-3 (150%) 
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5.3.5 Robustness Study 
The robustness of the method was evaluated by assaying test solutions after slight but 
deliberate changes in the analytical conditions. The factor chosen for this study were the 
flow rate (±0.1 mL/min), mobile phase composition [acetonitrile-water (38: 62 and 42: 
58), v/v], and using different lots of HPLC column. 
 
 
Change in flow rate 
In this parameter, analytical method was deliberately changed to flow rate. Sample was 
assayed by changing flow rate to 1.4 ml min-1 and 1.6 ml min-1 flow respectively. 
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Fig.25: Chromatogram of standard preparation at 1.4 ml/min flow rate: 
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Fig.26: Chromatogram of test preparation at 1.4 ml/min flow rate: 
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Fig.27: Chromatogram of standard preparation at 1.6 ml/min flow rate: 
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Fig.28: Chromatogram of test preparation at 1.6 ml/min flow rate: 
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Change in mobile phase composition 
In this parameter, analytical method was deliberately changed for composition of 
mobile phase. Sample was assayed by changing mobile phase composition 40:60 to 
38:62, v/v (increase aqueous component of mobile phase) and 42:58, v/v (increase 
organic component of mobile phase) respectively. 
 
Fig.29: Chromatogram of standard preparation of Acetonitrile-Buffer (38:62, v/v): 
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Fig.30: Chromatogram of test preparation of Acetonitrile-Buffer (38:62, v/v): 
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Fig.31: Chromatogram of standard preparation of Acetonitrile-Buffer (42:58, v/v): 
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Fig.32: Chromatogram of test preparation of Acetonitrile-Buffer (42:58, v/v): 
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Change in column lot 
In this parameter, column used in analytical method was changed to different lot. 
Sample was assayed by changing the lot of column, keeping other conditions as such. 
 
Fig.33: Chromatogram of standard preparation of column change parameter: 
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Fig.34: Chromatogram of test preparation of column change parameter: 
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Table 2: Evaluation Data of Robustness study 
Conditions 
Assay 
(%) 
RT 
(min) 
System suitability data 
Theoretical 
plates 
Asymmetry 
1.4 ml/min Flow 101.21 5.93 8560 1.15 
1.6 ml/min Flow 101.63 4.86 9102 1.11 
ACN : water (38:62, v/v) 99.95 5.91 8643 1.10 
ACN : water (42:58, v/v) 100.16 4.90 8751 1.08 
Column change 99.84 5.41 7866 1.12 
 
 
5.3.4 Solution Stability Study 
Stability of solution was evaluated for the standard preparation and the test preparation. The 
solutions were stored at 5° C and at ambient temperature, without protection of light and 
tested after 12, 24, 36 and 48 hrs. The responses for the aged solution were evaluated by 
comparison with freshly prepared solutions (Table 3). 
 
Table 3: Evaluation of solution study data 
Replicate 
STSSS (At RT) LTSSS (At 3-5ºC) 
0.0 hr(Area) 12.0 hr(Area) 0 DAY(Area) 12 DAY(Area) 
1 2476220 2470023 2480456 2468230 
2 2479541 2468790 2482987 2474666 
3 2474990 2473222 2471362 2477155 
4 2479344 2474145 2476110 2474685 
5 2471072 2474832 2488005 2477987 
Average 2476233 2472202 2479784 2474544 
Mean Area Ratio 1.0016 1.0021 
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Fig.35: Chromatogram of standard preparation (0.0 hr) 
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Fig.36: Chromatogram of test preparation (12.00 hr) 
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Fig.37: Chromatogram of test preparation (0 day) 
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Fig.38: Chromatogram of test preparation (12 days) 
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6.0 Content Uniformity Study 
 
Evaluation Data of Content Uniformity Study: 
Study Set No. Assay (%) Mean Assay (%) SD RSD (%) 
Content 
Uniformity 
Set-1 99.8 
100.23 0.40 0.40 
Set-2 99.7 
Set-3 100.3 
Set-4 99.9 
Set-5 100.7 
Set-6 100.6 
Set-7 99.8 
Set-8 100.4 
Set-9 100.8 
Set-10 100.3 
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7.0 System Suitability Study 
A system suitability test for the chromatographic system was performed before 
each validation parameter. Five replicate injections of standard preparation were 
injected and asymmetry, theoretical plate and % RSD of peak area were 
determined for same. 
 
Table 4.System suitability Summery 
System suitability data RSD (%) Theoretical plats Asymmetry 
In-House limit NMTa2.0 NLTb 8000 NMTc2.0 
        
Specificity 0.62 8441 1.05 
Linearity 0.28 8544 1.02 
Precision       
For Assay 0.45 8640 1.06 
For Content uniformity 0.37 8721 0.98 
Intermediate Precision       
For Assay 0.41 8667 1.01 
For Content uniformity 0.55 8327 1.06 
Accuracy 0.34 8591 1.00 
Solution stability 0.27 8638 0.99 
Robustness 0.46 8212 1.02 
 
aRelative standard deviation, bnot less than, cnot more than 
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Comparison of the present method with two of published method in reputed journals: 
 
Parameters Sankar et al. Gomes et al. Present method 
column 
RP-C18 (250x4.6 
mm), 5µm 
Lichrospher RP-C18 
(250x4.6 mm), 5µm 
YMC C8 (150x4.6 
mm), 5µm 
Mobile phase 
water: acetonitrile 
(48:52, v/v) pH 3.0 
phosphoric acid, 
containing 0.3% 
triethylamine 
methanol: water (60:40, 
v/v) pH 3.0 using 
phosphoric acid 
Acetonitrile: water 
(40:60, v/v) pH 3.5 
using phosphoric acid 
Flow rate 1.0 ml/min 1.0 ml/min 1.5 ml/min 
Detector UV UV PDA 
Wave length 245 nm 238 nm 242 nm 
LOD NA 1.55 (µg/ml) 0.1 (µg/ml) 
LOQ NA 4.7 (µg/ml) 0.5 (µg/ml) 
Linear range 5-30 (µg/ml) 6-22 (µg/ml) 0.5-80 (µg/ml) 
R2 0.9999 0.999 0.999 
Remarks 
less precise and 
accurate, stability 
study was not done, 
% assay was not 
calculated and 
content uniformity 
was not mentioned 
less sensitive and accurate, 
stability study data and % 
degradation of the drug was 
not mentioned, solution 
stability was not done , % 
assay of the drug was not 
calculated and content 
uniformity of the tablet was 
not done 
Simple, precise and 
accurate, stability 
study and % assay of 
the drug and content 
uniformity was 
mentioned 
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8.0 Calculation and Data 
 
1.  Calculation formula for % assay  
 
potency
TestWeight
WeightStandard
AreaStandardMean
AreaTestMean
Assay ××××=
10
510
5
%  
 
 
2. Relative standard deviation  
 
100
tsMeasuremenofValueMean
tMeasuremenofDeviationStandard
RSD ×=
 
 s
%  
 
 
3. % Recovery  
 
100
AddedAmount
FoundAmount
Recovery% ×=  
 
 
4. Amount Found  
 
ionConcentratStandard
AreaMean
AreaTestMean
mlmgFoundAmount ×=
Standard
)/(  
 
 
5. Amount added 
 
Volume
WeightmlmgAddedAmount =)/(  
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8.2 Observation and calculation for linearity study: 
Data for standard preparation 
Replicate Area 
1 2471511 
2 2471640 
3 2472860 
4 2484540 
5 2484788 
Mean 2477067 
SD 6954.8522 
%RSD 0.28 
 
Data for test preparation 
Linearity Level Replicate Area Mean Area 
Level-1 (40%) 
1 932420 
932557.5 
2 932695 
Level-2 (60%) 
1 1450988 
1450995 
2 1451002 
Level-3 (80%) 
1 1925610 
1925728 
2 1925846 
Level-4 (100%) 
1 2483630 
2483316 
2 2483002 
Level-5 (120%) 
1 2966270 
2976691 
2 2987111 
Level-6 (140%) 
1 3452232 
3455619 
2 3459006 
Level-7 (160%) 
1 3945654 
39433822 
2 3941990 
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8.3 Observation and calculation for LOD & LOQ study: 
 
Data for standard preparation 
Replicate Area 
1 2471762 
2 2468213 
3 2472540 
4 2465666 
5 2476704 
Mean 2470977 
SD 4233. 9148 
%RSD 0.17 
 
Data for standard preparation 
Replicate Area 
1 38535 
2 38098 
3 38741 
4 39033 
5 38954 
Mean 38672.2 
SD 375.1169 
%RSD 0.96 
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8.4 Observation and calculation for method precision study: 
Data for standard preparation: 
Replicate Area 
1 2466140 
2 2479422 
3 2485120 
4 2462123 
5 2486610 
Mean 2475883 
SD 11148.75 
%RSD 0.45 
 
Data for test preparation:  
Set No. Replicate Area Mean area 
1 
1 2480416 
2480684 
2 2480953 
2 
1 2473145 
2474172 
2 2475200 
3 
1 2489325 
2488697 
2 2488070 
4 
1 2469707 
2466909 
2 2464111 
5 
1 2486562 
2484256 
2 2481950 
6 
1 2462722 
2463860 
2 2464998 
 
Calculation: 
Prototype calculation for method precision set-1: 
potency
claim Label
Weight Avg.
WeightTest
WeightStd
AreaStandardMean
AreaTestMean
Assay ××××××=
5
50100
50
5
100
%
 
90.99
5
50
2.775
100
50
5
1002475883
2480684% ××××××=
10
155.0450.16Assay  
   = 100.41% 
Chapter 3   Rosuvastatin calcium 
108 
8.5 Calculation for intermediate precision study: 
Data for standard preparation: 
Replicate Area 
1 2466052 
2 2468330 
3 2485760 
4 2484535 
5 2486686 
Mean 2478272.6 
SD 10176.71 
%RSD 0.41 
 
Data for test preparation: 
Set No. Replicate Area Mean area 
1 
1 2482110 
2482539 
2 2482969 
2 
1 2475881 
2475897 
2 2475913 
3 
1 2469555 
2470160 
2 2470765 
4 
1 2486014 
2485181 
2 2484348 
5 
1 2486440 
2489248 
2 2492057 
6 
1 2475123 
2473970 
2 2472818 
 
Calculation: 
Prototype calculation for intermediate precision set-1: 
potency
claim Label
Weight Avg.
WeightTest
WeightStd
AreaStandardMean
AreaTestMean
Assay ××××××=
5
50100
50
5
100
%
 
90.99
5
50
5.768
100
50
5
1002478272
2482539% ××××××=
10
153.250.11Assay  
   = 100.16% 
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8.6 Calculation for accuracy study: 
Data of standard preparation: 
Replicate Area 
1 2469270 
2 2471762 
3 2477544 
4 2488148 
5 2486436 
Mean 2478632 
SD 8477.68 
%RSD 0.34 
 
Data of test preparation: 
Accuracy  
Level Set No. Replicate Area Mean area 
50% 
1 
1 1242680 
1244851 
2 1247022 
2 
1 1271021 
1273417 
2 1275814 
3 
1 1263510 
1265512 
2 1267514 
100% 
1 
1 2483006 
2483096 
2 2483187 
2 
1 2498100 
2498558 
2 2499017 
3 
1 2496210 
2495942 
2 2495674 
150% 
1 
1 3755014 3755892 
 2 3756770 
2 
1 3782348 3782628 
 2 3782908 
3 
1 3796506 
3797017 
2 3797529 
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Prototype calculation for set-1: 
 
Recovery  
100
AddedAmount
FoundAmount
Recovery% ×=  
100
2504.62
2504Recovery% ×=  
  =100.02 % 
 
Amount Found  
ionConcentratStandard
AreaMean
AreaTestMean
FoundAmount ×=
Standard
 
15.50
2478632
1244851 ×=FoundAmount =  25.19 µg/mL 
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8.6 Calculation for robustness study: 
 
8.6.1 Change in floe rate:  
Data for standard preparation: flow rate 1.4 ml min-1 
Replicate Area 
1 2568824 
2 2570212 
3 2569004 
4 2567815 
5 2568157 
Mean 2568802.4 
SD 924.6054833 
%RSD 0.03599364 
 
Data for Test preparation: flow rate 1.4 ml min-1 
Replicate Area 
1 2572600 
2 2570980 
Mean 2571790 
Std wt. 50.09 
Test wt. 781.2 
 
 Assay calculation for flow rate 1.4 ml min-1: 
 
potency
claim Label
Weight Avg.
WeightTest
WeightStd
AreaStandardMean
AreaTestMean
Assay ××××××=
5
50100
50
5
100
%
 
90.99
5
50
2.781
100
50
5
1002568802
2571790% ××××××=
10
156.250.09Assay  
   
   = 100.21%  
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Data for standard preparation: flow rate 1.6 ml min-1 
Replicate Area 
1 2240797 
2 2240960 
3 2241058 
4 2239993 
5 2240600 
Mean 2240681.6 
SD 422.2940916 
%RSD 0.01884668 
 
Data for Test preparation: flow rate 1.6 ml min-1 
Replicate Area 
1 2243125 
2 2242640 
Mean 2242882 
Std wt. 50.03 
Test wt. 766.8 
 
Assay calculation for flow rate 1.6 ml min-1: 
 
potency
claim Label
Weight Avg.
WeightTest
WeightStd
AreaStandardMean
AreaTestMean
Assay ××××××=
5
50100
50
5
100
%
 
90.99
5
50
8.766
100
50
5
1002240681
2242882% ××××××=
10
152.850.03Assay  
    = 99.21%  
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8.6.2 Change in mobile phase composition: 
Data for standard preparation: (Acetonitrile-Buffer 38:62, v/v) 
Replicate Area 
1 2431235 
2 2429701 
3 2424666 
4 2430789 
5 2432521 
Mean 2429782.4 
SD 3033.4549 
%RSD 0.12 
 
Data for Test preparation: (Acetonitrile-Buffer 38:62, v/v) 
Replicate Area 
1 2454130 
2 2451333 
Mean 2452731.5 
Std wt. 49.06 
Test wt. 765.5 
 
Assay calculation for Acetonitrile-Buffer 38:62, v/v: 
 
potency
claim Label
Weight Avg.
WeightTest
WeightStd
AreaStandardMean
AreaTestMean
Assay ××××××=
5
50100
50
5
100
%
 
90.99
5
50
5.765
100
50
5
1002432521
2452731% ××××××=
10
154.249.06Assay  
   = 99.54%  
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Data for standard preparation: (Acetonitrile-Buffer 42:58, v/v) 
Replicate Area 
1 2371128 
2 2370860 
3 2366262 
4 2372470 
5 2368008 
Mean 2369745.6 
SD 2536.237134 
%RSD 0.107025713 
 
Data for Test preparation: (Acetonitrile-Buffer 42:58, v/v) 
Replicate Area 
1 2398707 
2 2408218 
Mean 2403462.5 
Std wt. 49.0 
Test wt. 756.8 
 
Assay calculation for Acetonitrile-Buffer 42:58, v/v: 
 
potency
claim Label
Weight Avg.
WeightTest
WeightStd
AreaStandardMean
AreaTestMean
Assay ××××××=
5
50100
50
5
100
%
 
90.99
5
50
8.756
100
50
5
1002369745
2403462% ××××××=
10
151.349.00Assay  
  
    = 99.25%  
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8.6.3 Change in column lot 
Data for standard preparation: (column change) 
Replicate Area 
1 2445300 
2 2448780 
3 2450140 
4 2447542 
5 2454157 
Mean 2449183.8 
SD 3301.117265 
%RSD 0.134784383 
 
Data for Test preparation: (column change) 
Replicate Area 
1 2460145 
2 2464470 
Mean 2462307.5 
Std wt. 50.15 
Test wt. 764.6 
 
Assay calculation for change in column lot: 
 
potency
claim Label
Weight Avg.
WeightTest
WeightStd
AreaStandardMean
AreaTestMean
Assay ××××××=
5
50100
50
5
100
%
 
90.99
5
50
6.764
100
50
5
1002449183
2462307% ××××××=
10
152.150.15Assay  
  
   = 100.19% 
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Chapter 4: “Validation of an Assay Method for the  Simultaneous 
  Determination of  Rosuvastatin Calcium And Amlodipine  
  Besylate In Tablet Formulations” 
 
 
 
1.0 Introduction 
 
1.1 Rosuvastatin Calcium 
Rosuvastatin calcium is, chemically, bis [(E)-7[4-(4-fluorophenyl)-6 isopropyl-2-
[methyl (methyl-sulphonyl) amino] pyrimidin-5-yl] (3R, 5S) -3, 5-dihydroxyhept-6-
enoic acid] calcium salt. Molecular formula of Rosuvastatin Calcium is 
(C22H27FN3O6S)2Ca having molecular weight 1001.14 g/mole. Its melting point is 
122º C [1] [2].  
 
Rosuvastatin Calcium is lipid lowering drug. It inhibits the enzyme 3-hydroxy-3-
methyl glutaryl coenzyme A (HMG-CoA) reductage, the rate limiting enzyme that 
converts HMG-CoA to mevalonate a precursor of cholesterol and thereby checks the 
synthesis of cholesterol. It is used in the treatment of hyper-cholesterolemia and 
dyslipidemia [3][4][5]. 
 
 
 
Chemical Structure of Rosuvastatin Calcium [7] 
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1.2 Pharmacology 
Rosuvastatin is a selective and competitive inhibitor of HMG-CoA reductase, the 
enzyme responsible for the conversion of HMG-CoA to mevalonate, and decreases 
hepatic biosynthesis of cholesterol. As a result, hepatocytes compensate by increasing 
the number of LDL surface receptors to increase LDL reuptake from the circulation. 
This process reduces the serum LDL concentration. 
 
Rosuvastatin is synthetically produced to contain a unique methylsulfonamide group 
(sulfone) with high affinity for HMG-CoA reductase. This sulfone group creates an 
additional polar bond with the side chain Arg of HMG-CoA, which gives 
Rosuvastatin the highest affinity for HMG-CoA reductase among all marketed statins 
In addition; this extra sulfone group increases the hydrophilicity of Rosuvastatin. The 
statin octanol-water coefficient for Rosuvastatin is -0.33 log D at pH 7.4, compared 
with -0.84 for pravastatin and between 1.0 and 2.0 for simvastatin, atorvastatin, and 
fluvastatin (where octanol coefficients < 1 indicate hydrophilicity). Hydrophilic drug 
distribution is primarily limited to hepatocytes; therefore, peripheral concentrations 
are decreased. Studies in rats show that, after the intravenous administration of 
Rosuvastatin, uptake clearance is highest in hepatocytes compared with renal tissue 
and other tissues (0.9, 0.2, and ≤ 0.2 ml/min, respectively).   
 
1.3 Amlodipine Besylate 
Amlodipine besylate is chemically described as 3-Ethyl-5-methyl (±)-2-[ (2-
aminoethoxy)methyl]-4- (2-chlorophenyl)-1,4-dihydro-6-methyl-3,5- pyridine- 
dicarboxylate, monobenzene sulphonate. Its empirical formula is 
C20H25ClN2O5·C6H6O3S. Amlodipine besylate is a white crystalline powder with a 
molecular weight of 567.1. It is slightly soluble in water and sparingly soluble in 
ethanol [7][8][9][10][11][12]. Amlodipine besylate is a calcium channel blocker, which is 
used as an antihypertensive agent. It is official in EP [10] and BP [11] 
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Chemical Structure of Amlodipine Besylate [7] 
 
1.4 Pharmacology 
Amlodipine is a dihydropyridine calcium antagonist (calcium ion antagonist or slow-
channel blocker) that inhibits the transmembrane influx of calcium ions into vascular 
smooth muscle and cardiac muscle. Experimental data suggest that amlodipine binds 
to both dihydropyridine and nondihydropyridine binding sites. The contractile 
processes of cardiac muscle and vascular smooth muscle are dependent upon the 
movement of extracellular calcium ions into these cells through specific ion channels. 
Amlodipine inhibits calcium ion influx across cell membranes selectively, with a 
greater effect on vascular smooth muscle cells than on cardiac muscle cells. Negative 
inotropic effects can be detected in vitrobut such effects have not been seen in intact 
animals at therapeutic doses. Serum calcium concentration is not affected by 
amlodipine. Within the physiologic pH range, amlodipine is an ionized compound 
(pKa=8.6), and its kinetic interaction with the calcium channel receptor is 
characterized by a gradual rate of association and dissociation with the receptor 
binding site, resulting in a gradual onset of effect. 
Amlodipine is a peripheral arterial vasodilator that acts directly on vascular smooth 
muscle to cause a reduction in peripheral vascular resistance and reduction in blood 
pressure. 
The precise mechanisms by which amlodipine relieves angina have not been fully 
delineated, but are thought to include the following: 
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Exertional Angina: In patients with exertional angina, amlodipine reduces the total 
peripheral resistance (afterload) against which the heart works and reduces the rate 
pressure product, and thus myocardial oxygen demand, at any given level of exercise. 
Vasospastic Angina: amlodipine has been demonstrated to block constriction and 
restore blood flow in coronary arteries and arterioles in response to calcium, 
potassium epinephrine, serotonin, and thromboxane A2 analog in experimental animal 
models and in human coronary vessels in vitro. This inhibition of coronary spasm is 
responsible for the effectiveness of amlodipine in vasospastic (Prinzmetal's or variant) 
angina. 
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2.0 Literature Review 
 
There are many reported method for the determination of either Rosuvastatin [13 to 22] 
or Amlodipine [23 to 27] alone or in combination with other drug [28 to 42] in 
pharmaceutical dosage forms or individually in biological fluids are as under: 
 
2.1 Literature review for rosuvastatin calcium 
 
2.1.1 Sankar DG, Kumar BA, Babu PJ and Madhavi PV have developed a simple 
and sensitive UV spectrophotometric method for the determination of gefitinib (GFB) 
and Rosuvastatin calcium (RSV) in bulk and pharmaceutical formulations.  These 
compounds had max absorption (λmax) at 264 nm for GFB and 258 nm for RSV and 
both the methods obeyed Beer's law in the concentration range 5-25 µg/mL.  The 
methods were accurate and precise and were extended to pharmaceutical formulations 
and there was no interference from any common pharmaceutical additives and 
excipients. The results of the analysis were validated statistically and by recovery 
studies[13]. 
 
2.1.2 Gupta A, Mishra P, Shah K have developed UV spectrophotometric method 
for determination of Rosuvastatin calcium in pure form and in pharmaceutical 
formulations. Rosuvastatin exhibits absorption maxima at 244 nm with apparent 
molar absorptivity of 7.2345-104 L/mol/cm in methanol.  Beer's law was found to be 
obeyed in the concentration range of 2-18 µg/mL.  The method is accurate, precise 
and economical. This method is extended to pharmaceutical preparations.  In this 
method, there is no interference from any common pharmaceutical additives and 
diluents.  Results of the analysis were validated statistically and by recovery studies 
[14]. 
 
2.1.3 Rajput SJ and Raj HA have developed method for simultaneous determination 
of ezetimibe and rosuvastatin using the zero-crossing technique. The measurements 
were carried out at wavelengths of 290 and 245.6 nm for ezetimibe and rosuvastatin, 
resp.  The method was found to be linear (r2 > 0.9994) in the range of 5- 40 μg/mL 
for ezetimibe at 290 nm.  The linear correlation was obtained (r2 > 0.9935) in the 
range of 5- 80μg/mL for rosuvastatin at 245.6 nm.  The limit of detection was 0.43 
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and 0.69μg/mL for ezetimibe and rosuvastatin, resp.  The limit of quantification was 
1.44 and 2.89μg/mL for ezetimibe and rosuvastatin, respectively. The method was 
successfully applied for simultaneous determination of ezetimibe and rosuvastatin in 
drug mixture [15]. 
 
2.1.4 Sane RT, Kamat SS, Menon SN, Inamdar SR and Mote MR have developed 
method for determination of  Rosuvastatin Calcium  in its bulk drug and 
pharmaceutical preparations by high-performance thin-layer chromatography. A 
normal-phase TLC method was established for the estimation of Rosuvastatin calcium 
in its bulk drug and pharmaceutical formulations. Analysis was performed in a Camag 
twin-trough chamber on silica gel 60F254 HPTLC plates. Aceclofenac was used as 
internal standard. The optimized mobile phase was toluene-methanol-Et acetate-
formic acid, 6.0 + 1.0 + 3.0 + 0.1 (vol./vol.).  Quantitation was performed 
densitometrically at 265 nm. A good correlation coefficient (r2 = 0.999) was obtained 
for the linearity for amts. of sample in the range 1.0 to 15.0 µg [16].  
 
2.1.5 Sharma MC, Sharma S, Kohli DV and Sharma AD have validated high 
performance liquid chromatographic (HPTLC) method for estimation of rosuvastatin 
calcium and ezetimibe in tablet dosage form.  The method involved separation  of 
components by TLC on a precoated silica gel 60 F254 using a mixture of n-butanol: 
methanol (3:1) as a mobile phase.  Detection of spots was carried out at 274 nm and 
230 nm for rosuvastatin calcium and ezetimibe combinations, resp.  The mean 
retardation factor for rosuvastatin calcium and ezetimibe were found to be 0.90 ± 
0.01, 0.82 ± 0.05, respectively. The linearity and range was 0.1 to 0.5 μg/spot for 2 
drugs.  The method was validated for precision, accuracy and reproducibility [17]. 
 
2.1.6 Sankar DG, Babu PJ, Kumar BA, Krishna MV have developed RP- HPLC   
method for the estimation of Rosuvastatin   calcium in bulk and pharmaceutical 
dosage forms. The separation was achieved on a reversed phase C18 column (250 × 
4.6 mm ID) using with a mobile phase comprising of water and acetonitrile (pH 3.0 
adjusted with phosphoric acid) in the ratio of (48: 52 vol./vol.) containing 0.30% of 
triethylamine. The mobile phase was pumped at a flow rate of 1 mL/min with UV 
detection at 245 nm.  The calibration curve was linear in the range of 5.0-30 µg/mL 
with a coefficient of correlation 0.9999.  Due to its high precision and accuracy, the 
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proposed HPLC method is useful for determination of Rosuvastatin calcium in bulk 
and pharmaceutical dosage forms [18] 
 
2.1.7 Gomes FP et all  have developed and validate HPLC method for simultaneous 
determination of determination pravastatin sodium (PS), fluvastatin sodium (FVS), 
atorvastatin calcium (ATC), and Rosuvastatin calcium (RC) in pharmaceuticals.  Two 
stability-indicating HPLC methods were developed with a small change (10%) in the 
composition of the organic modifier in the mobile phase.  The HPLC method for each 
statin was validated using isocratic elution.  An RP-18 column was used with mobile 
phases consisting of methanol-water (60:40, vol./vol., for PS and RC and 70:30, 
vol./vol., for FVS and ATC).  The pH of each mobile phase was adjusted to 3.0 with 
orthophosphoric acid, and the flow rate was 1.0 mL/min.  Calibration plots showed 
correlation coefficients  (r) > 0.999, The detection limit and quantitation limit were 
1.22 and 3.08 µg/mL for PS, 2.02 and 6.12 µg/mL for FVS, 0.44 and 1.34 µg/mL for 
ATC, and 1.55 and 4.70 µg/mL for RC. The methods were applied successfully for 
quant. determination of statins in pharmaceuticals [19]. 
 
2.1.8 Pandya CB, Channabasavaraj KP, Chudasama JD and Mani TT have 
developed and validate a simple, specific, accurate, and precise RP-HPLC method for 
the determination of rosuvastatin calcium in pharmaceutical dosage forms.  A Thermo 
hypersil reversed phase C-18, 5 μm column having 100 × 4.6 mm id in gradient mode, 
with mobile phase containing HPLC grade Acetonitrile : Potassium dihydrogen 
orthophosphate (50 : 50 vol./vol., pH 3) was used.  The flow rate was 0.5 mL/min and 
effluents were monitored at 243 nm.  Chromatogram showed a main peak of RC at 
retention time was 3.333 ± 0.004 min.  The method was validated for linearity, 
accuracy, precision, limit of detection, limit of quantitation, robustness and 
ruggedness.  The limit of detection and limit of quantitation for estimation of RC was 
found to be 0.14 μg/mL and 0.46 μg/mL, respectively.  Recovery of RC was found to 
be in the range of 98.50-100.17%.  Proposed method was successfully applied for the 
quantitative determination of RC in pharmaceutical dosage forms [20]. 
 
2.1.9 Krishnaiah CH, Murthy MV, Prasad BJ and Durga SB have developed a 
simple, gradient, stability indicating RP-HPLC method for the quantification of 
rosuvastatin and its related substances and of degradation products generated by 
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decomposition. When rosuvastatin was subjected to acid hydrolytic, oxidative, 
photolytic, and thermal stress, degradation was observed  Chromatographic separation 
was achieved among rosuvastatin and related substances and degradation products, 
which were obtained from stress conditions like acid, base, water hydrolysis, and 
oxidation  The optimized conditions are there by a step wise gradient elution mode on 
a C18 column using a mixture of 0.02 M Potassium dihydrogen orthophosphate, pH 
adjusted to 3.0 and acetonitrile in the ratio of (80:20) (vol./vol.) as solvent-A and 
further using a mixture of acetonitrile and water in the ratio (90:10) (vol./vol.) as 
solvent-B.  The method was completely validated in terms of linearity, accuracy, 
precision, specificity, and robustness. The LOD and LOQ values of rosuvastatin, 
rosuvastatin lactone and rosuvastatin ester are 0.05, 0.075, 0.077 μgmL-1 and 0.2, 
0.30, 0.31 μgmL-1, resp.  The present RPLC can be able to det. rosuvastatin and its 
related substances simultaneously in bulk drug and finished dosage forms of 
rosuvastatin [21].  
  
2.1.10 Guiqin M, Changjiang Z, Liyun N and Guangcai Y have developed a HPLC 
method for analysis of rosuvastatin calcium and diastereomer. Kromasil C18 (4.6 mm 
× 250 mm, 5 μm) column was used for separation.  The mobile phase consisted of 
water-methanol-acetonitrile (60:10:30, adjusted to pH 3.5 by glacial acetic acid).  The 
flow rate was 1.0 mL/min-1. The detection wavelength was 242 nm.  The temperature 
of column was controlled at 30°.  This method could separate rosuvastatin calcium 
and diastereomer, and it was confirmed that the isomer was diastereomer by LC-MS 
method.  The method was successfully applied to analyze rosuvastatin calcium and 
diastereomer [22]. 
 
2.2 Literature Review for Amlodipine Besylate 
 
2.2.1 Fakhari AR, Nojavan S, Haghgoo S and Mohammadi A have developed a 
simple, accurate, precise, and sensitive method using cyclodextrin (CD) for separation 
and stability indicating assay of enantiomers of amlodipine in the com. tablets was 
established.  Several types of CD were evaluated and best results were obtained using 
a fused-silica capillary with phosphate running buffer (100 mM, pH 3.0) containing 5 
mM hydroxypropyl-α-CD.  The method has shown adequate separation for 
amlodipine enantiomers from its degradation products. The drug was subjected to 
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oxidation hydrolysis, photolysis, and heat to apply stress conditions.  The range of 
quantitation for both enantiomers was 5-150 μg/mL.  Intra- and inter-day RSD (n = 6) 
was < 4%.  The limit of quantification that produced the requisite precision and 
accuracy was found to be 5 μg/mL for both enantiomers.  The LOD for both 
enantiomers was found to be 0.5 μg/mL.  Degradation products produced as a result 
of stress studies did not interfere with the detection of enantiomers and the assay can 
thus be considered stability indicating [23]. 
 
2.2.2 Kamat K and Chaturvedi SC have developed and validate a novel stability 
indicating HPLC method for estimation of amlodipine in tablet formulation. The 
mobile phase consists of 0.05 M ortho-phosphoric acid buffer, methanol and 
acetonitrile in the ratio of 50:35:15 and the results show that the method is 
reproducible and accurate.  Degradation of amlodipine was performed in various 
conditions and the resulting solution was analyzed on HPLC using ODS column 
(150×4.6 mm) with a detection maxima of 361 nm.  The method gave a good 
separation between drug and degradation peaks.  Recovery studies gave results 
between 99.7 to 100.7% for 5 mg tablets [24]. 
 
2.2.3 Gazy A and Abdel K have developed a simple and accurate method for the 
determination of amlodipine besylate in tablets.  These methods are based on the 
reaction of amlodipine with 2,4-dinitrofluorobenzene (DNFB) in presence of borate 
buffer (pH = 9) to give yellow colored product measured at 364 nm (A), Formation of 
meisenheimer complex of amlodipine with 2,4-dinitrofluorobenzene (DNFB) in 
presence of dipolar aprotic solvent (DMSO) (B), Formation of ion-assocn. complex 
between drug and eosin at pH = 3 with subsequent measurement 
spectrophotometrically at 543 nm without extn. and fluorimetrically at 545 nm using 
excitation wavelength at 310 nm (C) and reaction of amlodipine with fluorescamine in 
borate buffer pH 9 and measure the relative fluorescence intensity of the reaction 
product at 472 nm with excitation wavelength at 390 nm (D).  All variables were 
studied.  Beer's law was valid over the concentration range 4-20 μg/mL (method A), 
4-14 μg/mL (method B), 8-10 μg/mL (method C) and 0.2-2.5 μg/mL (method D). 
 The detection limits were ranged from (0.014-1.028) μg/mL.  The proposed methods 
were successfully applied without any interference from excipients to the assay of 
amlodipine in tablets [25]. 
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2.2.4 Cetin G and Sungur S have developed a rapid and sensitive method for the 
spectrophotometric assay of amlodipine is based on the formation of a colored derived 
during the reaction of the drug with Na 1,2-naphthoquinone-4-sulfonate.  The reaction 
proceeds quant. at pH 10 and 70° in 20 min.  After the extraction of the derived with 
BuOH, the absorbance was measured at 494 nm.  The method was applied to com. 
tablets and the results were statistically compared with those obtained by an UV 
spectrophotometric method, using t- and F-tests.  There was no significant difference 
between the 2 methods [26]. 
 
2.2.5 Chandrashekhar TG, Rao PSN Smrita K and Vyas SK have developed a 
sensitive high-performance TLC (HPTLC) for the determination of amlodipine 
besylate in tablets.  The method is the first HPTLC method proposed for the 
determination of amlodipine in pharmaceutical preparations.  The minimum 
detectable limit for the proposed method is 0.2 ng.  The results were statistically 
validated by performing seven replicate recoveries on samples of tablet spiked with 
the drug at 3 different levels [27]. 
 
2.3 Literature Review for combination 
 
2.3.1 Doshi N, Sheth A, Sharma A, Dave JB and Patel CN have developed a 
Simple, accurate and precise RP-HPLC method for the simultaneous determination of 
rosuvastatin calcium and telmisartan in marketed formulation.  The determination was 
carried out on a Inertsil ODS 3V C18 (250 × 4.6 mm, 5 μm) column using a mobile 
phase of Ammonium Dihydrogen Phosphate (pH 3) Buffer: Methanol (65:35 vol./vol. 
pH 3.0).  The flow rate was 1.5 mL/min with detection at 298 nm.  The retention time 
for rosuvastatin was 6.1 min and for telmisartan 16.2 min.  Rosuvastatin calcium and 
telmisartan showed a linear response in the concentration range of 6-18 μg/mL 24-72 
μg/mL respectively. The correlation co-efficient for rosuvastatin and telmisartan were 
0.9986 and 0.9961 respectively. The percentage recoveries obtained for rosuvastatin 
calcium and telmisartan ranges from 100.04 to 100.57% [28]. 
 
2.3.2 Pandya CB, Channabasavaraj KP and Shridhara HS have developed a 
simple, sensitive, accurate and reproducible method for simultaneous estimation of 
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both the drugs by the simultaneous equation method, using methanol as solvent. 
 Rosuvastatin calcium has absorbance maxima at 243.60 nm and ezetimibe at 232.60 
nm and both shows linearity in the concn. range of 5-40 μg/mL.  The LOD were 
found to be 1.5 μg/mL and 1.65 μg/mL for rosuvastatin calcium and ezetimibe 
respectively.  The LOQ for rosuvastatin calcium and ezetimibe were found to be 4.5 
μg/mL and 4.96 μg/mL respectively. Recovery study was performed to confirm the 
accuracy of the method [29]. 
 
2.3.3 Sharma S, Sharma MC, Kohli DV and Chaturvedi SC have developed and 
validated HPLC method for estimation of rosuvastatin calcium and ezetimibe in tablet 
dosage form.  HPLC separation was achieved on Licrosphere C18 column (250 × 4.6 
mm) using methanol:acetonitrile: phosphate buffer, pH 3.5 (60:20:20 vol./vol.) at 
flow rate of 1.0 mL/min at 25° temperature. Quantitation was achieved by UV 
detection at 279 nm over the concentration range 5-10 mg/mL for both the drugs with 
mean recoveries of 99.01% ± 0.12 and 100.64% ± 0.20 for ROS and EZE 
respectively. Method is simple, precise and sensitive and it is applicable for the 
simultaneous estimation of ROS and EZE in tablet dosage form [30]. 
 
2.3.4 Rathee P, Rathee S, Thakur S and Kumar V have developed a new second 
derivative UV-Spectrophotometric method for the simultaneous assay of Amlodipine 
Besylate and Lisinopril Dihydrate in bulk drug and in tablet dosage forms using 
double distilled water as the solvent.  The method is based on simultaneous equation 
or Vierodt's method.  The λmax values for Amlodipine Besylate and Lisinopril 
Dihydrate in the solvent medium were found to be 256 nm and 216 nm, resp.  The 
systems obey Beer's law in the range of 10.0 to 70.0 μg/mL and 4.0 to 40.0 μg/mL 
with correlation coeff. of 0.9994 and 0.9996 for Amlodipine Besylate and Lisinopril 
Dihydrate, respectively.  Repeatability, Interday and intraday precision were found to 
be 0.134, 0.280, 0.349 and 0.205, 0.530, 0.569, respectively. T-Test and F-test were 
applied for the recovery studies of the method.  The method was successfully applied 
to the assay of Amlodipine and Lisinopril Dihydrate in tablet formulations [33]. 
 
2.3.5 Rathee P, Rathee S, Thakur S and Kumar V have developed UV-
Spectrophotometric method for the simultaneous assay of Amlodipine Besylate and 
Atenolol in bulk drug and in tablet dosage forms using aq. medium as the solvent. 
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 The method is based on simultaneous equation or Vierodt's method.  The λmax 
values for Amlodipine Besylate and Atenolol in the solvent medium were found to be 
238.4 nm and 273.4 nm resp.  The systems obey Beer's law in the range of 4.0 to 32.0 
μg/mL and 20.0 to 200.0 μg/mL with correlation coefficient of 0.9984 and 0.9996 for 
Amlodipine Besylate and Atenolol resp.  Repeatability, Interday and intraday 
precision were found to be 0.562, 0.474, 0.456 and 0.238, 1.31, 0.337 respectively. 
 No interference was observed from common tablet adjuvants.  T-Test and F-test were 
applied for the recovery studies of the method.  The method was successfully applied 
to the assay of Amlodipine Besylate and Atenolol in tablet formulations [34]. 
 
2.3.6 Joshi SJ, Karbhari PA and Bhoir SI have developed and validated simple and 
rapid LC method for simultaneous estimation of nebivolol and amlodipine in a bi-
layer tablet formulation. Efficient chromatographic separation was achieved on (USP 
L10) Hypersil BDS cyano, 5 μm, 250 mm × 4.6 mm column with simple mobile 
phase compn. delivered in isocratic mode.  The method had requisite accuracy, 
selectivity, sensitivity, robustness and precision to assay nebivolol and amlodipine in 
pharmaceutical dosage form.  Degradation products resulting from the stress studies 
did not interfere with the detection of nebivolol and amlodipine, these peaks remained 
pure and thus proved to be stability indicating. The mass balance of the stressed 
sample was in the range 99.0-100.2% for amlodipine and 99.3-100.3% for nebivolol 
[35].  
 
2.3.7 Younus M, Reddy TK, Reddy YR and Arif MF have developed a simple, 
specific, accurate and precise RP-HPLC method for simultaneous estimation of 
amlodipine besylate, valsartan and hydrochlorothiazide in tablet dosage form on RP 
C18 column (Hypersil 250 × 4.6 mm) using acetonitrile:mixed phosphate buffer (6.8 
pH) (55:45) (buffer was prepd. by mixing the equal proportions of 0.01M potassium 
dihydrogenphosphate and 0.001M dipotassium hydrogenphosphate). pH was adjusted 
with orthophosphoric acid as mobile phase.  The flow rate was 1.0 mL/min and 
effluent was monitored at 237 nm.  The retention time for VAT, HTZ and AB was 
found to be as 2.28, 2.99, and 4.57 respectively. Proposed method was validated for 
precision, accuracy, linearity range, robustness and ruggedness [36]. 
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2.3.8 Tamboli AM, Chavan C and Mohite SK have developed a simple, 
reproducible and efficient RP-HPLC method for estimation of amlodipine besylate 
and enalapril maleate in its tablet dosage forms by C-8(4.6 × 250 mm, id 4.6 μm) 
column.  Acetonitrile:water, pH 3.8 with glacial acetic acid (60:40) as mobile phase. 
 The detection wavelength is 223 nm the method was demonstrated to be precise, 
accurate, specific and robust [37]. 
 
2.3.9 Mahant SS, Shetty AS, Gopinath B, Ahmed M and Sridhar BK have 
developed and validate a new reverse RP-HPLC method for the simultaneous 
determination of amlodipine besylate and telmisartan in combined dosage form. 
Supelco 516 C18 column having dimensions of 25 cm × 4.6 mm and particle size of 5 
μm in isocratic mode, with mobile phase containing a mixture of acetonitrile and 0.02 
M sodium dihydrogen orthophosphate dihydrate in the ratio of 60:40 was used.  The 
pH of mobile phase was adjusted to 4.5 with orthophosphoric acid.  The flow rate was 
1 mL/min and the column effluents were monitored at 240 nm.  The retention time for 
amlodipine besylate and telmisartan was found to be 3.58 and 5.38 min. respectively.  
The method was found to be linear in the range of 4-12 μg/mL and 32-96 μg/mL for 
amlodipine besylate and telmisartan, respectively [38]. 
 
2.3.10 Jayaseelan S, Rajasekar M, Ganesh S, Sekar V and Perumal P have 
developed a HPLC method for the simultaneous analysis of Losartan potassium, 
amlodipine besylate and hydrochlorthiazide in combined solid dosage form.  The 
mobile phase consisting of phosphate buffer (pH 7.0), methanol and acetonitrile in 
ratio of 60:20:20% vol./vol. was delivered at the flow rate of 1.0 mL/min and UV 
detection was carried out at 238 nm.  The sepn. was achieved using C18 reverse-phase 
column (250 × 4.6 mm I.D., particle size 5 μm).  The method was linear over the 
concn. range of 200.24-300.36 μg/mL for losartan potassium and 27.84-41.76 μg/mL 
for amlodipine besylate and 50.00-75.00 μg/mL for hydrichlorthiazide. The recovery 
obtained was 100.15%.  The validation of method carried out as per ICH guidelines 
[39]. 
 
2.3.11 Rajamanickam V and Rathinaraj B have developed a HPLC method for the 
simultaneous determination of metoprolol succinate and amlodipine besylate in a 
combined pharmaceutical-dosage form.  The separation was achieved on Inertsil ODS 
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- CV C18 (150 × 4.6 mm), using a mobile phase of sodium acetate buffer (the pH was 
adjusted to 3.0 ± 0.05 with orthophosphoric acid), acetonitrile and methanol (80:20 
vol./vol.) at 1mL/min flow rate, detector wavelength 215 nm. The method was 
validated and shown to be linear for Metaprolol succinate and amlodipine.  The 
correlation coefficient for metoprolol succinate and amlodipine are 0.999963 and 
0.999979, respectively.  The relative std. deviations for six replicate measurements in 
two sets of each drug in the tablets is always less than 2% and mean % error of active 
recovery not more than ± 1.5%. The proposed method was successfully applied to the 
pharmaceutical dosage forms containing the above-mentioned drug combination 
without any interference by the excipients [40]. 
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3.0 Aim of Present Work 
The aim of the present work is to developed analytical method for combine fixed dose 
formulation, which is novel to the market. The work of interest is Rosuvastatin 
Calcium and Amlodipine Besylate in the combine dosage form. There is no analytical 
method reported for the simultaneous determination of Rosuvastatin Calcium and 
Amlodipine Besylate in novel combination. Various publication are available 
regarding determination method of Rosuvastatin Calcium and Amlodipine Besylate 
but most of the methods are applicable to alone Rosuvastatin or Amlodipine in 
pharmaceutical dosage form or in biological fluids. 
 
There are few method reported in the literature for analysis of Rosuvastatin calcium in 
the pure form and pharmaceuticals formulation by UV- spectrophotometer[6]. 
Reversed phase HPLC and High performance thin layer chromatography (HPTLC) [7] 
[8][9][10] But HPLC method has many advantages over HPTLC method for 
quantization. Moreover, HPLC is often the first choice of chromatographers compared 
to HPTLC. A number of spectrophotometric  [17][18][19][20][21][22].  and HPLC[23][24][25]  
methods are reported in the literature for the estimation of Amlodipine, individually 
as well as in combination with other drugs. 
 
Present work deals with the development and validation of high performance liquid 
chromatographic assay method for the determination of Rosuvastatin Calcium and 
Amlodipine Besylate in bulk formulation. The combination formulation was validated 
as per ICH recommended guidelines, thus validated method can recommend for the 
routine quality control analysis  
 
The aim and scope of the proposed work are as under 
1. To developed suitable HPLC method for simultaneous determination of 
Rosuvastatin Calcium and Amlodipine Besylate in tablet formulation. 
2. Perform the validation for the developed method as per ICH guidelines. 
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4.0 Experimental 
 
4.1 Materials Chemicals and Reagents 
Drug samples and standard formulation was provided by Orbit Life science Pvt. Ltd., 
Mumbai, India. Analytical-grade Hydrochloric acid (35%), orthophosphoric acid (88%), 
Sodium hydroxide pellets were from Ranbaxy Fine Chemicals (New Delhi, India). 
acetonitrile and water, both HPLC-grades, were from Spectrochem Pvt. Ltd. 
(Mumbai, India). Nylon syringe filters (0.45 µm) were from Millex-HN, Millipore 
(Mumbai, India). 
 
4.2 Instrumental 
The chromatographic system used to perform development and validation of this 
method consisted of an LC-10ATvp binary pump, an SPD-M10Avp photodiode array 
detector and a rheodyne manual injector model 7725i with 20μl loop (Shimadzu, 
Kyoto, Japan) connected to a multi-instrument data acquisition and data processing 
system (Class-VP 6.13 SP2, Shimadzu). 
 
4.3 Chromatographic Conditions 
Chromatographic analysis was performed on YMC Pro C8 (150mm × 4.6mm id, 5 
µm particle size) column. The mobile phase consisted of acetonitrile and 20mM 
potassium dihydrogen phosphate buffer (pH adjusted to pH 3.5 with the help of dilute 
ortho-phosphoric acid) in the ratio of (45:55, v/v). The flow rate was 1.0 mL/min, the 
injection volume was 20 µL, and detection was performed at 242 nm using a photodiode 
array detector (PDA). 
 
4.4 Mobile Phase Preparation 
The mobile phase was consisted of 20mM potassium dihydrogen phosphate buffer pH 
3.5- acetonitrile (55:45, v/v). To prepare the buffer solution, 2.72 g potassium 
dihydrogen phosphate was weighed and dissolves in 1000 ml Milli-Q water, pH 
adjusted to pH 3.5 with the help of dilute ortho-phosphoric acid. Mobile phase was 
filtered through a 0.45 μm nylon filter (Millipore Pvt. Ltd. Benglore, India) and 
degassed in an ultrasonic bath (Spincotech Pvt. Ltd., Mumbai). 
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4.5 Diluent Preparation 
Mixed both the solvents acetonitrile : water, 50:50. 
 
4.6 Preparation of stock and standard solutions 
Stock solution of rosuvastatin (500µg/mL) and amlodipine (250µg/mL) was 
prepared by transferring accurately weighed, 25 mg rosuvastatin and 12.5 mg amlodipine  
into a 50 ml volumetric flask and adding 20 mL water- acetonitrile (50:50, v/v). The 
mixture was sonicated for 2 min to dissolve the content and the solution was then diluted 
to volume with the same solvent mixture. Standard solution, rosuvastatin (100µg/mL) 
and amlodipine (50µg/mL) was prepared by diluting 10 ml standard stock solution 
to 50 mL, in a volumetric flask, with the same solvent mixture. 
 
4.7 Preparation of stock and test solutions 
To prepare stock solution (500 + 250µg/mL) for assay, 20 tablets were weighed and 
mixed. An aliquot of powder equivalent to the weight of 5 tablets was accurately weighed 
and transferred to 100 ml volumetric flask. Water- acetonitrile (50:50, v/v), 60 mL was 
added to the flask and the mixture was sonicated for 10 min with normal hand shaking. 
The contents of the flask were then left to return to room temperature and diluted to 
volume with the same solvent mixture. This solution (20 mL) was filtered through a 
0.45-µm nylon syringe filter. 
To prepare test solution (100 + 50 µg/mL) for assay 10 mL test stock solution was 
transferred to 50 ml volumetric flask and diluted to volume with water-acetonitrile 
(50:50, v/v). 
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5.0 Result and Discussion 
 
5.1 Development and Optimization of the HPLC Method 
In the presence work, an analytical method based on high performance liquid 
chromatography using photodiode array detection was developed and validated for 
assay determination of Rosuvastatin Calcium and Amlodipine Besylate in bulk 
formulation. The analytical conditions were selected, keeping in mind the different 
chemical nature, molecular weight and solubility of Rosuvastatin Calcium and 
Amlodipine Besylate. Rosuvastatin Calcium and Amlodipine Besylate dissolved in 
polar solvent hence RP-HPLC was selected to estimate them. The column selection 
has been done on the basis of backpressure, resolution, peak shape, theoretical plates 
and day-to-day reproducibility of the retention time and resolution between 
Rosuvastatin Calcium and Amlodipine Besylate peak. After evaluating all these 
factors, YMC Pro C8 (150mm × 4.6mm id, 5 µm particle size) column was found to 
be giving satisfactory results. The selection of buffer based on chemical structure of 
both the drugs. For mobile phase selection, preliminary trials using mobile phases of 
different composition containing water adjusted to acid pH by addition of 
orthophosphoric acid and methanol resulted in poor peak shape. When methanol and 
water were replaced by acetonitrile and phosphate buffer (pH adjusted to pH 3.5 with 
the help of dilute ortho-phosphoric acid) in the ratio of (45:55, v/v) better peak shape 
was obtained. The proportion of the mobile phase components was optimized to reduce 
retention times and enable good resolution between both molecules. A detection 
wavelength of 242 nm was selected after scanning the standard solution over the range 
190-370 nm by use of the PDA detector. Detection at 242 nm resulted in good response 
and good linearity. Figure 3 and Figure 4 represent the chromatograms of standard and 
test preparation respectively. 
 
5.2 Method Validation 
 
5.2.1 Linearity: For linearity, seven points calibration curve were obtained in a 
concentration range from 20-80 µg/ml for amlodipine and 40-160 µg/ml for 
rosuvastatin. The response of the drug was found to be linear in the investigation 
concentration range and the linear regression equation for amlodipine was y = 22772x 
+ 38920 with correlation coefficient 0.9987 (Figure 10) and for rosuvastatin was y = 
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57261x + 6644.2 with correlation coefficient 0.9987 (Figure 11). Where x is the 
concentration in µg/ml and y is the peak area in absorbance unit. Chromatogram 
obtain during linearity study were shown in Fig. 5-11. 
 
 
Fig 1: Linearity curve for Amlodipine Besylate 
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Fig 2: Linearity curve for Rosuvastatin Calcium 
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Fig 3: Linearity study chromatogram of level-1 (40%) 
Minutes
0 1 2 3 4 5 6 7 8 9 10
m
A
U
0
100
200
A
m
lo
di
pi
ne
R
os
uv
as
ta
tin
 
 
Fig 4: Linearity study chromatogram of level-2 (60%) 
Minutes
0 1 2 3 4 5 6 7 8 9 10
m
A
U
0
100
200
300
A
m
lo
di
pi
ne
R
os
uv
as
ta
tin
 
 
Fig 5: Linearity study chromatogram of level-3 (80%) 
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Fig 6: Linearity study chromatogram of level-4 (100%) 
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Fig 7: Linearity study chromatogram of level-5 (120%) 
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Fig 8: Linearity study chromatogram of level-6 (140%) 
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Fig 9: Linearity study chromatogram of level-7 (160%) 
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5.2.2 LOD and LOQ: The limit of detection and limit of quantification were 
evaluated by serial dilutions of amlodipine besylate and rosuvastatin calcium stock 
solution in order to obtain signal to noise ratio of 3:1 for LOD and 10:1 for LOQ. The 
LOD value for amlodipine besylate and rosuvastatin calcium were found to be 0.1 
ppm and 0.1 ppm, respectively and the LOQ value 0.5 ppm and 0.4 ppm, respectively. 
Chromatogram of LOD and LOQ study were shown in Figure 12-15 
 
5.2.3 Precision  
Precision study was established by evaluating method precision and intermediate 
precision study. System precision was evaluated by analyzing the standard solution five 
times. Method precision of the analytical method was determined by analyzing six 
sets of sample preparation. Assay of all six replicate sample preparations was 
determined and mean % assay value, standard deviation, % relative standard deviation 
was calculated. 
 
Intermediate precision of the analytical method was determined by performing 
method precision on another day by another analyst under same experimental 
condition. Assay of all six replicate sample preparations was determined and mean % 
assay value, standard deviation, % relative standard deviation was calculated. 
 
Data obtain from precision experiments are given in Table 1 for intraday and interday 
precision study for both amlodipine besylate and rosuvastatin calcium. The RSD 
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values for intraday precision study and interday precision study was < 2.0% for 
amlodipine besylate and rosuvastatin calcium, which confirm that the method was 
precise. 
 
Table 1: Results of precision study 
Set 
Rosuvastatin Calcium Amlodipine Besylate 
Intraday 
(n = 6) 
Interday 
(n = 6) 
Intraday 
(n = 6) 
Interday 
(n = 6) 
1 101.44 100.94 100.88 101.59 
2 100.96 99.58 101.33 100.65 
3 100.32 99.03 100.48 100.33 
4 100.50 99.50 100.41 100.50 
5 100.07 99.01 99.65 100.20 
6 99.19 98.57 98.97 99.55 
Mean 100.41 99.43 100.28 100.47 
Std. deviation 0.772 0.8225 0.8523 0.6673 
% RSD 0.76 0.82 0.84 0.66 
 
 
Fig 10: Chromatogram of std. preparation of method precision study: 
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Fig 11: Chromatogram of test preparation of method precision study set-1: 
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Fig 12: Chromatogram of standard preparation of intermediate precision study: 
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Fig 13: Chromatogram of test preparation of intermediate precision study (set-1) 
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5.2.4Accuracy 
Accuracy was assessed by determination of the recovery of the method at three different 
concentrations (corresponding to 50, 100 and 150% of test solution concentration) Known 
amounts of amlodipine (25, 50, and 75 µg/ml) and Rosuvastatin (50, 100, and 150 µg/ml) 
were added to a diluent preparation and the amount of amlodipine and rosuvastatin 
recovered, was calculated. For each concentration, three sets were prepared and injected in 
duplicate. % Recovery was calculated at each level and recorded as shown in Table-2 and 3 
The mean recovery of rosuvastatin calcium was between 98.96% and 101.94%, and The 
mean recovery of amlodipine besylate was between 98.37% and 101.79%, which is 
satisfactory. 
 
Table 2: For Rosuvastatin Calcium: 
Accuracy Amount 
added 
Amount 
found 
% 
Recovery Mean 
Std. 
dev. 
% 
RSD 
Level 
50% 
49.92 50.8041 101.76 
101.87 0.09 0.09 50.24 51.2147 101.94 
50.08 51.0367 101.91 
100% 
100.12 99.0767 98.96 
99.56 0.54 0.54 99.88 99.8898 100.01 
100.16 99.8678 99.71 
150% 
150.04 150.071 100.02 
100.47 0.42 0.41 149.96 151.229 100.85 
149.92 150.765 100.56 
 
Table 3: For Amlodipine Besylate: 
Accuracy Amount 
added 
Amount 
found 
% 
Recovery Mean 
Std 
dev. 
% 
RSD 
Level 
50% 
24.92 24.9377 100.07 
101.17% 0.95 0.94 25.04 25.4542 101.65 
25.08 25.5287 101.79 
100% 
49.84 49.0252 98.37 
98.5% 0.11 0.11 49.92 49.1868 98.53 
49.96 49.2613 98.60 
150% 
74.8 73.6240 98.43 
98.77% 0.3 0.3 74.88 74.1461 99.02 
74.84 73.9902 98.86 
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Fig 14: Chromatogram of accuracy study level- 50% (set-1): 
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Fig 15: Chromatogram of accuracy study level- 100% (set-1): 
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Fig 16: Chromatogram of accuracy study level- 150% (set-1): 
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5.2.5 Robustness  
The robustness of the method was evaluated by assaying test solutions after slight but 
deliberate changes in the analytical conditions. The factor chosen for this study were the 
flow rate (±0.1 mL/min), pH of buffer solution (±0.2) and mobile phase composition 
[acetonitrile-water, 50: 50 and 40:60, v/v] 
 
The result of robustness study of the developed assay method was established in 
Table 4 and Table 5. The result shown that during all variance conditions, assay value 
of the test preparation solution was not affected and it was in accordance with that of 
actual. System suitability parameters were also found satisfactory; hence the 
analytical method would be concluded as robust. Chromatogram obtain during 
robustness study were shown in Fig23-28. 
 
Table 4: Evaluation data of robustness study of amlodipine besylate 
Robust Conditions % Assay 
System Suitability Parameters 
Asymmetry % RSD 
Flow 0.9 ml/min 99.82 1.14 0.27 
Flow 1.1 ml/min 100.09 1.12 0.28 
Buffer-ACN 
(50:50,v/v) 100.04 1.09 0.11 
Buffer-ACN 
(60:40,v/v) 99.93 1.11 0.26 
Buffer pH 3.3 99.94 1.06 0.21 
Buffer pH 3.7 100.01 1.08 0.15 
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Table 5: Evaluation data of robustness study of rosuvastatin calcium 
Robust Conditions % Assay 
System Suitability Parameters 
Asymmetry % RSD 
Flow 0.9 ml/min 99.91 1.16 0.23 
Flow 1.1 ml/min 99.67 1.12 0.10 
Buffer-ACN 
(50:50,v/v) 
99.27 1.05 0.08 
Buffer-ACN 
(60:40,v/v) 
99.66 1.10 0.16 
Buffer pH 3.3 99.86 1.03 0.22 
Buffer pH 3.7 99.81 1.10 0.08 
 
 
Fig 17: Chromatogram of standard preparation (flow rate 0.9 mL/min) 
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Fig 18: Chromatogram of standard preparation (flow rate 1.1 mL/min) 
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Fig 19: Chromatogram of standard preparation (Buffer pH 
3.3)
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Fig 20: Chromatogram of standard preparation (Buffer pH 3.7) 
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Fig 21: Chromatogram of standard preparation (mobile phase ratio 50:50) 
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Fig 22: Chromatogram of standard preparation (mobile phase ratio 60:40) 
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5.2.6 Solution stability Study 
The stability of the test solution was evaluated by two ways as short term stock 
solution stability (STSSS) for 12 hours & long term stock solution stability (LTSSS) 
for 12 days the solution was stored at room temperature and 2-5˚ C and tested at 
intervals of 12 hours & 12 days. The responses for the aged solution were evaluated 
using a freshly prepared standard solution. 
 
Table shows the results obtained in the solution stability study at different time 
intervals for the test preparations. It was concluded that the test preparation solution 
was stable up to 12 hrs at room temperature and 12 days at 2˚-5˚C because during this 
time, the result did not decrease below the minimum percentage. 
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Table 6: Stability data of amlodipine besylate 
Replicates 
STSSS(At RT) LTSSS(At 3-5ºC) 
0.0 hr(area) 12.0 hr(area) 0 Day(area) 12 Day(area) 
1 2255780 2250041 2266745 2262320 
2 2252800 2251870 2260560 2261981 
3 2252671 2253436 2268351 2264002 
4 2256089 2252256 2273154 2267412 
5 2258158 2252998 2267149 2257010 
Mean 2255099 2252120 2267191.8 2262545 
Mean Area 
Ratio 1.0013 1.0020 
 
Table 7: Stability data of rosuvastatin calcium 
Replicates 
STSSS(At RT) LTSSS(At 3-5ºC) 
0.0 hr(area) 12.0 hr(area) 0 Day(area) 12 Day(area) 
1 5571317 5575982 5576002 5568953 
2 5578740 5568120 5571940 5559560 
3 5568675 5562400 5578033 5565842 
4 5571052 5560871 5569625 5567097 
5 5567089 5568433 5572785 5570134 
Mean 5571374.6 5567161.2 5573677 5566317.2 
Mean Area 
Ratio 1.0007 1.0013 
 
5.2.7 System suitability  
A system suitability test of the chromatographic system was performed before each 
validation run. Five replicate injections of standard preparation were injected and 
asymmetry, theoretical plate, resolution and % RSD of peak area were determined for 
same. Acceptance criteria for system suitability, asymmetry should not be more than 
2.0, theoretical plate should not be less then 2000 and % RSD of peak area should not 
be more then 2.0, were full fill during all validation parameters  
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6.0 Calculation 
 
6.1 Formula and Equation  
Calculation formula for % assay  
 
Potency
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WeightStandard
AreaStandardMean
AreaTestMean
Assay ×××=%  
 
Relative standard deviation  
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6.2 Observation and calculation for linearity 
 
Data for standard preparation 
Replicate Area amlo Area rosu 
1 2248666 5563120 
2 2249100 5549451 
3 2253745 5566001 
4 2241987 5555937 
5 2260065 5569756 
   
Mean 2250712.6 5560853 
SD 6700.522017 8140.596753 
%RSD 0.297706692 0.146391152 
 
Data for test preparation 
Linearity Level 
(%) 
Area amlo Mean area amlo Area rosu Mean area rosu 
40% 
969445 
969565 
2341170 
2344773 
969685 2348376 
60% 
1391926 
1397995 
3423395 
3441260 
1404063 3459125 
80% 
1869488 
1874577 
4596182 
4608744 
1879665 4621305 
100% 
2234411 
2247968 
5555874 
5557363 
2261524 5558852 
120% 
2780646 
2783364 
6908210 
6901561 
2786082 6894911 
140% 
3267412 
3270094 
8125076 
8135689 
3272775 8146301 
160% 
3700183 
3669376 
9219749 
9139522 
3638569 9059295 
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6.3 Observation and calculation for precision study: 
 
Method precision study 
Data for standard preparation: 
Replicate Amlodipine Rosuvastatin 
1 2256711 5572630 
2 2259186 5568111 
3 2258366 5569578 
4 2265202 5588008 
5 2263146 5579654 
   
Mean 2260522.2 5575596.2 
SD 3526.497157 8239.596665 
%RSD 0.156003651 0.147779652 
 
Data for test preparation: 
Set No. Area amlo Mean area amlo Area rosu Mean area rosu 
Set-1 
2215956 
2260540 
5588039 
5590004 
2305123 5591969 
Set-2 
2300303 
2298121 
5634382 
5631538 
2295939 5628694 
Set-3 
2285480 
2284526 
5614223 
5609923.5 
2283572 5605624 
Set-4 
2277855 
2276256.5 
5599348 
5602966.5 
2274658 5606585 
Set-5 
2272082 
2265793 
5598976 
5595446 
2259504 5591916 
Set-6 
2260066 
2263769.5 
5589810 
5579847 
2267473 5569884 
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Prototype Calculation for set-1: 
 
Potency
claimLabel
WeightAvg.
WeightTest
WeightStandard
AreaStandardMean
AreaTestMean
Assay ×××=%  
 
For amlodipine besylate 
82.99
52.197
98.4
2260522
2260540% ×××= 200.1Assay  
% Assay = 100.88% 
 
For rosuvastatin calcium 
91.99
102.197
98.9
5575596
5590004% ×××= 200.1Assay  
% Assay = 101.43% 
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Intermediate precision study 
Data for standard preparation: 
Replicate Area amlo Area rosu 
1 2250129 5599515 
2 2254410 5605420 
3 2256333 5614786 
4 2256840 5600986 
5 2264096 5628305 
   
Mean 2256362 5609802 
SD 5067.166 11936.79 
%RSD 0.224572 0.212784 
 
Data for test preparation: 
Set No. Area amlo Mean area amlo Area rosu Mean area rosu 
Set-1 
2252641 
2254174 
5590778 
5585321 
2255707 5579864 
Set-2 
2263686 
2260383 
5579489 
5577552 
2257080 5575615 
Set-3 
2256566 
2258778 
5562873 
5560491 
2260989 5558109 
Set-4 
2245047 
2255911 
5567489 
5569989 
2266774 5572489 
Set-5 
2256207 
2256035 
5544491 
5559248 
2255862 5574004 
Set-6 
2254653 
2254685 
5561844 
5567845 
2254716 5573846 
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Prototype Calculation for set-1: 
Potency
claimLabel
WeightAvg.
WeightTest
WeightStandard
AreaStandardMean
AreaTestMean
Assay ×××=%  
 
For amlodipine besylate 
82.99
52.197
02.5
2256362
2254174% ×××= 200.1Assay  
% Assay = 101.59% 
 
For rosuvastatin calcium 
91.99
102.197
10
5609802
5585321% ×××= 200.1Assay  
% Assay = 100.94% 
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6.4 Observation and calculation for accuracy 
Data for standard preparation 
Replicate Area amlo Area rosu 
1 2258640 5556374 
2 2256398 5562107 
3 2251746 5561447 
4 2269101 5569513 
5 2263725 5549855 
Mean 2259922 5559859.2 
SD 6701.22985 7297.263268 
%RSD 0.296524829 0.131249066 
Std. wt (mg) 2.4760 5.0015 
 
Data for test preparation 
Sat no. Area amlo Mean area amlo Area rosu Mean area rosu 
50-Set-1 
1114815 
1138074 
2803220 
2823791 
1161333 2844362 
50-Set-2 
1157379 
1161646 
2855170 
2846611 
1165913 2838052 
50-Set-3 
1166551 
1165045 
2833862 
2836718 
1163539 2839574 
100-Set-1 
2225820 
2237343 
5468806 
5506873 
2248865 5544940 
100-Set-2 
2243617 
2244716 
5555531 
5552071 
2245814 5548610 
100-Set-3 
2248240 
2248120 
5552220 
5550846 
2247999 5549472 
150-Set-1 
3348282 
3359946 
8301967 
8341235 
3371610 8380502 
150-Set-2 
3393033 
3383773 
8428013 
8405568 
3374512 8383123 
150-Set-3 
 
3375440 
3376661 
8380420 
8379816 
3377881 8379212 
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For Rosuvastatin Calcium 
Accuracy 
level Set. No. 
Wt. 
taken  
(in gms) 
Vol.-1 Vol.-2 Vol.-3 
Amount 
added 
(ppm) 
50% 
1 12.48 50 10 50 49.92 
2 12.56 50 10 50 50.24 
3 12.52 50 10 50 50.08 
100% 
1 25.03 50 10 50 100.12 
2 24.97 50 10 50 99.88 
3 25.04 50 10 50 100.16 
150% 
1 37.51 50 10 50 150.04 
2 37.49 50 10 50 149.96 
3 37.48 50 10 50 149.92 
 
Amount added: Prototype calculation for set-1 
 
 
 
 
 
 
 
1000
3
2
1
)( ×
−
−×
−
=
Vol
Vol
Vol
WeightppmAddedAmount
1000
50
10
50
48.12)( ××=ppmAddedAmount
92.49)( =ppmAddedAmount
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Accuracy Amount 
added 
Amount 
found 
% 
Recovery Mean 
Standard 
dev. 
% 
RSD 
Level 
50% 
49.92 50.8041 101.76 
101.87 0.09 0.09 50.24 51.2147 101.94 
50.08 51.0367 101.91 
100% 
100.12 99.0767 98.96 
99.56 0.54 0.54 99.88 99.8898 100.01 
100.16 99.8678 99.71 
150% 
150.04 150.071 100.02 
100.47 0.42 0.41 149.96 151.229 100.85 
149.92 150.765 100.56 
 
Amount Found: Prototype calculation for set-1 
 
ionConcentratStandard
AreaMean
AreaTestMean
ppmFoundAmount ×=
Standard
)(  
 
100.03 ppmFoundAmount ×=
5559859
2823791)(  
 
50.80 ppmFoundAmount =)(  
 
 
% Recovery: Prototype calculation for set-1 
 
100
AddedAmount
FoundAmount
Recovery% ×=  
 
100
49.92
50.80Recovery% ×=  
 
101.76Recovery% = % 
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For Amlodipine Besylate 
Accuracy 
level Set. No. 
Wt. 
taken  
(in gms) 
Vol.-1 Vol.-2 Vol.-3 
Amount 
added 
(ppm) 
50% 
1 6.23 50 10 50 24.92 
2 6.26 50 10 50 25.04 
3 6.27 50 10 50 25.08 
100% 
1 12.46 50 10 50 49.84 
2 12.48 50 10 50 49.92 
3 12.49 50 10 50 49.96 
150% 
1 18.7 50 10 50 74.8 
2 18.72 50 10 50 74.88 
3 18.71 50 10 50 74.84 
 
Amount added: Prototype calculation for set-1 
 
 
 
 
 
 
 
1000
3
2
1
)( ×
−
−×
−
=
Vol
Vol
Vol
WeightppmAddedAmount
1000
50
10
50
23.6)( ××=ppmAddedAmount
92.24)( =ppmAddedAmount
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Accuracy Amount 
added 
Amount 
found 
% 
Recovery Mean 
Standard 
dev. % RSD 
Level 
50% 
24.92 24.9377 100.07 
101.17 0.95 0.94 25.04 25.4542 101.65 
25.08 25.5287 101.79 
100% 
49.84 49.0252 98.37 
98.5 0.11 0.11 49.92 49.1868 98.53 
49.96 49.2613 98.60 
150% 
74.8 73.624 98.43 
98.77 0.3 0.3 74.88 74.1461 99.02 
74.84 73.9902 98.86 
 
Amount Found: Prototype calculation for set-1 
 
ionConcentratStandard
AreaMean
AreaTestMean
ppmFoundAmount ×=
Standard
)(  
 
49.52 ppmFoundAmount ×=
2259922
1138074)(  
 
24.9377 ppmFoundAmount =)(  
 
 
% Recovery: Prototype calculation for set-1 
 
 
100
AddedAmount
FoundAmount
Recovery% ×=  
 
100
24.92
24.9377Recovery% ×=  
 
100.07Recovery% = % 
Chapter 4      Rosuvastatin Calcium and Amlodipine Besylate… 
160 
6.5 Observation and calculation for robustness: 
Summary of robustness study for amlodipine 
Std. 
Replicate 
Flow 
Rate 0.9 
mL/min 
Flow 
Rate 1.1 
mL/min 
Buffer: 
ACN 
50: 50 
Buffer: 
ACN 
60: 40 
Buffer 
pH 3.3 
Buffer 
pH 3.7 
1 2510150 2065147 2242523 2070450 2201780 2259222 
2 2522412 2071487 2242844 2077124 2202146 2250651 
3 2525127 2081006 2247640 2072582 2209337 2253487 
4 2515778 2069155 2248004 2083306 2211019 2252690 
5 2509962 2074508 2246625 2081421 2200852 2256710 
Mean 2516686 2072261 2245527 2076977 2205027 2254552 
SD 6942.505 5966.141 2647.093 5516.9 4763.244 3401.652 
%RSD 0.27 0.28 0.11 0.26 0.21 0.15 
Test 
Replicate 
2508146 
2522634 
2102515 
2051035 
2243578 
2243817 
2057417 
2088528 
2201648 
2202450 
2253649 
2252877 
Mean 2515390 2076775 2243698 2072973 2202049 2253263 
Standard 
wt (mg) 4.98 4.98 5.03 5.03 4.98 4.98 
Test wt 
(mg) 199.2 199.2 200.7 200.7 198.8 
198.8 
 
Avg. test 
wt (mg) 200.1 200.1 200.1 200.1 200.1 200.1 
% Assay 99.82 100.09 100.04 99.93 99.94 100.01 
 
Prototype Calculation for amlodipine besylate: 
 
Potency
claimLabel
WeightAvg.
WeightTest
WeightStandard
AreaStandardMean
AreaTestMean
Assay ×××=%  
 
82.99
52.199
98.4
2516686
2515390% ×××= 200.1Assay  
 
 % Assay = 99.82% 
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Summary of robustness study for rosuvastatin 
 
Std. 
Replicate 
Flow 
Rate 0.9 
mL/min 
Flow 
Rate 1.1 
mL/min 
Buffer: 
ACN 
50: 50 
Buffer: 
ACN 
60: 40 
Buffer 
pH 3.3 
Buffer 
pH 3.7 
1 6170215 5079630 5600776 5049458 5426740 5549085 
2 6154025 5074123 5600912 5033084 5429202 5548232 
3 6179800 5071479 5602135 5053786 5408114 5547120 
4 6149656 5073888 5608242 5050903 5413604 5542303 
5 6181913 5066251 5609974 5050718 5400488 5553758 
Mean 6167122 5073074 5604408 5047590 5415630 5548100 
SD 14711.09 4843.591 4366.345 8262.328 12221.97 4109.934 
%RSD 0.23 0.10 0.08 0.16 0.22 0.08 
Test 
Replicate 
6208267 
6208267 
5074078 
5074078 
5603401 
5603401 
5023666 
5023666 
5426746 
5426746 
5545257 
5545257 
Mean 6188933 5073873 5601930 5043417 5415730 5545476 
Standard 
wt (mg) 9.93 9.93 9.97 9.97 9.93 9.93 
Test wt 
(mg) 199.2 199.2 200.7 200.7 
198.8 
 
198.8 
 
Avg. test 
wt (mg) 200.1 200.1 200.1 200.1 200.1 200.1 
% Assay 100.01 99.67 99.27 99.66 99.86 
99.81 
 
 
Prototype Calculation for rosuvastatin calcium: 
 
Potency
claimLabel
WeightAvg.
WeightTest
WeightStandard
AreaStandardMean
AreaTestMean
Assay ×××=%  
 
91.99
102.199
93.9
6167122
6188933% ×××= 200.1Assay  
 
% Assay = 100.01% 
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Chapter 5:  “Simultaneous estimation of four drugs by HPLC, used 
  as anti-acidity and side therapy” 
 
  
 
1.0 Introduction to Drugs 
 
1.1 Domperidone 
Domperidone is chemically  5- chloro- 1- [1- [3- (2- oxo- 2, 3- dihydro- 1H-
benzimidazol- 1- yl) propyl]- piperidin- 4- yl]- 1, 3- dihydro- 2H benzimidazol- 2- 
one. Molecular formula of Domperidone is C22H24ClN5O2 having molecular weight 
425.911 g/mol. and its melting point is 244°C – 246°C [1,2,3]. 
 
Domperidone blocks the action of dopamine. It has strong affinities for the D2 and D3 
dopamine receptors, which are found in the chemoreceptor trigger zone, located just 
outside the blood brain barrier, which - among others - regulates nausea and vomiting. 
Acts by selectively antagonizing the peripheral dopaminergic D2 receptors in the 
gastrointestinal wall, thereby enhancing gastrointestinal peristalsis and motility and 
increasing lower esophageal sphincter tone. This increased gastrointestinal motility 
can facilitates the movement of acid contents further down in the intestine preventing 
reflux esophagitis and thereby controlling nausea and vomiting.[4] Domperidone is 
used, together with metoclopramide, cyclizine, and 5HT3 receptor antagonists (such 
as granisetron) in the treatment of nausea and vomiting 
 
1.2 Ranitidine Hydrochloride 
Ranitidine Hydrochloride is chemically N-(2-[(5-(dimethylaminomethyl)furan-2-
yl)methylthio]ethyl)- N-methyl-2-nitroethene-1,1-diamine. Molecular formula of 
Ranitidine HCl is C13H22N4O3S having molecular weight 314.4 g/mol. Its melting 
point is 133°C – 134°C [1,2,3]. 
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Histamine is a natural chemical that stimulates the stomach cells to produce acid. 
Ranitidine belongs to a class of medications, called H2-blockers that block the action 
of histamine on stomach cells, thus reducing stomach acid production. Ranitidine is 
useful in promoting healing of stomach and duodenal ulcers, and in reducing ulcer 
pain. Ranitidine has been effective in preventing ulcer recurrence when given in low 
doses for prolonged periods of time. In doses higher than that used in ulcer treatment, 
ranitidine has been helpful in treating heartburn and in healing ulcer and inflammation 
of the esophagus resulting from acid reflux. 
 
1.3 Famotidine Hydrochloride 
Famotidine is chemically 3-([2-(diaminomethyleneamino)thiazol- 4-yl]methylthio)-
 N'-sulfamoylpropanimidamide, Molecular formula of Famotidine is C8H15N7O2S3 
having molecular weight 337.449 g/mol. Its melting point is 163°C – 164°C [1,2,3]. 
 
Famotidine is a histamine H2-receptor antagonist that inhibits stomach 
acid production, and it is commonly used in the treatment of peptic ulcer disease 
(PUD) and gastro esophageal reflux disease (GERD/GORD). Famotidine has no 
effect on the cytochrome P450 enzyme system, and does not appear to interact with 
other drugs. Histamine is a chemical made by the body that stimulates cells lining the 
stomach to produce acid. Famotidine belongs to a class of medications called H2-
blockers that blocks the action of histamine on stomach cells, thus reducing 
production of acid by the stomach. 
 
1.4 Omeprazole 
The chemical IUPAC name of omeprazole is 6-methoxy-2-[(4-methoxy-3,5-
dimethylpyridin-2-yl)methylsulfinyl]-1H-benzimidazole. Its empirical formula is 
C17H19N3O3S. 
 
Omeprazole Mg is a white to off-white free-flowing crystalline powder with a 
molecular weight of 713.1 g/mol[1,2,3]. Omeprazole is highly effective inhibitor of 
gastric acid secretion used in the therapy of stomach ulcers and zollinger-ellison 
syndrome. The drug inhibits the H(+)-K(+)-ATPase (H(+)-K(+)-exchanging ATPase) 
in the proton pump of gastric parietal cells. [PubChem] [5,6].  
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Figure 1: Chemical Structure of Ranitidine, Famotidine, Omeprazole, and 
Domperidone 
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2.0 Literature Review 
There are many reported method for the determination of Domperidone, Ranitidine, 
Famotidine and Omeprazole, also there are many reported method for the 
determination of Domperidone with Ranitidine or Omeprazole as a combine dosage 
forms or in combination with other drug in pharmaceutical dosage forms or 
individually in biological fluids. Brief details for the same are as under: 
 
2.1 Literature Review for Famotidine Hydrochloride 
 
2.1.1 Helali N and Monser L have developed and validated a simple, sensitive and 
rapid HPLC method for the simultaneous determination of famotidine and related 
impurities in pharmaceuticals.  Chromatographic separation was accomplished within 
10 min on a porous graphitic carbon (PGC) column using 50:50 vol./vol. ACN-water 
containing 0.5% pentane sulfonic acid (PSA) as the mobile phase separation was 
achieved with a flow rate of 1 mL/min and a detection wavelength of 265 nm.  The 
calibration curves were linear over a concentration range of 1.5-100 μg/mL.  The 
intra- and interday RSDs (n = 5) for the retention times and peak area were all less 
than 2%.  The method was sensitive with an LOD (S/N = 3) of 0.1 μg/mL for FMT, 
impurity C and 0.05 μg/mL for impurity 2, A and D[9]. 
  
2.1.2 Basavaiah K., Prameela HC, Chandrashekar U, Somashekar BC have 
developed a rapid assay method for the determination of famotidine in pharmaceutical 
preparations for assessment of product quality utilizing high-performance liquid 
chromatography. The HPLC separation could be undertaken on a reversed phase 
Accurasil SS C18 (5 μm) column (25 cm × 4.6 mm i.d.) by a mobile phase consisting 
of acetonitrile-0.1% phosphoric acid (pH 3.0) (80:20) at a flow rate 1.0 mL/min.  The 
detector wavelength was at 268 nm with a sensitivity of 0.2 AUFS  The calibration 
graph was linear from 5.0 to 330 μg/mL with the limits of detection (LOD) and 
quantification(LOQ) being 1.0 and 3.0 μg/mL, respect. Recoveries ranged from 
96.28% to 102.21%[10]. 
 
2.1.3 Cakir B, Tosun AU, Sahin MF have developed a rapid and specific HPLC 
method for determination of famotidine in pharmaceuticals.  The method was applied 
to medicines on the Turkish market. LiChrospher RP-18 column, HP-1050 UV-
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detector and MeOH-0.1M aq. NH4OAc (30:70) as the mobile phase (flow rate 1.0 mL 
min-1) were used.  The determination was carried out at 254 nm[11]. 
 
2.1.4 Husain S, Khalid S, Nagaraju V, Nageswara RR  have developed a simple 
and rapid HPLC method for the separation and determination of small amounts of 
process impurities. The separation was achieved on a RP-C8 column using 
acetonitrile-0.01M aq. KH2PO4 (25:75; pH 3.15) as eluent.  The method was used not 
only for quality assurance but also for monitoring the reactions involved in process 
development of famotidine.  The mean recovery of famotidine from authentic samples 
was 99.48 ± 1.87% and the limit of detection was 5 × 10-9 g[12]. 
 
2.1.5 Sheikh MA, Alkaysi HN, Badwan AA have developed a RP-HPLC method for 
the quantitation of famotidine in tablet formulation using a mobile phase consisting of 
0.1M phosphate buffer (84%), MeCN (11%), and MeOH (5%) at a pH of 6.5.  The 
detection wavelength was set at 285 nm [13]. 
 
2.1.6 Parasrampuria J and Das Gupta V have developed a stability-indicating 
HPLC method for the determination of famotidine in injections, suspensions, and 
tablets.  The method is precise and accurate with a percent relative std. deviation of 
1.1-1.3.  The excipients present in the dosage forms did not interfere with the assay 
procedure. The samples decomposed under drastic conditions showed a total of 3 new 
peaks in the chromatograms [14]. 
 
2.2 Literature Review for Ranitidine Hydrochloride 
 
2.2.1 Asad R, Abdul I and Zeshan M have developed a rapid, simple and sensitive 
spectrophotometric method for the determination of ranitidine hydrochloride in 
pharmaceutical pure and dosage forms.  The method depends on the charge-transfer 
complex formation between ranitidine bases as n-electron donor with chloranil as 
acceptor to give a colored complex that absorbs maximally at 550 nm.  Beer's law is 
obeyed in the concentration ranges 2-40 μg/mL with molar absorptivity of 2.5104 
L/mol-1/cm-1. Statistical comparison of the results was performed with regard to 
accuracy and precision using student's t-test and F-ratio at 95% confidence level[15]. 
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2.2.2 Lin G, Zeng XP, Yu ST have developed HPLC method for determination of 
ranitidine hydrochloride capsules. Hypersil ods c18 column was used with 
acetonitrile-0.05 mol/L-1citric acid (pH was adjusted to 3.5 with triethylamine) 
(13:87) as the mobile phase.  The flow rate was 1.0 mL/min-1.  The detection 
wavelength was 314 nm.  The linear range was 5.0-50.0 μg/mL-1 (r = 0.9999).  The 
av. recovery rate was 100.0%.  RSD was 0.95% (n = 6) [16]. 
 
2.2.3 Lau-Cam CA, Rahman M, Roos RW have developed HPLC method with 
spectrophotometric detection for the rapid assay of ranitidine in dosage forms and 
samples from tablet dissolution testing. Analyses were carried out on a Microsorb-
MV C18 column, with a (1:1) mixture of MeOH-0.01M Na2HPO4 (pH 7.0) as the 
mobile phase, and detection at 320 nm.  At a flow rate of 1.0 mL/min, typical 
retention times for ranitidine and its S-oxide were 3.50 min and 1.95 min, 
respectively.  Detector responses were linearly related to on column concentrations of 
ranitidine and ranitidine S-oxide in the ranges 0.035-9.00 μg and 0.005-0.320 μg, 
respectively.  Recoveries of ranitidine from spiked synthetic formulations simulating 
tablets, injections and syrups ranged from 99.7% to 100.5% of the added amount [17]. 
 
2.2.4 Aboul Enein HY and Rafiqul IM have developed a sensitive, accurate and 
reproducible method for the determination of ranitidine in pharmaceuticals is 
described.  An isocratic HPLC elution method was employed which requires about 10 
min to be performed.  The concentration of ranitidine was 98.19 and 98.33% in 
Zantac and Apo-ranitidine tablets, respectively [18]. 
 
2.2.5 Das Gupta V has developed a stability-indicating reverse-phase HPLC method 
to quantify ranitidine in pharmaceutical dosage forms.  The method is accurate and 
precise with a percent relative std. deviation of 1.5% based on 5 injections. The 
extration procedure for I from tablets is very simple and there was no interference 
from the excipients present.  I appear to be stable to heat on the acidic side and very 
susceptible to decomposition on the basic side.  It lost 84.4% of potency on 20-min 
boiling with NaOH with a new peak in the chromatogram.  It lost 37.8% of the 
potency on treatment with H2O2 solution for 20 min at room temperature with 2 new 
peaks in the chromatogram [19]. 
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2.2.6 Kulkarni VL and Mahulikar PP have developed a simple, rapid, and 
reproducible isocratic reverse phase high performance liquid chromatographic assay 
method for determination of Ranitidine in solid dosage form.  The chromatographic 
separation was performed on YMC C18, ODS-AM stainless steel column (150 mm × 
4.6 mm ID, particle size 5 μ).  The mobile phase comprised of 50 mM ammonium 
acetate in water having pH 5 and MeOH.  The detection was performed using PDA 
detector.  The percentage recovery of the Ranitidine in the tablets was in the range of 
100.9% to 102%.  The chromatographic response of the analyte was linear in the 
range of 100 to 500 μg/mL with correlation coefficient > 0.99 [20]. 
 
2.3 Literature Review for Domperidone Hydrochloride 
 
2.3.1 Rajendraprasad Y et all have developed a simple RP-HPLC method for the 
estimation of domperidone in bulk and pharmaceutical formulations.  The estimation 
was carried out on Gemini, Phenomonex, C-18 (250 × 4.6 mm, 5 μ) column using a 
mobile phase consisting of potassium dihydrogen phosphate buffer-acetonitrile-
methanol (40:30:30).  The eluent was monitored at 288 nm.  The results have been 
validated statistically and recovery studies confirmed the accuracy of proposed 
method [21]. 
 
2.3.2 Zhuang R and Li S have developed a HPLC method for content and uniformity 
determination of domperidone tablets.  Kromasil C18 column (250 mm × 4.6 mm, 5 
μm) was used with the mobile phase of methanol-water (3:1) at the flow rate of 1 
mL/min under the detection wavelength at 287 nm.  The linear range of domperidone 
was 5.004-30.024 μg/mL (r = 0.9999), and the av. recovery was 100.03% (RSD = 
0.75%) [22]. 
 
2.3.3 Zhang C et all have developed a HPLC method for determination of 
domperidone and its related substances from gel dosage form.  Inertsil ODS-3 column 
was used with MeOH-0.1% wt./vol. aq. ammonium acetate buffer (70:30, vol./vol.) as 
mobile phase.  The flow rate was 1.0 mL/min-1, column temperature was set at 35° 
and detecting wavelength was set at 287 nm.  The peak of domperidone was 
completely separated with other impurity peaks.  Calibration of domperidone was 
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performed over the range of 10.0-100.0 μg/mL-1 (r = 0.9999).  The average recovery 
rate was 101.0% and RSD was 1.1% (n = 9) [23]. 
 
2.3.4 Zhou DJ, Xu LP, Zhang HM have developed a HPLC method for the 
determination of the related substances of domperidone orally disintegrating tablets. 
 The RP-HPLC was performed on ODS C18 column (5 μm, 4.6 mm × 150 mm) at 
room temp., with mobile phase of methanol-0.5% acetic ammonium solution (65:35) 
at a flow rate of 1.0 mL/min-1, and detection wavelength of 286 nm.  Good resolution 
was obtained after the sample was destroyed by acid, alkali, heat, and light [24].   
  
2.3.5 Sadana SG and Potdar A have developed a normal phase HPLC method for 
the determination of domperidone, and statistically evaluated for its accuracy and 
precision in the assay of domperidone in commercial preparations.  Excipients and 
impurities normally present did not interfere, and the mean recoveries were 100.05% 
for domperidone [25]. 
 
2.4 Literature Review for Omeprazole Sodium 
 
2.4.1 Trivedi HK and Patel MC have developed a liquid chromatographic method 
for the determination of omeprazole and its related substances in bulk material and 
com. dosage forms.  A gradient elution of filtered sample was performed on Zorbax 
XDB C8 (150 × 4.6), 5μ column with Glacine buffer (pH-8.8) as a mobile phase-A, 
Acetonitrile : Methanol (83:17) as a mobile phase-B and UV detection at 302 nm. 
 Mobile phase was delivered at flow of 1.2 mL/min and at maintaining the column 
temperature at 25°C. The active ingredient - omeprazole was successfully separated 
from its all related substances, including process impurities and other possible 
impurities of oxidation and decomposition [26]. 
 
2.4.2 Xiao H et al have developed a HPLC method for content determination of S-
omeprazole sodium and its related substances.  The separation of S-omeprazole 
sodium and the related substances was carried out on a Phenomenex Luna C18 
column, and the mobile phase consisted of methanol-0.033 mol/L-1 ammonium 
dihydrogen phosphate-triethylamine.  The detection wavelength was 302 nm, the flow 
rate was 1.0 mL/min-1, the column temp. was 25°, and the sample size was 20 μL. 
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 The linear range of omeprazole sodium was 10-500 mg/L-1 (r = 0.9997).  The av. 
recovery rate was 100.27% (RSD = 0.74%) [27].  
  
2.4.3 Iuga C, Bojita M, Leucuta SE have developed a gradient RP-LC method for 
the determination of omeprazole and its process-related impurities (noted as: impurity 
A, B, C, D, G, H). Separation was achieved with a Zorbax Extend C18 column and 
acetonitrile: water: triethylaminel% (pH adjusted to 9.5) as eluent, at a flow rate of 0.8 
mL/min.  UV detection was performed at 280 nm.  The described method was linear 
over a range of 40.6-203μg/mL for omeprazole, 0.9556-14.334μg/mL for impurity A, 
1.1568-17.352μg/mL for impurity B, 1.0772-16.158μg/mL for impurity C, 1.289-
19.344 μg/mL for impurity D, and 0.7968-11.952μg/mL for impurity H [28]. 
  
2.4.4 Wang L and Ma C have developed a HPLC method for determination of the 
content of omeprazole in omeprazole enteric-coated capsules.  The Diamonsil C18 
(250 mm × 4.6 mm, 5 μm) was used, methanol-phosphate butter solution (its pH = 
7.6) (80:20) was as mobile phase, the flow rate was 1.0 mL/min-1, and the detection 
wavelength was at 302 nm.  The linear range of omeprazole was 10-50 μg (r = 
0.9999), and the av. recovery was 99.60% (RSD = 1.36%).  The method was simple, 
rapid and accurate, and could be used for the quality control of omeprazole [29]. 
 
2.4.5 Murakami FS et al have developed and Validate a HPLC method was to 
quantify omeprazole in delayed release tablets. The analysis was carried out using a 
RP-C18 column with UV detection at 280 nm. Phosphate buffer (pH 7.4) and 
acetonitrile (70:30 vol./vol.) at a flow-rate of 1.5 mL/min-1 used as a mobile phase. 
The retention time of omeprazole was about 5 minute.  The linearity in the range of 
10.0-30.0 μg/mL presented a correlation coefficient of 0.9995 [30]. 
 
2.5 Literature Review for Combinations 
 
2.5.1 Gawande VV and Puranik MP have developed a RP-HPLC method for 
simultaneous estimation of domperidone in combination with esomeprazole 
magnesium in capsule formulation.  Chromatography was performed on Inertsil C18 
(250 mm × 4.6 mm i.d. particle size 5 μm) column in isocratic mode with mobile 
phase containing. 0.05 M potassium dihydrogen phosphate:acetonitrile:methanol in 
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the ratio 40:30:30 % (vol./vol./v) and pH of the final mobile phase was adjusted to 
7.44 ± 0.03 with 5 M KOH.  The flow rate was 1.0 mL/min and the eluent was 
monitored at 284 nm.  The selected chromatographic conditions were found to 
effectively separated domperidone (run time 9.74 ± 0.33 min) and esomeprazole 
magnesium (run time 7.16 ± 0.44 min).  Linearity for domperidone and esomeprazole 
magnesium found in the range of 3-300 and 4-400 μg/mL respectively [31]. 
 
2.5.2 Sivasubramanian L and Anilkumar V have developed a RP-HPLC method 
for the determination of omeprazole and domperidone from tablet formulations.  The 
determination was carried out on a Hypersil, ODS, C18 (150 × 4.6 mm, 5 μ) column 
using a mobile phase of methanol:0.1 M ammonium acetate (pH 4.9) (60:40).  The 
flow rate and runtime were 1 mL/min and 10 min. respectively. The eluent was 
monitored at 280 nm.  The method was reproducible, with good resolution between 
omeprazole and domperidone.  The detector response was found to be linear in the 
concentration range of 10-60 μg/mL for omeprazole and 5-30 μg/mL for domperidone 
[32]. 
 
2.5.3 Patel NM, Fursule AR, Shirkhedkar AA have developed a RP-HPLC method 
for the simultaneous determination of ranitidine and ondansetron in tablets.  This was 
resolved by using a mobile phase (MeOH-pH 5.8 0.05M phosphate buffer (60:40)) at 
a flow rate of 1.0 mL/min on an isocratic HPLC system, a UV-Vis detector, an ODS 
C18 reversed-phase column (250 × 4.6 mm) at 310 nm.  The linear dynamic range for 
ranitidine at 35.0-195.0 and for ondansetron at 1.0-5.0 μg/mL was obtained by this 
method [33]. 
 
2.5.4 Sultana N, Arayne MS, Naveed S have developed a RP-HPLC method for 
analysis of enalapril in the presence of H2-receptor antagonists. Enalapril maleate was 
separated from H2-receptor antagonists by use of a 250 mm × 4.6 mm, 5-μm particle, 
C18 column with 86:14 (vol./vol.) methanol-water, pH adjusted to 3.5, as mobile 
phase, at a flow rate of 1.5 mL min-1.  UV detection was performed at 227 nm.  The 
retention times of enalapril maleate, ranitidine, cimetidine, and famotidine were 3, 5, 
7, and 7.5 min, resp.  The detection limit for enalapril was 10 ngmL-1 and the 
calibration plot was linear in the range 2.5-50 μg mL-1.  In vitro interaction of 
enalapril with the commonly administered H2-receptor antagonists cimetidine, 
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ranitidine, and famotidine in simulated gastric juice at different pH and 37°C was also 
studied by use of this method [34]. 
 
2.5.5 Saisho K et all have developed a method for simultaneous analysis of 4 H2-
receptor-antagonists (ranitidine, cimetidine, nizatidine and famotidine) HPLC.  The 
H2-antagonists were separated by using an ODS column with a 9:1 mixture of 0.08 
vol% CF3CO2H-MeOH, with monitoring at 230 nm.  Linear calibration curves were 
obtained in the concentration range of 0.005 to 0.04 mg/mL for these H2 antagonists. 
The proposed method was applied to the analysis of commercial preparations of H2-
antagonists (tablets, powders, granules and capsules). The analysis results were in the 
range from 98.8 to 100.6% [35]. 
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3.0 Aim of Present Work 
 
Various publications are available regarding determination method of Domperidone, 
Ranitidine, Famotidine and Omeprazole but most of the methods are applicable to 
single drug itself in pharmaceutical dosage form or in biological fluids. There are 
some methods reported for the determination of Domperidone with Ranitidine or 
Omeprazole as a combine dosage forms or in combination with other drug in 
pharmaceutical dosage forms. To our knowledge, no analytical method for the 
simultaneous determination of Domperidone, Ranitidine, Famotidine and Omeprazole 
in combine dosage forms has been published 
 
The aim and scope of the proposed work to developed and validate a simple and 
suitable HPLC method for simultaneous determination of Domperidone, Ranitidine, 
Famotidine and Omeprazole, Which could de readily applicable for Purity and Assay 
determination in either single dosage form or in combine dosage form 
 
 Domperidone Hydrochloride 
 Ranitidine Hydrochloride 
 Famotidine Hydrochloride 
 Omeprazole Sodium 
 Omeprazole Magnesium 
 Domperidone + Omeprazole (Na/Mg salt) 
 Domperidone + Ranitidine 
 Domperidone + Famotidine 
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4.0. Experimental 
 
4.1 Materials Chemicals and Reagents 
Drug samples and standard formulation was provided by Orcave Pharma, Rajkot, Gujarat, 
India and SMS pharmaceuticals, Ankleshwar, Gujarat, India Analytical-grade 
Hydrochloric acid (35%), orthophosphoric acid (88%) and Sodium hydroxide pellets were 
from Ranbaxy Fine Chemicals (New Delhi, India). acetonitrile and water, both HPLC-
grade, were from Spectrochem Pvt. Ltd. (Mumbai, India). Nylon syringe filters (0.45 
µm) were from Millex-HN, Millipore (Mumbai, India). 
 
4.2 Instrumental 
Liquid chromatography was performed with Waters equipment with TM 600 
quaternary pump, Waters 2489 UV/Vis detector, Waters 600 controller, Waters in-
line degasser AF and manual injector with 20 µl loop. The equipment was connected 
to a multi-instrument data-acquisition and data-processing system (Empower 
software).  
 
4.3 Chromatographic condition 
Chromatographic analysis was performed on Phenomenex, Gemini C-18 (250 × 4.6 
mm, 5μ) column. The mobile phase consisted of acetonitrile and 20mM potassium 
dihydrogen phosphate buffer (pH adjusted to pH 3.0 with the help of dilute ortho-
phosphoric acid) in gradient programming as shown in table 1. The flow rate was 1.0 
mL/min, the injection volume was 20 µL, and detection was performed at 272 nm using 
UV detector. 
 
4.4 Mobile Phase Preparation 
The mobile phase consist of acetonitrile and Potassium dihydrogen phosphate 
buffre(pH 3.5 adjusted with ortho-phosphoric acid) in the). Mobile phase was 
degassed by sonication with an ultrasonic bath. 
 
Gradient programming 
Time (A) ACN (B) Buffer Curve 
0.0 2 98 6 
15.0 98 2 6 
15.1 2 98 6 
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4.5 Diluent Preparation 
Mixed both the solvents Acetonitrile:Water :: 50:50. 
 
4.6 Preparation of stock and standard solutions 
Standard stock solution (500µg/mL) was prepared by transferring accurately 
weighed, 25 mg of each drug working standards into a 50 ml volumetric flask and adding 
20 mL water- acetonitrile (50:50, v/v). The mixture was sonicated for 2 min to dissolve 
the content and the solution was then diluted to volume with the same solvent mixture. 
Standard solution (100µg/mL) was prepared by diluting 10 mL standard stock 
solution to 50 mL, in a volumetric flask, with the same solvent mixture. 
 
4.7 Preparation of stock and test solutions 
Test stock solution (500µg/mL) was prepared by transferring accurately weighed, 25 
mg of each drug samples into a 50 ml volumetric flask and adding 20 mL water- 
acetonitrile (50:50, v/v). The mixture was sonicated for 2 min to dissolve the content and 
the solution was then diluted to volume with the same solvent mixture. Standard solution 
(100µg/mL) was prepared by diluting 10 mL standard stock solution to 50 mL, in a 
volumetric flask, with the same solvent mixture. 
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5.0 Result and Discussion 
 
Development and Optimization of the Method 
In the present work, an analytical method based on LC using UV detection was 
developed and validated for simultaneous estimation of Ranitidine Famotidine, 
domperidone and Omeprazole. The analytical conditions were selected; keeping in 
mind the different chemical nature of domperidone and omeprazole and almost same 
chemical nature of ranitidine and famotidine. 
 
The column selection has been done on the basis of backpressure, resolution, peak 
shape, theoretical plates and day-to-day reproducibility of the retention time and 
resolution between all the drugs as ranitidine and famotidine were eluting on the same 
time with almost all normal isocratic modes. After evaluating all these factors, 
Phenomenex, Gemini C-18 (250 × 4.6 mm, 5μ) column was found to be giving 
satisfactory results. 
  
The selection of buffer based on chemical structure of the drugs. The acidic pH range 
was found suitable for resolution, stability, theoretical plates and peak shape of both 
components. Best results were obtained with 20mM potassium dihydrogen phosphate 
pH adjusted to 3.0 by using dilute orthophosphoric acid solution in combination with 
acetonitrile as organic phase in gradient programming. For the selection of organic 
constituent of mobile phase, acetonitrile was chosen to reduce the longer retention 
time and to attain good peak shape. Optimized mobile phase proportion was providing 
good resolution between all four drugs. 
 
5.1 Method Validation 
 
5.1.1 Linearity 
For linearity six points calibration curve were obtained by plotting concentration of 
analyte against peak area, in the concentration range from 40-140 µg/mL (corresponded 
to 40% to 140%, respectively, of the test solution concentration) for each drug. The 
response of the drug was found to be linear in the investigation. Concentration range 
and the linear regression equation for each drug are as under. 
 
Chapter 5  Simultaneous estimation of four drugs by HPLC… 
180 
Drug 
Linear regression 
equation 
Correlation 
coefficient 
Famotidine y = 30614x + 37887 0.9993 
Ranitidine y = 74974x + 909.24 0.9999 
Domperidone y = 40935x + 87005 0.9990 
Omeprazole y = 30027x - 67801 0.9998 
 
Where x is the concentration in mg/ml and y is the peak area in absorbance unit. 
Chromatogram obtain during linearity study were shown in Fig 1-4 
 
Fig 1: Linearity curve for famotidine  
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Fig 2: Linearity curve for Ranitidine 
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Fig 3: Linearity curve for Domperidone 
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Fig 4: Linearity curve for Omeprazole 
y = 30027x - 67801
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Evaluation of Linearity Study 
 
 
Fig 5: Chromatogram of 40% Linearity level: 
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Fig 6: Chromatogram of 60% Linearity level: 
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Fig 7: Chromatogram of 80% Linearity level: 
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Fig 8: Chromatogram of 100% Linearity level: 
7
.6
3
5
8
.1
2
4
1
0
.3
1
6
1
2
.1
7
5
A
U
0.00
0.20
0.40
0.60
0.80
Minutes
0.00 1.70 3.40 5.10 6.80 8.50 10.20 11.90 13.60 15.30 17.00
 
 
 
Fig 9: Chromatogram of 120% Linearity level: 
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Fig 10: Chromatogram of 140% Linearity level: 
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Fig 11: Chromatogram of 160% Linearity level: 
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5.1.2 Limit of detection and Limit of quantitation study 
The limit of detection (LOD) and limit of quantification (LOQ) were evaluated by 
serial dilutions of single dug stock solution in order to obtain signal to noise ratio of 
3:1 for LOD and 10:1 for LOQ. The LOD value was found to be 0.1 ppm for 
Ranitidine, 0.1ppm for Famotidine 0.1 for Omeprazole and 0.1 for Domperidone and 
the LOQ value was found to be 0.4 ppm for Ranitidine, 0.4ppm for Famotidine 0.5 for 
Omeprazole and 0.5 for Domperidone respectively. Chromatograms of LOQ study 
were shown in Fig 13-16. 
 
Six replicate sample preparations were determined and standard deviation, % relative 
standard deviation was calculated to find out the reproducibility at LOQ level.  
 
Fig 13: Chromatogram of LOQ Preparation of Famotidine 
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Fig 14: Chromatogram of LOQ Preparation of Ranitidine: 
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Fig 15: Chromatogram of LOQ Preparation of Domperidone: 
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Fig 16: Chromatogram of LOQ Preparation of Omeprazole: 
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5.1.3 Precision Study  
 
Precision study was established by evaluating method precision and intermediate 
precision study. System precision was evaluated by analyzing the standard solution five 
times. Method precision of the analytical method was determined by analyzing six 
sets of sample preparation. Standard deviation, % relative standard deviation and 
assay was calculated for six replicate sample preparations 
 
Intermediate precision of the analytical method was determined by performing 
method precision on another day by another analyst under same experimental 
condition. Standard deviation, % relative standard deviation and assay was calculated 
for six replicate sample preparations 
 
The developed method was found precise as the %RSD values for system precision, 
method precision and intermediate precision study were < 2.0% for each drug, which 
confirms that the method is precise. The result of repeatability and intermediate 
precision study are shown in Table 1. 
 
Results of precision study: 
Set 
Famotidine Ranitidine Domperidone Omeprazole 
Intraday 
(n = 6) 
Interday 
(n = 6) 
Intraday 
(n = 6) 
Interday 
(n = 6) 
Intraday 
(n = 6) 
Interday 
(n = 6) 
Intraday 
(n = 6) 
Interday 
(n = 6) 
1 99.70 99.79 99.37 99.62 99.59 99.43 100.43 100.05 
2 99.50 100.14 99.06 99.88 99.78 99.48 100.94 100.12 
3 99.05 99.04 99.65 99.09 99.10 100.28 99.78 99.98 
4 99.29 99.93 99.36 99.23 99.93 100.14 99.64 99.15 
5 99.56 99.81 100.52 99.97 101.07 99.45 100.65 99.69 
6 100.67 99.23 100.53 99.16 100.84 99.21 101.40 100.38 
Mean 99.62 99.65 99.74 99.49 100.05 99.66 100.47 99.89 
SD 0.55 0.42 0.62 0.38 0.75 0.43 0.67 0.42 
%RSD 0.56 0.42 0.63 0.38 0.75 0.43 0.67 0.42 
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Fig 11: Chromatogram of test preparation (set 1) of method precision study: 
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Fig 12: Chromatogram of test preparation (set 1) of intermediate precision 
study: 
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5.1.4 Accuracy 
Accuracy was assessed by determination of the recovery of the method at three different 
concentrations (corresponding to 50, 100 and 150% of test solution concentration) Known 
amounts of each drug (50, 100, and 150 µg/ml) were added to a diluent preparation and 
the amount of drug recovered, was calculated. For each concentration, three sets were 
prepared and injected in duplicate. % Recovery was calculated at each level and recorded as 
shown in Table-2. The mean recovery of Rosuvastatine calcium was between xx% and 
xx%, which is satisfactory. 
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5.1.5 Robustness  
The robustness of the method was evaluated by assaying test solutions after slight but 
deliberate changes in the analytical conditions. The factor chosen for this study were the 
flow rate (±0.1 mL/min) and pH of buffer solution (±0.2) and column temperature (±10˚ 
C). 
 
The result of robustness study of the developed assay method was established in 
Table 4 and Table 5. The result shown that during all variance conditions, assay value 
of the test preparation solution was not affected and it was in accordance with that of 
actual. System suitability parameters were also found satisfactory; hence the 
analytical method would be concluded as robust. Chromatogram obtain during 
robustness study were shown in Fig20-25. 
 
Table 4: Evaluation data of robustness study of famotidine 
Robust 
Conditions % Assay 
System Suitability Parameters 
Asymmetry % RSD 
Flow 0.9 ml/min 99.84 1.31 0.26 
Flow 1.1 ml/min 99.36 1.21 0.18 
Buffer pH 2.8 100.03 1.18 0.24 
Buffer pH 3.2 100.18 1.20 0.13 
Column temp 15˚C 99.48 1.18 0.22 
Column temp 35˚C 99.27 1.22 0.23 
 
Table 5: Evaluation data of robustness study of ranitidine 
Robust 
Conditions % Assay 
System Suitability Parameters 
Asymmetry % RSD 
Flow 0.9 ml/min 99.89 1.29 0.12 
Flow 1.1 ml/min 100.03 1.24 0.14 
Buffer pH 2.8 99.62 1.25 0.11 
Buffer pH 3.2 100.38 1.27 0.09 
Column temp 15˚C 100.42 1.19 0.14 
Column temp 35˚C 99.45 1.19 0.18 
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Table 6: Evaluation data of robustness study of domperidone 
Robust 
Conditions % Assay 
System Suitability Parameters 
Asymmetry % RSD 
Flow 0.9 ml/min 99.81 1.39 0.18 
Flow 1.1 ml/min 99.34 1.31 0.24 
Buffer pH 2.8 98.92 1.22 0.12 
Buffer pH 3.2 99.58 1.28 0.13 
Column temp 15˚C 100.17 1.34 0.31 
Column temp 35˚C 99.24 1.28 0.29 
 
 
Table 7: Evaluation data of robustness study of omeprazole 
Robust 
Conditions % Assay 
System Suitability Parameters 
Asymmetry % RSD 
Flow 0.9 ml/min 100.02 1.36 0.40 
Flow 1.1 ml/min 100.24 1.33 0.28 
Buffer pH 2.8 100.56 1.26 0.19 
Buffer pH 3.2 100.20 1.17 0.19 
Column temp 15˚C 99.55 1.31 0.22 
Column temp 35˚C 99.92 1.32 0.18 
 
 
Fig 16: Chromatogram of test preparation (flow rate 0.9 mL/min) 
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17: Chromatogram of test preparation (flow rate 1.1 mL/min) 
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Fig 18: Chromatogram of test preparation (Buffer pH 2.8) 
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Fig 19: Chromatogram of test preparation (Buffer pH 3.2) 
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6.0 Calculation and Data 
 
6.1 Formula and Equation  
 
Calculation formula for % assay  
 
potency
TestWeight
5WeightStd
AreaStandardMean
AreaTestMean
Assay ×××××=
15
2510
2510
%  
 
 
Relative standard deviation  
 
100
tsMeasuremenofValueMean
tMeasuremenofDeviationStandard
RSD ×=
 
 s
%  
 
 
% Recovery  
 
100
AddedAmount
FoundAmount
Recovery% ×=  
 
Amount Found  
 
ionConcentratStandard
AreaMean
AreaTestMean
mlmgFoundAmount ×=
Standard
)/(  
 
Amount added 
 
Volume
WeightmlmgAddedAmount =)/(  
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6.2 Observation and calculation for linearity 
 
Data for standard preparation 
Replicate Famo Rani Dom Ome 
1 3125009 7463120 4250366 2889977 
2 3133754 7471423 4256985 2896015 
3 3130742 7477003 4242091 2900468 
4 3127066 7468135 4252156 2899444 
5 3129606 7474555 4243642 2901070 
     Mean 3129235 7470847 4249048 2897394.8 
SD 3368 5455 6164 4584 
%RSD 0.10 0.07 0.14 0.15 
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6.3 Observation and calculation for precision study: 
 
Method precision study 
Data for standard preparation: 
Replicate Famo Rani Dom Ome 
1 3132110 7449404 4238636 2866170 
2 3136512 7448182 4237511 2867212 
3 3135220 7450760 4240542 2869440 
4 3135924 7454695 4244078 2871789 
5 3137146 7454920 4243938 2870692 
Mean 3135382 7451592 4240941 2869060 
SD 1963 3074 3002 2346 
%RSD 0.06 0.04 0.07 0.08 
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Prototype Calculation for set-1: 
 
For famotidine 
potency
TestWeight
5WeightStd
AreaStandardMean
AreaTestMean
Assay ×××××=
15
2510
2510
%  
 
89.99
15
25
991.4
10
25103135382
3136000% ×××××= 54.981Assay  
 
% Assay = 99.70% 
 
For Ranitidine 
potency
TestWeight
5WeightStd
AreaStandardMean
AreaTestMean
Assay ×××××=
15
2510
2510
%  
 
91.99
15
25
003.5
10
25107451592
7451866% ×××××= 54.976Assay  
 
% Assay = 99.37% 
 
For Domperidone 
potency
TestWeight
5WeightStd
AreaStandardMean
AreaTestMean
Assay ×××××=
15
2510
2510
%  
 
82.99
15
25
007.5
10
25104240941
4239694% ×××××= 54.997Assay  
 
% Assay = 99.59% 
 
For Omeprazole 
potency
TestWeight
5WeightStd
AreaStandardMean
AreaTestMean
Assay ×××××=
15
2510
2510
%  
 
93.99
15
25
976.4
10
25102869060
2861184% ×××××= 55.015Assay  
 
% Assay = 100.43% 
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Intermediate precision study 
Data for standard preparation: 
Replicate Famo Rani Dom Ome 
1 3122980 7432501 4238909 2850145 
2 3122654 7430051 4238711 2848748 
3 3123474 7428122 4235025 2848303 
4 3128110 7425008 4237569 2845444 
5 3126433 7426026 4242688 2847181 
Mean 3124730 7428341 4238580 2847964 
SD 2412 3030 2768 1764 
%RSD 0.07 0.04 0.06 0.06 
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Prototype Calculation for set-1: 
 
For Famotidine 
potency
TestWeight
5WeightStd
AreaStandardMean
AreaTestMean
Assay ×××××=
15
2510
2510
%  
 
89.99
15
25
991.4
10
25103124730
3128156% ×××××= 54.981Assay  
 
% Assay = 99.79% 
 
For Ranitidine 
potency
TestWeight
5WeightStd
AreaStandardMean
AreaTestMean
Assay ×××××=
15
2510
2510
%  
 
91.99
15
25
992.4
10
25107428341
7431026% ×××××= 54.976Assay  
 
% Assay = 99.62% 
 
For Domperidone 
potency
TestWeight
5WeightStd
AreaStandardMean
AreaTestMean
Assay ×××××=
15
2510
2510
%  
 
82.99
15
25
022.5
10
25104238580
4243411% ×××××= 54.997Assay  
 
% Assay = 99.43% 
 
For Omeprazole 
potency
TestWeight
5WeightStd
AreaStandardMean
AreaTestMean
Assay ×××××=
15
2510
2510
%  
 
93.99
15
25
011.5
10
25102847964
2849127% ×××××= 55.015Assay  
 
% Assay = 100.05% 
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6.4 Observation and calculation for accuracy 
Data for standard preparation 
Replicate Famo Rani Dom Ome 
1 3156104 7439622 4248486 2868693 
2 3152187 7444513 4242521 2862535 
3 3155425 7445680 4246600 2867771 
4 3159006 7435190 4249274 2872306 
5 3160355 7440756 4250135 2869950 
     
Mean 3156615 7441152 4247403 2868251 
SD 3201 4178 3025 3620 
%RSD 0.10 0.05 0.07 0.12 
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Amount added: 
Accuracy 
level 
Set. 
No. 
Famotidine Ranitidine Domperidone Omeprazole 
Wt. 
taken 
gms 
Amount 
added 
(ppm) 
Wt. 
taken 
gms 
Amount 
added 
(ppm) 
Wt. 
taken 
gms 
Amount 
added 
(ppm) 
Wt. 
taken 
gms 
Amount 
added 
(ppm) 
50% 
1 12.42 49.68 12.48 49.92 12.51 50.04 12.46 49.84 
2 12.50 50.00 12.55 50.20 12.58 50.32 12.58 50.32 
3 12.55 48.24 12.53 50.12 12.44 49.76 12.45 49.80 
100% 
1 25.03 100.12 25.11 100.44 24.92 99.68 25.12 100.48 
2 24.98 99.92 25.06 100.24 24.99 99.96 25.01 100.04 
3 25.00 100.00 25.07 100.28 24.94 99.76 25.09 100.36 
150% 
1 37.52 150.08 37.47 149.88 37.44 149.76 37.46 149.84 
2 37.47 149.88 37.50 150.00 37.51 150.04 37.56 150.24 
3 37.49 149.96 37.43 149.72 37.56 150.24 37.448 149.76 
 
Amount added: Prototype calculation for set-1 
 
 
 
 
 
 
 
1000
3
2
1
)( ×
−
−×
−
=
Vol
Vol
Vol
WeightppmAddedAmount
1000
50
10
50
42.12)( ××=ppmAddedAmount
68.49)( =ppmAddedAmount
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Amount Found: Prototype calculation for set-1: Ranitidine 
 
ionConcentratStandard
AreaMean
AreaTestMean
ppmFoundAmount ×=
Standard
)(  
99.98 ppmFoundAmount ×=
7441152
3739878)(  
 
50.24 ppmFoundAmount =)(  
 
Amount Found: Prototype calculation for set-1: Domperidone 
 
ionConcentratStandard
AreaMean
AreaTestMean
ppmFoundAmount ×=
Standard
)(  
99.94 ppmFoundAmount ×=
4247403
2120522)(  
 
49.89 ppmFoundAmount =)(  
 
Amount Found: Prototype calculation for set-1: Omeprazole 
 
ionConcentratStandard
AreaMean
AreaTestMean
ppmFoundAmount ×=
Standard
)(  
99.92 ppmFoundAmount ×=
2868251
1441899)(  
 
50.23 ppmFoundAmount =)(  
 
% Recovery: Prototype calculation for set-1 
 
100
AddedAmount
FoundAmount
Recovery% ×=  
100
49.92
50.80Recovery% ×=  
 
101.76Recovery% = %
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6.5 Observation and calculation for robustness: 
 
Summary of robustness study for famotidine 
Std. 
Replicate 
Flow Rate 
1.1 mL/min 
Flow Rate 
0.9 mL/min 
Buffer 
pH 2.8 
Buffer 
pH 3.2 
1 2770874 3570622 3145605 3139506 
2 2774505 3565120 3152879 3138415 
3 2762636 3569100 3139654 3144525 
4 2759687 3581474 3158321 3148700 
5 2776140 3576855 3156417 3144420 
Mean 2768768 3572634.2 3150575 3143113 
SD 7276 6499 7800 4183 
%RSD 0.26 0.18 0.24 0.13 
Test 
Replicate 
2777202 
2770145 
 
3562980 
3560117 
 
3168741 
3155488 
 
3166201 
3152722 
 
Mean 2773673 3561548 3162115 3159462 
Standard 
wt (mg) 4.995 4.995 4.995 4.995 
Test wt 
(mg) 5.006 5.006 5.006 5.006 
Potency 99.89 99.89 99.89 99.89 
% Assay 99.84 99.36 100.03 100.18 
 
Prototype Calculation for Famotidine: 
 
potency
TestWeight
5WeightStd
AreaStandardMean
AreaTestMean
Assay ×××××=
15
2510
2510
%  
 
89.99
15
25
006.5
10
25102768768
2773673% ×××××= 54.995Assay  
 
% Assay = 99.84% 
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Summary of robustness study for Ranitidine 
Std. 
Replicate 
Flow Rate 
1.1 mL/min 
Flow Rate 
0.9 mL/min 
Buffer 
pH 2.8 
Buffer 
pH 3.2 
1 6687690 8282386 7488202 7432908 
2 6690258 8269474 7496110 7429874 
3 6674512 8250265 7474546 7439540 
4 6680451 8276769 7482188 7444580 
5 6671403 8270135 7477493 7427300 
Mean 6680863 8269805.8 7483708 7434840 
SD 8137 12132 8644 7109 
%RSD 0.12 0.14 0.11 0.09 
Test 
Replicate 
6654305 
6659477 
 
8256986 
8247821 
 
7440126 
7433489 
 
7448248 
7442006 
 
Mean 6656891 8252403.5 7436808 7445127 
Standard 
wt (mg) 5.013 5.013 5.013 5.013 
Test wt 
(mg) 4.996 4.996 4.996 4.996 
Potency 99.91 99.91 99.91 99.91 
% Assay 99.89 100.03 99.62 100.38 
 
Prototype Calculation for Famotidine: 
 
potency
TestWeight
5WeightStd
AreaStandardMean
AreaTestMean
Assay ×××××=
15
2510
2510
%  
 
91.99
15
25
996.4
10
25106680863
6656891% ×××××= 55.013Assay  
 
% Assay = 99.89% 
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Summary of robustness study for Domperidone 
Std. 
Replicate 
Flow Rate 
1.1 mL/min 
Flow Rate 
0.9 mL/min 
Buffer 
pH 2.8 
Buffer 
pH 3.2 
1 3822167 4747597 4299114 4280111 
2 3829654 4725654 4300217 4269878 
3 3836458 4720630 4288689 4266902 
4 3838412 4732987 4290214 4276533 
5 3825105 4719347 4298414 4279416 
Mean 3830359 4729243 4295330 4274568 
SD 7022 11574 5431 5891 
%RSD 0.18 0.24 0.12 0.13 
Test 
Replicate 
3859654 
3848400 
 
4732745 
4739521 
 
4288147 
4278621 
 
4292925 
4289159 
 
Mean 3854027 4736133 4283384 4291042 
Standard 
wt (mg) 4.986 4.986 4.986 4.986 
Test wt 
(mg) 5.017 5.017 5.017 5.017 
Potency 99.82 99.82 99.82 99.82 
% Assay 99.81 99.34 98.92 99.58 
 
Prototype Calculation for Famotidine: 
 
potency
TestWeight
5WeightStd
AreaStandardMean
AreaTestMean
Assay ×××××=
15
2510
2510
%  
 
82.99
15
25
017.5
10
25103830359
3854027% ×××××= 54.986Assay  
 
% Assay = 99.81% 
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Summary of robustness study for Omeprazole 
Std. 
Replicate 
Flow Rate 
1.1 mL/min 
Flow Rate 
0.9 mL/min 
Buffer 
pH 2.8 
Buffer 
pH 3.2 
1 2586775 3120844 2836548 2872205 
2 2586003 3136741 2851214 2873414 
3 2578365 3133852 2846502 2868689 
4 2563214 3145789 2844666 2859357 
5 2569254 3134895 2840117 2870763 
Mean 2576722 3134424.2 2843809 2868886 
SD 10345 8937 5682 5609 
%RSD 0.40 0.28 0.19 0.19 
Test 
Replicate 
2580369 
2588412 
 
3148547 
3152528 
 
2866879 
2868158 
 
2888923 
2876184 
 
Mean 2584391 3150537 2867519 2882554 
Standard 
wt (mg) 5.023 5.023 5.023 5.023 
Test wt 
(mg) 5.033 5.033 5.033 5.033 
Potency 99.93 99.93 99.93 99.93 
% Assay 100.02 100.24 100.56 100.20 
 
Prototype Calculation for Famotidine: 
 
potency
TestWeight
5WeightStd
AreaStandardMean
AreaTestMean
Assay ×××××=
15
2510
2510
%  
 
93.99
15
25
033.5
10
25102576722
2584391% ×××××= 55.023Assay  
 
% Assay = 100.02% 
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SUMMARY 
 
A comprehensive summary of the work incorporated in the thesis entitled “Method 
Development & Analytical Study of Some API’s & Related Products” has been 
described as under. 
 
Chapter 1 includes the historical review as well as introduction to various types of 
chromatographic techniques, basic principles of high performance liquid 
chromatography, gas chromatography, analytical method validation and discussion of 
its requirements and experimental parameters. 
 
Chapter 2 covers “Method Development and Validation for Assay of Magnesium 
Valproate by Gas Chromatography” which deals with the Gas Chromatographic 
analysis of Magnesium salt of Valproic Acid. The developed method is capable 
enough to separate the various process impurities and by-products, as the most of the 
impurities are eluting at the same time as Valproic Acid. The method is very well 
applicable to various Valproic Acid salts. 
 
Chapter 3 entitled “Development and Validation of Stability-Indicating RP-HPLC 
Method of Rosuvastatin calcium for its Assay and Content Uniformity in Tablets 
Dosage form” deals with the stability-indicating liquid chromatographic method of 
Rosuvastatin calcium for its assay and content uniformity in tablet formulation. Method 
has the significance because total analysis time of just 10 minutes, degradation products 
didn’t interfere with the desired drug peak and it also includes the validation of method 
as per ICH guidelines. 
 
Chapter 4 depicts “Validation of an Assay Method for the Simultaneous 
Determination of Rosuvastatin Calcium and Amlodipine Besylate in Tablet 
Formulations” which deals with the development of liquid chromatographic assay 
method for Rosuvastatin calcium and Amlodipine Besylate in combine dosage form in bulk 
formulations. Method has the significance as total analysis time is 10 minutes. Method 
validation carried out as per ICH guidelines. 
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Chapter 5 entitled “Simultaneous estimation of four drugs by HPLC, used as anti-
acidity and side therapy” deals with the simultaneous estimation of Ranitidine, 
Famotidine, Omeprazole and Domperidone by liquid chromatography with total run 
time of 17 minutes. Current findings are functional in pharmaceutical dosage forms as 
the method is well applicable to almost five single dosage forms and three combine 
dosage forms. 
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